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ABSTRACT 
 
The most common type of thyroid cancer, differentiated thyroid cancer (DTC), is 
diagnosed by radioactive iodine whole body scanning (WBS) and treated with 
radiotherapy using iodine-131 (131I). The success of this diagnosis/treatment approach 
relies on the relatively selective localisation of the sodium/iodide symporter (NIS) in 
cells of the thyroid gland. However, in some de-differentiated thyroid cancers, NIS 
expression is lost. This results in the inability of WBS to stage the disease and it also 
decreases the effectiveness of treatment with 131I.  A number of reports have shown that 
de-differentiated thyroid carcinomas, however, continue to express thyroid stimulating 
hormone receptor (TSHR). TSHR is, therefore, a potential target for the diagnosis and 
treatment of radioiodine resistant de-differentiated thyroid carcinoma. In this study an 
anti-TSHR monoclonal antibody (mAb9) and human recombinant TSH (rhTSH) were 
radiolabelled and evaluated for their potential use in the diagnosis and treatment of 
radioiodine resistant thyroid cancer. A number of radiolabelling methods and quality 
control experiments were initially carried out to ensure high purity radiolabelled mAb9 
and rhTSH were produced.  In vitro studies were conducted to assess the binding 
affinity of 125I-mAb9, 111In-mAb9 and 125I-rhTSH to the TSHR in thyroid cancer cell 
lines, TPC-1, FTC-133, and FRTL5, and in a TSHR transfected cell line, GPI. 
SPECT/CT animal studies were performed in mice to investigate whether 125I-mAb9, 
111In-mAb9 and 125I-rhTSH bound to TSHR in the thyroid of mice in vivo. 
125I-mAb9, 111In-mAb9 and 125I-rhTSH bound to GPI cells but did not bind specifically 
to the TSHR in FTC-133, TPC-1 and FRTL5 cells as well as to the thyroid of normal 
mice in vivo.  Radiolabelled mAb9 and radiolabelled rhTSH are therefore unlikely to be 
of use in the diagnosis and treatment of radioiodine resistant de-differentiated thyroid 
cancer.  
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1.1 The Thyroid Gland and Thyroid C
The thyroid gland is a butterfly
(voice box). This gland is composed of right and left lateral lobes, which lie on either 
side of the trachea. Connecting 
anterior to the trachea (
follicles, which are microscopic spherical sacs. The
primarily of cells called follicular cells, most of which extend to the lumen (internal 
space) of the follicle 
cuboidal to squamous, but under the influence of TSH they become cuboidal or low 
columnar and actively secretory. Parafollicular or C cells, which produce the 
calcitonin and comprise around 1% of human thyroid cells, can also be found 
to the thyroid follicles and reside in the connective tissue. Calcitonin regulates calcium 
homeostasis [1, 2]. 
Figure 1.1: Anatomy of the 
 
 
The thyroid is essential for normal development, differentiation, and metabolic balance.  
Most, if not all of the actions of thyroid hormones occur as thyroid hormones bind and 
activate their nuclear receptors. The thyroid hormone receptors are chromatin b
CHAPTER 1. INTRODUCTION 
ells 
-shaped organ located in the neck inferior to the larynx 
the lobes is a mass of tissue called 
figure 1.1) [1, 2]. The thyroid gland is made mostly by thyroid 
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[1]. When the follicular cells are inactive, their 
human thyroid and thyroid cells. Adapted from  [3]
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alter the transcription of specific genes. Thyroid hormones increase basal metabolic rate 
(BMR) by stimulating the use of cellular oxygen to produce ATP [1, 2]. Plasma 
membrane Na+/K+ ATPase pumps act to maintain the Na+/K+ gradients in all cells of the 
body and use a large portion of the ATP produced by most cells. A major effect of the 
thyroid hormones is to stimulate synthesis of Na+/K+ ATPase. As cells use more oxygen 
to produce ATP, more heat is given off, and body temperature rises. This phenomenon 
is called the calorigenic effect of the thyroid hormones and in this way the thyroid 
hormones play an important role in the maintenance of normal body temperature [1, 2]. 
In the regulation of metabolism, the thyroid hormones stimulate protein synthesis and 
increase the use of glucose for ATP production. They also increase lipolysis and 
enhance cholesterol excretion in  bile, thus reducing blood cholesterol levels [1, 2]. 
Furthermore, the thyroid hormones also enhance some actions of the catecholamines 
(norepinephrine and epinephrine) because they up-regulate β adrenal receptors. 
Together with human growth hormone and insulin, thyroid hormones accelerate body 
growth and are, thus, essential for normal human development. The important role of 
the thyroid in development is illustrated by the fact that regions of iodine deficiency 
have a high occurrence of cretinism. Cretinism is characterised by mental retardation, 
short stature, delay in motor development, coarse hair and a protuberant abdomen [1, 2].  
 
1.2 Synthesis of Thyroid hormones 
The thyroid gland produces two principal hormones: tetraiodothyronine (T4 or 
thyroxine) and triiodothyronine (T3), which contain four and three atoms of iodine 
respectively [1, 2].  
The major steps in the synthesis, storage and release of thyroid hormones include: the 
uptake of iodide ion by the thyroid, the oxidation of iodide into iodine and the 
iodination of tyrosyl groups on thyroglobulin, coupling of iodotyroside residues to 
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generate iodotyrosines, the conversion of T4 to T3 in the thyroid and the release of T3 
and T4 into the blood, and each of these steps are described below [1, 2].                
In the first step, iodide ingested in the diet is actively transported by thyroid follicular 
cells from the blood into the cytosol of the thyroid follicular cells via a specific, 
membrane-bound protein, the sodium iodide symporter (NIS) [4-6], and this process is 
called iodine trapping.  The sodium ATP-ase pump localised in the basolateral region of 
follicular cells generates a sodium electrochemical gradient by actively transporting 
sodium into the follicular cells. NIS utilises this sodium gradient to transport iodide into 
the cell [4-6]. For every two sodium ions that are transported along the sodium gradient 
out of the cells, one iodide is transported into the follicular cells. As a result, the I- 
concentration inside follicular cells is 20-40 times that of blood plasma [4-6]. The 
iodide transport system is stimulated by the thyroid stimulating hormone (TSH) and is 
also controlled by a negative feedback loop control mechanism, in which decreased 
levels of iodine in the thyroid lead to an increase in iodide uptake and the administration 
of iodide can reverse this situation. NIS has been identified in many other tissues, 
including the salivary gland, gastric mucosa, midportion of the small intestine, choroid 
plexus, skin and mammary glands, all of which maintain a concentration of iodide 
greater than that of the blood [7].  It is not clear what the purpose of the NIS is in these 
other sites; however it is evident that NIS is not unique to the thyroid gland. At the same 
time that the follicular cells trap I-, they also synthesise thyroglobulin, a high molecular 
weight glycoprotein (approximately 660 kDa) that contains around 5500 amino acid 
residues. More than 100 of these amino acids are tyrosines, a few of which become 
iodinated. Negatively charged iodide ions (2I-) cannot bind to tyrosine until they 
undergo oxidation to form iodine (I2). The enzyme that catalyses this reaction is thyroid 
peroxidase in the presence of hydrogen peroxide (H2O2). In thyroid follicular cells 
thyroid peroxidise is mostly concentrated close to or in the membrane adjacent to the 
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colloid. H2O2, that is needed as a substrate for this reaction, is produced by a generator 
system of H2O, in which thyroid oxidases 1 and 2 (THOX 1 and 2) are essential [2]. 
This organification process is completely inhibited by tiocine, perchlorate and other 
anions [8, 9]. As the iodide ions are being oxidised, they pass through the apical 
membrane into the colloid where they react with tyrosine amino acids that are part of 
thyroglobulin (Tg) molecules in the colloid. Binding of a single iodine atom to a 
tyrosine yields monoiodotyrosine (T1), while binding of two iodines yields 
diiodotyrosine (T2) [2]. 
During the last step in the synthesis of the thyroid hormones, two T2 molecules join to 
form T4, or one T1 and one T2 join to form T3 (figure 1.2). Each Tg ultimately contains 
about six T1, five T2, and one T4. There is a single T3 in one of every four 
thyroglobulins. Thus, thyroid hormones are stored as part of Tg molecules within the 
colloid [2]. Vesicles of colloid containing Tg are taken up into follicular cells by 
pinocytosis and once inside the follicular cell they merge with lysosomes. Digestive 
enzymes then break down Tg, cleaving off molecules of T3 and T4. T1 and T2 are also 
released, but they undergo deiodination and the liberated iodine is reused to synthesise 
more T3 and T4. Because T3 and T4 are lipid-soluble, they diffuse through the plasma 
membrane to enter the blood and more than 99% of both the T3 and the T4 combine with 
transport proteins in the blood, mainly thyroxine-binding globulin [2]. An illustration of 
thyroid hormone synthesis can be found in figure 1.3. 
 
Figure 1.2: Chemical structures of T3 and T4. T3 is on the left side and T4 on the right side. Adapted from 
[10] 
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Figure 1.3: Thyroid hormone synthesis steps. Adapted from [1, 2] Including the uptake of iodide ion by 
the thyroid, the oxidation of iodine and the iodination of tyrosyl groups of thyroglobulin, coupling of 
iodotyroside residues to generate iodotyrosine and the release of T3 and T4 into the blood. Abbreviations: 
NIS- Sodium Iodide symporter; TSH- Thyroid stimulating hormone; TSHR- thyroid stimulating hormone 
receptor; TPO- thyroid peroxidase; TG- thyroglobulin; MIT- monoiodotyrosine; DIT – diiodotyrosine; 
T3- triiodothyronine; T4- thyroxine 
 
1.3  Thyroid hypothalamic-pituitary-thyroid axis.   
Thyroid stimulating hormone (TSH) is secreted by the pituitary gland and it acts to 
regulate thyroid function. The binding of TSH to the thyroid stimulating hormone 
receptors (TSHRs) on the thyroid follicular cells ultimately mediates thyroid hormone 
synthesis and secretion [11]. The thyroid stimulating hormone receptor (TSHR) on the 
thyroid follicular cells is a member of the family of G protein coupled receptors 
(GPCRs). TSHR activates adenylyl cyclase via Gαs which leads to an increase in 
intracellular cyclic adenosine monophosphate (cAMP). cAMP is the main second 
messenger of TSH action in the human thyroid. Intracellular concentrations of cAMP 
control the maintenance of the differentiated phenotype of thyrocytes, the level of 
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functional activity of the gland (trapp
growth [12, 13]. TSH production in turn is controlled
(TRH), which is produced in the hypothalamus and transported to the anterior pituitary 
gland (figure 1.4). TRH binds and activates the TRH receptor on the cell membranes of 
the thyrotrophs, and this stim
[2]. The level of thyroid hormones (T
release of TSH; when the levels of T
increased, and, on the converse, when levels of T
decreased. This effect creates a regulatory 
Figure 1.4: Thyroid hormone
TSH- thyroid stimulating hormone
 
1.4 TSH structure  
TSH, also known as thyrotropin, is a glycoprotein with approximate molecular weight 
of 28-30 kDa, consisting of two distinct subunits, an 
by non-covalent bonds. Each subunit forms a cysteine knot structure with three disul
bridges [14]. The mature human TSH 
ing of iodide, secretion of thyroid hormones) and 
 by thyrotropin releasing hormone, 
ulates an increase in both the synthesis and release of TSH 
3 and T4) in the blood has an effect on the pituitary 
3 and T4 are low, the production of TSH is 
3 and T4 are high, TSH production is 
negative feedback loop.
 negative feedback loop. Abbreviations: TRH- thyroid releasing hormone; 
. Adapted from [1, 2] 
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identity with canine, rat, equine, mouse, bovine, porcine, and feline TSH β [14]. The 
mature human α subunit shares 69%-73% amino acid identity with canine, rabbit, rat, 
mouse, bovine, porcine, feline and equine α subunit [14].  The synthesis of the α and β 
subunit of TSH occurs in the thyrotrophs, which comprise around 5% of anterior 
pituitary gland. The gene that encodes the α subunit is located on chromosome 5, while 
the β subunit gene is located on chromosome 2 [14].  The TSH α subunit contains 92 
amino acids with five disulfide bridges contributing to its tertiary structure and the β 
subunit contains 118 amino acids with six disulfide bridges (figure 1.5) [14]. The 
glycoprotein hormones TSH, FSH, and LH all share a common α subunit, however the 
β subunit is specific to TSH. In order for TSH to exert biological activity the two 
subunits must be joined [14].  
 
Figure 1.5: Structure of α and β TSH subunit genes. Exons are denoted by the boxes, and introns or 
flanking DNA sequences are denoted by lines. The length of exons and introns are shown in base pairs. 
Coding regions of exons are shaded; noncoding regions are white. Transcription start site is shown by a 
bent arrow. Adapted from SZKUDLINSKI et al.[14]. 
 
TSH is glycosylated, which protects it from intracellular degradation, and it also enables 
it to fold properly by allowing the formation of disulfide bonds.  The carbohydrate 
chains in the human TSH constitute 15-25% of its molecular weight [14-16].  
  
The human TSH α subunit has two carbohydrate chains linked to Asn
respectively, and the human TSH  
Asn-23 (figure 1.6).  
important for TSH stimulated 
β subunit is essential for its stability and secretion 
the α subunit have different functions: the glycosylation site at Asn
integrity of the hormone as the carbohydrates joined to Asn
of the β subunit, while the carbohydrates joined to glyc
the stability of the heterodimer, making it therefore important for the association of the 
two subunits in the intact heterodimer of TSH 
 
. The structure and charge of the three N
activity; the most complex forms have lower activity but a longer half life 
Figure 1.6: Typical N-linked oligosaccharides of 
mannose (O), N-acetylglucosamine (_), N
(NeuAc) ( ) [14]. 
 
1.5 TSHR  
TSHR is a G protein coupled receptor (GPCR) located on the basal surface of thyroid 
follicular cells. The TSHR
[20], canine [21], human 
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exists, with the overall DNA sequence identity varying from 75 to 90% between the 
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molecular weight of 84.5 kDa. TSHR, like most GCPRs, contains a large extracellular 
N-terminal domain or ectodomain (ECD), a 7 transmembrane domain and a short c-
terminal cytoplasmic tail [25-27]. The 7 TMDs are joined intracellularly by connecting 
loops that interact with G proteins when the receptor is activated [28] whereas the 
extracellular loops, outside the cell, have secondary roles in receptor structure and 
activation (figure 1.7) [29].  The transmembrane domain and the intracellular domain 
are coded for by 9 exons (exon 2-8). The ECD domain is composed of a highly 
glycosylated structure of 394 amino acids coded by the tenth and largest exon. [25-27].  
The TSHR structure includes 2 non homologous segments within the TSHR ECD 
(residues 38–45 and 316–366) not found in otherwise closely related glycoprotein 
hormone receptors such as luteinising hormone (LH) and follicle-stimulating hormone 
(FSH) [25-27]. TSHR, unlike the other glycoprotein hormone receptors, is first 
synthesised as a single chain molecule (precursor) and then cleaved into two disulphide-
linked subunits [25-27]. The A or α subunit, wich comprises the large extracellular 
ectodomain is encoded by exons 1-8 and it binds TSH.  The B or β subunit, which 
comprises a short transmembrane and intracellular domain, is encoded by exons 9-10 
and interacts with G proteins to initiate signalling [25, 26]. The hydrophilic A subunit 
has a molecular weight of about 50 kDa and the hydrophobic B subunit has a molecular 
weight of about 35 kDa [25-27].  The ligand-binding glycoprotein A subunit is linked to 
the membrane-spanning B subunit by disulfide bonds [25-27].  The extracellular 
domain is approximately 414-418 amino acids long and contain six potential N-linked 
glycosylation sites in the human TSHR [25, 26].  
Studies demonstrated that TSH does not bind with high affinity to recombinant TSHR 
ECD, expressed in isolation [30, 31]. However, when the TSHR ECD is anchored to the 
plasma membrane through a short lipid tail, the TSH  is able to bind with high affinity 
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[32, 33]. Therefore, the TSHR ECD, consisting mainly of 9 leucine-rich repeats (LRRs) 
and an N-terminal tail, forms the binding domain for TSH.  
Shepherd et al. used monoclonal antibodies that recognise a number of different 
sequences on the human native TSHR ECD [34]. This study concluded that region 337-
342 is not involved in binding TSH, region 355-358 is near to an interaction site and 
region 381-384 is part of a TSH interaction site because all the antibodies which reacted 
with this site inhibited radiolabelled TSH binding. The findings from this study agrees 
with results from the Kosugi et al. study [32], in which a mutation of Tyr385 affected 
TSH binding and De Roux et al. [35] in which a mutation in Cys390 inhibited the 
binding of radiolabelled TSH.  Overall these studies together conclude that region 381-
384 of the TSHR is the ligand binding site of TSH. Recent studies have documented the 
tendency of G protein–coupled receptors to form homo- and heterodimeric forms, and 
these forms may have functional roles in protein trafficking [36], internalisation [37], 
receptor stability [38], and signalling [39]. While unstimulated TSHRs were found in 
multimeric forms [40], this multimeric state was reversed by TSH [41].  
 
 
Figure 1.7: Thyroid stimulating hormone receptor structure. Adapted from [26]. 
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1.6 Localisation of TSHR  
TSHR has been shown to be expressed at low levels on the surface of thyrocytes [42] 
and the number of receptors expressed per cell vary from about 2 x 104 to 2 x 106 sites 
in different studies [43-45]. The expression of TSHR has been reported not only in the 
thyroid [11, 46-50] but also in several other sites including adipose [51], adrenal [52], 
brain[53, 54], eye [55], heart [56], kidney [52], skin [57], and thymus [52]. 
The physiological significance of the extra-thyroidal TSHR expression is still poorly 
understood. However, there have been several studies indicating that TSH may regulate 
the functions of many organs. For example it has been shown that it regulates the 
functions of intraepithelial lymphocytes as well as enterocytes via a TSHR-mediated 
mechanism [58]. In support of this concept, mice with TSHR mutations were reported 
to display signs of impaired gastrointestinal immunity [23, 58]. Additionally, further 
studies on TSHR knock out mice suggested that TSH may serve as a negative regulator 
of osteoblast and osteoclast formation [59,60]. 
 
1.7 TSHR internalisation 
As with other GPCRs, prolonged stimulation of the TSHR by TSH leads to their 
internalisation into endosomes [61-64].  
Internalisation not only serves as a major mechanism of signal desensitisation but also 
has been shown to function in receptor resensitisation [64-66].   Also, some GPCRs 
have been shown to translocate to the nucleus where they might activate gene 
transcription [67]. Upon agonist binding to the TSHR, the GPCR goes through a 
conformational change and  G protein coupled receptor kinases (GPKs) then 
phosphorylate the agonist activated GPCR on intracellular domains. This initiates 
arrestin recruitment. Arrestin binding to the receptor inhibits G protein coupling and 
terminates signalling, a process called desensitization. Receptor/arrestin complexes are 
  
then targeted to chlatrin
with clathrin, adapter protein 2 (AP2) and phosphoinositides, resulting in receptor 
internalisation into endosomes. The endocytosed receptors can either be dissociated 
from the ligand and the receptors re
lysosomes where they are
Figure 1.8:  Receptor internalisation of GPCR
(GPCR) leads to the activation of heteromeric G protein, 
proteins. Persistant stimulation o
of B-arrestins (Barr), even
internalised into endosomes. Internalised GPCRs are either targeted to lysosomes for degradation or 
dephosphorylated and recycled back to the membrane.
 
1.8 The sodium iodide s
NIS is a glycoprotein of 643 amino acids and molecular weight of 70
84% amino acid identity with 
Levy et a.l. [70] and is composed of 13 transmembrane segments, one extracellular N
-coated pits, where arrestin forms a multicomponent complex 
cycled back to the cell surface or directed into the 
 degraded (figure 1.8) [68, 69]. 
s. Binding of radiolabelled antibody/peptide to the TSHR 
which in turn stimulate or inhibit effector 
f GCPRs leads to their phosphorylation by GRKs and GRKs recruitment 
ts responsible for signal desensitisation. Subsequently, GCPRs are often 
 Adapted from  [68, 69]. 
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terminal domain and one intracellular C-terminal domain. The transmembrane segments 
are composed of 20 to 28 amino acids, apart from the V segment that has 18 amino 
acids. The NIS protein contains 7 hydrophilic segments, 5 of which are extracellular 
[71]. The carboxy terminal is a large hydrophilic region composed of 94 amino acids 
and one potential site for cAMP dependent phosphorylation. NIS has 3 potential 
glycosylation sites: aspargine position 225, 485 and 497, that can be glycosylated in the 
endoplasmatic reticulum. Glycosylation is not essential for the function of the protein 
since non glycosylated NIS can be localised in the plasma membrane and transport 
iodide, with a similar value to the glycosylated NIS [70]. Levy et al. [70] conducted an 
in vivo study with high affinity anti-NIS antibodies in FRTL5 cells, and showed that 
NIS protein is initially synthesised as a precursor, with molecular weight of 56 kDa, and 
after glycosylation, it evolves into a mature form. In order for the iodine transport to 
occur it is necessary for the NIS protein to be expressed, migrated and localised in the 
plasma membrane. 
 
1.9 NIS localisation 
With the cloning of NIS in 1996 [5], molecular studies were performed to detect NIS 
expression in tissues. NIS mRNA expression was detected not only in the thyroid but 
also in non-thyroid tissues which have been shown to be able to concentrate radioiodine 
including salivary glands, stomach, thymus and breast [72, 73]. Lower levels of 
expression were detected in prostate, ovary, adrenal gland, lung and heart [72, 73].  
Under physiological conditions, the salivary glands and stomach accumulate iodide via 
NIS, however in other glands, the functional expression occurs only in the final stages 
of pregnancy and lactation. The cDNA of the NIS cloned from these three organs is 
identical to the thyroid [72]. NIS mRNA was detected in various other tissues, however 
only salivary glands and gastric mucosa exhibit sodium dependent accumulation of 
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iodine and are sensitive to perchlorate [74] suggesting that the detection of mRNA is 
not sufficient for the functional expression of NIS. 
 
1.10 Thyroid cancer  
Thyroid cancer is one of the most common endocrine malignancies but overall 
constitutes less than 1% of all human cancers in the world [75-81]. Furthermore, there is 
evidence that thyroid cancer incidence is rapidly increasing in the western world [82]. 
Despite this relatively low figure, the prevalence of thyroid cancer in the western world 
is high (approximately 1 in 1000) due to the long survival of most patients [82].  
The most common thyroid carcinomas are differentiated thyroid carcinomas (DTC) 
which account for 94% of thyroid cancers reported per year in the United States [75-
81]. DTCs derive from thyroid follicular cells and cause either papillary or follicular 
thyroid cancer. Another 5% derive from the parafollicular cells of the thyroid and cause 
medullary thyroid carcinomas. DTC survival rates are generally high, ranging from 92 
to 98% in the western world [75-81]. 
1 to 2% of thyroid cancers can de-differentiate into very aggressive thyroid cancers, 
which have an extremely low survival rate of 13% in the Western World [77, 80, 81, 
83] and these de-differentiated thyroid cancers also account for more than half of the 
1200 deaths per year attributed to thyroid cancer in the United States [80, 81, 83]. Long 
term survival of de-differentiated thyroid carcinoma is rare, with >75% of patients 
presenting  cervical nodal disease, >50% of patients presenting with metastases and 
another 25% developing metastasis during the course of the illness [79, 82, 84, 85]. The 
most common sites of metastasis are the lungs (80%), bone (6-15%) and the brain (5-
13%) [86]. Most de-differentiated thyroid cancers derive from a pre existing thyroid 
nodular goitre or DTC and are usually associated with p53 gene mutations [78, 80, 81, 
86] . The peak incidence of the disease is from 60 to 70 and is most common in women 
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[78, 80, 81, 86]. De-differentiated thyroid carcinoma is usually characterised by being  
radioiodine resistant [78, 80, 81, 86]. This is due to the loss of the sodium iodide 
symporter (NIS), which is responsible for the uptake of iodine into the thyroid [87-89].  
 
1.10.1 Diagnosis and treatment of thyroid cancer 
The cancerous growth of thyroid tissue usually gives rise to abnormally high levels of 
TSH, T4 and T3 and the development of radioimmunoassay and, more recently, 
chemiluminescent and enzyme-linked immunoassays for T4, T3 and TSH have greatly 
improved the laboratory diagnosis of thyroid disorders [90]. However measurement of 
the total hormone concentration in plasma may not give an accurate picture of the 
activity of the thyroid gland as it does not distinguish between bound and free T4/T3. 
Most of the thyroid hormone circulating in the blood is bound to transport proteins. 
Only a very small fraction of the circulating hormone is free (unbound) and biologically 
active, hence measuring concentrations of free thyroid hormones is of great diagnostic 
value. When thyroid hormone is bound, it is not active, so the amount of free T3/T4 is 
what is important. For this reason, measuring total thyroxine in the blood can be 
misleading. When thyroid cancer is suspected, a thyroid nodule physical examination is 
normally conducted to detect a suspected abnormal growth [76, 77, 80]. However, this 
nodule examination cannot distinguish a benign from a malignant nodule. Fine needle 
aspiration cytology should therefore be carried out to determine if the nodule is 
malignant or benign [76, 77, 80]. If a malignant tumour is identified, surgery should be 
conducted to remove all cancerous tissue of the thyroid. Total thyroidectomy, where all 
(or virtually all) of the thyroid is removed is the most common chosen method as it 
results in a lower recurrence rate. Thyroidectomy is usually followed by radioactive 
ablative therapy with 131I  [76, 77, 80]. Ablative therapy with 131I is carried out in order 
to kill most of the remaining thyroid cells to try and prevent the recurrence of the cancer 
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[76, 77, 80, 91].  Differentiated thyroid cancer cells are characterised by presenting a 
number of features that are found in the normal thyroid cells. For example, most 
differentiated thyroid cancer cells express proteins that are normally expressed in 
follicular thyroid cells, such as thyroglobulin and NIS [76, 77, 80, 91]. It is due to these 
features that patients with differentiated thyroid cancer can be given therapeutic doses 
of 131I after total thyroidectomy [76, 77, 80, 91]. However, in some cases not all thyroid 
cancer cells are destroyed and this results in the recurrence of thyroid cancer. 
Approximately 10% to 30% of patients thought to be disease-free after initial treatment 
will develop recurrence and/or metastases [92]. In the majority of these cases, thyroid 
cancer recurs in the differentiated form. These patients again undergo radioiodine 
therapy which cures most cases. However, in a small proportion of patients the therapy 
fails and the cancer transforms into de-differentiated thyroid cancer which is associated 
with normal thyroglobulin levels but lack of radioiodine uptake [76, 77, 80] 
 
1.10.1 Recurrent thyroid cancer 
To diagnose differentiated recurrent disease, serum thyroglobulin testing (Tg) is used, 
followed by radioactive iodine (RAI) whole body scanning (WBS) [76, 77, 80]. 
Thyroglobulin is a glycoprotein that is produced only by normal or cancerous thyroid 
follicular cells. Therefore if a patient (after total thyroidectomy) has thyroglobulin in the 
blood, it indicates the presence of recurrent disease [76, 77, 80].  
Although thyroglobulin testing already confirms the presence of thyroid cancer, it is 
essential to carry out a WBS, so that the cancer can be staged and metastasis detected. 
Staging thyroid cancer with WBS will also help to plan and prepare further treatment 
options [76, 77, 80]. 
Diagnosing de-differentiated thyroid cancer with WBS causes a major problem as de-
differentiated tumours lose the ability to express NIS, which is responsible for the 
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uptake of iodide into the thyroid [91]. This results in the inability of WBS to stage de-
differentiated thyroid cancer [78, 80, 81, 86]. 
De-differentiated metastatic cancer is usually untreatable and palliative approaches are 
used in order to increase the quality of life of the patient. Surgery is considered to 
relieve airway obstruction, however it does not usually alter the course of the disease. 
External beam radiation with 131I has some benefits, though most of these cancers are 
resistant to radiotherapy and treatment is usually unsuccessful [76, 77, 80].  
New treatment approaches have been evaluated for their ability to improve the outcome 
of de-differentiated thyroid carcinoma.  
Studies in rat thyroid cancer cells (FRTL-Tc) without iodide transport activity showed 
that transfection with rat NIS cDNA using electroporation restored radioiodine 
accumulation in vitro and in vivo. However, the effective half life of 131I in NIS-
transfected FRTL-Tc xenografts in rats was only 6 hours and did not allow a therapeutic 
effect of 131I (1 mCi) [93]. Mitchell et al. [94] reported that 10 of 17 patients who 
received high dose radiotherapy had a partial or complete response, however the 
toxicity was intolerable [94].  De-differentiated thyroid cancer treated with radiotherapy 
in combination with doxorubicin (used as a radiosensitizing agent) was also studied, but 
results were again poor [95]. Hyperfractionated local radiotherapy studies have also 
been carried out, but again, initial results were disappointing, particularly due to the 
high sensitivity of patients to adverse effects caused by radioiodine radiotherapy [95].  
Overall, none of these approaches so far proved successful in the treatment of de-
differentiated thyroid cancer. It is therefore essential to carry out more research in this 
area. 
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1.11 Use of rhTSH 
Post-thyroidectomy radioiodine ablative therapy of thyroid remnant tumour is 
recommended for many patients with differentiated thyroid carcinoma (DTC). Even in 
those patients in which recurrence rates and mortality are not directly modified by this 
treatment, the follow-up with serum thyroglobulin (Tg) and iodine-131 scanning  
facilitates the ablation of thyroid remnants [76, 77, 80] . After the initial treatment of 
DTC, the recurrence rate can reach 35% in a period of 40 years, with most cases in the 
first decade.  
Therefore, the long-term follow-up, especially in the first year after treatment, is fully 
justified. Whereas the early detection of relapse may influence the outcome of therapy , 
sensitive tests should be used to follow these patients.  
The measurement of Tg and TSH in serum is currently the most sensitive test for the 
diagnosis of persistent or tumor recurrence [76, 77, 80]. The radioactive whole body 
scan is traditionally, the most frequently used test to be used to identify the location of 
metastases, however, some metastasis still cannot be detected with this diagnostic scan 
and for these a new tracer, the 18F fluorodeoxyglucose  (FDG) has proved promising. 
18F-FDG is a radiolabelled sugar (glucose) molecule. Imaging with 18F-FDG PET is 
used to determine sites of abnormal glucose metabolism and can be used to characterise 
and localise many types of tumours. 
In order for the radioactive iodine whole body scan and the FDG positron emission 
tomography to be successful, high levels of TSH are required [76, 77, 80]. High TSH 
levels lowers thyroid hormone levels and causes the pituitary gland to release more 
TSH, which in turn stimulates thyroid cancer cells to take up the radioactive iodine. 
Until recently this was only possible through the withdrawal of thyroid hormone, 
therapy, resulting in a poorer quality of life, due to symptoms of hypothyroidism (i.e 
32 
 
 
tiredness, depression, weight gain, sleepiness, constipation, muscle aches, and reduced 
concentration), aggravation of the disease and the possibility of tumour growth due to 
prolonged exposure to elevated TSH. Another way to raise TSH levels before a scan is 
to administer an injectable form of TSH (rhTSH or Thyrogen®) to the patient, which 
can make it unnecessary to withhold thyroid hormone therapy for a long period of time 
and thus avoids the side effects caused by thyroid hormone withdrawal [96]. Since its 
approval for clinical use in 2001 in Europe (1998 in the USA), rhTSH has greatly 
enhanced the surveillance of thyroid cancer patients [96]. 
Currently, rhTSH is only approved for diagnostic monitoring of differentiated thyroid 
cancer patients. However, rhTSH can potentially also be used to assist treatment of 
patients with thyroid cancer and nodular goiter. 
rhTSH was successfully produced in vitro by transfecting both the TSH β subunit and 
common α subunit into Chinese hamster ovary cells (CHO) [96-98]. The recombinant 
TSH produced in CHO cells is not glycosylated as the endogenous TSH produced by 
the human thyroid, as CHO cells do not have the ability to fully glycosylate the TSH. 
rhTSH produced in CHO cells is therefore mostly made of TSH in which the three 
carbohydrate chains terminate in sialic acid residues without the penultimate N-
acetylgalactosamine and terminal sulphate moieties [96-98].  
Still, studies performed with rhTSH demonstrated that rhTSH mimicked endogenous 
human TSH as rhTSH stimulated cAMP, cell proliferation and Tg production in vitro 
[99].  
The effect of rhTSH has also been comprehensively studied in mice [100] , which 
makes the mouse a good species candidate to study the effects of TSH in vivo. In mice, 
rhTSH induces an increase in T3 levels [100], while in humans, rhTSH has been shown 
to increase the levels of T3 and T4 [101] and also to increase radioactive iodine uptake 
[102].  
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Although rhTSH has only been approved for the diagnostic imaging of thyroid cancer, 
some studies demonstrated that it can also be used successfully to prepare patients for 
thyroid remnant ablation with 131I [103, 104]. This is because high levels of TSH in the 
blood would lead to an increase in NIS expression and consequently result in a more 
successful radioactive iodine therapy. rhTSH was also found to be successful in the 131I 
treatment of recurrent metastatic differentiated thyroid cancer, where patients were 
stimulated with rhTSH prior to 131I treatment [105]. 
 
1.12 NIS in thyroid tumours 
The ability of the thyroid to concentrate iodine has great importance in the evaluation, 
diagnosis and treatment of various thyroid maladies including cancer. The 
understanding of the complex mechanisms that regulate the uptake of iodine via NIS, 
could potentially lead to better therapy options in tumours that cannot uptake iodine. 
One of the first hypothesis proposed for the reduced function of NIS was the mutation 
of the NIS gene, however Russo et al. [106] did not find any mutation in the samples of 
papillary cancers studied. By using RT-PCR, Rturi et al. [107] found the loss of 
expression of NIS in some papillary, follicular and anaplastic tumours. In 1997, 
Smamik et al. [74] detected lower levels of NIS mRNA in thyroid cancer samples 
compared with normal thyroid tissues, using Northern blotting. Other authors that 
quantified NIS mRNA with RT-PCR also found lower levels in tumour nodules [108], 
[109].  
From these studies it can be observed that varying levels of NIS mRNA expression are 
found in thyroid cancers. However, these variation found in levels of mRNA may not 
reflect the expression of NIS protein, nor its cellular localization, since NIS goes 
through a complex transcriptional, post-transcriptional and post-transductional process. 
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So the mere fact that mRNA is present is not sufficient to indicate the quantity of NIS 
protein, localisation or function [110]. Neumann et al. [108] showed that NIS mRNA 
quantity did not reflect the quantity of NIS protein expression in cold nodules of 
thyroid, suggesting that post-transcriptional factors play an important role. For this 
reason it is important to also study the expression of the NIS protein which can be done 
via immunohistochemistry. One advantage of this technique is that it also gives 
indication about the cellular localisation of NIS protein. Immunohistochemistry studies 
of NIS protein in thyroid tumours showed a decrease in the basolateral localisation of 
the protein, when compared with normal tissues. Cailou et al. [111] studied follicular, 
papillary and anaplastic cancers and showed decreasing immunoereactivity for the NIS 
protein in follicular and papillary cancers and lack in anaplastic cancer which suggested 
that the higher the de-differentiation, the lower the immuno-positivity of the protein. 
Jhiang et al. [112] did not detect NIS protein in a small sample of thyroid cancers and 
Castro et al. [113, 114] confirmed the lack of immunopositivity of NIS protein in 
anaplastic and Hurthle cells.  
It is apparent from these studies that there are discrepancies in the NIS expression 
profile. These reported differences could be due to a number of reasons such as: 
methodologies employed, non-pairing of tumour samples, size of analysed samples, 
lack of information about TSH value in patients and possible use of levothyroxine, 
histological types analysed and finally the complexity of transcritptional and post-
transcriptional processes in the synthesis of NIS. 
 
1.13 TSHR in thyroid tumours 
It is thought that reduced TSHR expression in thyroid cancers may occur as a 
consequence of de-differentiation and it has been shown that loss of TSHR expression is 
usually associated with loss of a number of thyroid differentiation markers. 
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A study by Gerard et al. [115] used immunohistochemistry in order to detect thyroid 
specific markers such as thyroglobulin, T4-thyroglobulin, NIS, penderin, TPO, THOXs 
and TSHR. In this study normal human thyroid tissues were used together with thyroid 
cancer tissue samples. This study concluded that TSHR was expressed not only in 
normal thyroid tissue but also in lower levels in follicular and papillary thyroid cancer 
tissues. It concluded therefore that TSHR was expressed in virtually all cases of thyroid 
tissues. 
Another study used RT-PCR and RNase protective assays to measure the expression of 
NIS, Tg and TSHR mRNA in primary and metastatic thyroid carcninoma tissues [116]. 
The expression of NIS, Tg and TSHR mRNA was studied in 23 cases of papillary 
carcinoma and the expression of NIS mRNA was studied in 7 pairs of primary and 
lymph node metastastic tissues.  The expression of TSHR was detected in all papillary 
carcinoma samples however at lower levels than normal thyroid tissue [116]. 
Matsumoto et al. [117] investigated 15 papillary thyroid cancer tissues, 8 poorly 
differentiated thyroid cancers (which are defined between differentiated papillary 
thyroid cancer and de-differentiated cancer) and de-differentiated (or undifferentiated) 
thyroid cancer using immunohistochemistry.  All papillary thyroid cancer tissues and 
poorly differentiated thyroid cancer tissues expressed TSHR. However the 
undifferentiated (de-differentiated) thyroid cancer tissue did not express the receptor. 
Another group [118] assessed the expression levels of TSHR, Tg and TPO mRNA in 
normal and neoplastic human thyroid tissues, 6 adenomas and 7 carcinomas, were 
investigated by Northern-blot and slot-blot analysis. The authors found that TSHR 
mRNA expression together with Tg mRNA levels were significantly lower in cancer 
tissues than in normal thyroid tissues. These results suggest that TSHR mRNA is 
expressed in relation to their degree of differentiation. Elisei et al. [119] used Northern 
blot analysis to study the mRNA expression of the TSHR, Tg, TPO, and calcitonin (CT) 
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genes in a total of 53 tissues from 30 patients with thyroid carcinoma and from 9 
patients with benign thyroid diseases.  With various degrees of expression, all 
differentiated thyroid carcinomas (20 papillary and 2 follicular) expressed TSH-R, Tg, 
and TPO, but not calcitonin mRNAs. On the contrary, samples from 2 patients with 
anaplastic carcinoma did not express TSHR, Tg, or TPO mRNA, but 1 of them 
expressed calcitonin mRNA. This study concludes that TSHR is expressed in all 
follicular and papillary thyroid cancers and in some medullary thyroid cancers. The 
expression of TSHR in anaplastic thyroid cancer was however lost. 
From the majority of these studies it is clear that TSHR is expressed in most cases of 
thyroid cancer, however there is a trend to its expression decreasing in relation to the 
levels of ongoing de-differentiation of the tumours. It is also noted from looking at these 
different studies that there appears to be discrepancies in the reported levels of 
expression of the TSHR in the different samples of thyroid carcinoma. This could be 
due to the sensitivity of the methodologies employed, differences in the tumour samples 
used in different studies, and differences in the sizes of the tissue samples. 
 
1.14 Use of Monoclonal antibodies for the diagnosis and treatment of cancer.  
Antibodies have a molecular weight of approximately 150 kDa and are composed of 
two polypeptide chains, a heavy chain (50 kDa) and a light chain (25kDa) [120]. The 
two chains are bound together by disulphide bounds. These molecules can be 
proteolytically cleaved to yield two Fab fragments (the antigen-binding part of the 
molecules) and an Fc fragment (the part of the molecule responsible for secondary 
biological functions of the antibody, e.g. the  complement activation).  Both the heavy 
and light chains are divided into V (variable) and C (constant) regions [120]. The V 
regions contain the antigen-binding site and the C region determines the fate of the 
bound antigen (figure 1.9). 
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Figure 1.9: Structure of IgG antibodies. Adapted from [120]. 
 
Antibodies have two main functions in the body. Firstly they recognise and bind with 
high specificity and affinity to a specific target (antigen) usually located in a bacterium, 
virus, or other pathogen but it can also be located on our own tissues. After binding to 
an antigen, they also stimulate a secondary immune response to the antigens (e.g. 
complement activation and phagocytosis) [120].  
The invention of a manufacturing process using hybridomas allowed monospecific 
antibodies to be generated [121].  This procedure has been standardised and applied on 
a massive scale to the preparation of monoclonal antibodies useful for research and 
clinical applications [120]. The basic technology involves fusion of an immortal cell 
with a specific predetermined antibody-producing B cell from immunised animals 
(usually mice). The resulting hybridoma cell is immortal and synthesises homogenous 
specific mAb which can be made in large quantities [121].  
Cancer targeting with monoclonal antibodies have proved advantageous, particularly 
due to the antibody specificity as well as effective manufacturing processes. [122, 123].  
Usually conventional cancer treatment using chemotherapy has produced a number of  
side effects (such as hair loss, fatigue, nausea,vomiting, and depression of the immune 
system) as they also damaged non cancerous healthy cells. Antibody therapy has the 
potential to reduce these side effects by only targeting specific proteins/molecular 
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Light chain 
Variable region 
Constant region of 
heavy chain 
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Antigen binding site 
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pathways that are primarily found in cancer cells [122, 123]. These target 
proteins/molecular pathways in cancer cells should be ideally present in high levels 
[122, 123]. The recent manufacturing process using hybridoma technology followed by 
purification also ensures that mAbs for radiolabelling are homogenous and free of 
contaminants that could compromise their safety and efficacy. 
Attaching radioactive compounds to monoclonal antibodies offer the potential of 
increasing the effectiveness and decreasing the side effects of radiotherapy [124-129]. 
The monoclonal antibodies used in radioimmunotherapy act as vehicles that transport 
the therapeutic radioiosotope to the tumour and these antibodies have cytotoxic effects 
mediated by apoptosis, complement-dependent cytotoxicity (CDC) and antibody-
dependent cellular cytotoxicity (ADCC). Furthermore the characteristics of the antigen 
against which a particular antibody is directed determines, in most cases, the efficiency 
of both the antibody and the directed radiation. In this way, the choice of antibody, 
target antigen and radioisotopes are critical for the success of radioimmunotherapy [124, 
125]. 
The ideal radiopharmaceutical should after i.v injection, travel to target cells and 
interact exclusively with the desired protein, then quickly be excreted from the body 
[123, 126, 127]. A successful radioimmunopharmaceutical should be retained in the site 
of the tumour in enough quantities and for long enough in order to destroy the tumour. 
The success of a radioimmunopharmaceutical depends on five main parameters: 
physical characteristics of the radionuclide, access to the tumour, specificity of the 
antibody, affinity of the antibody, and in vivo stability of the radionuclide in the site of 
tumour.  The specificity of radiolabelled monoclonal antibodies is determined mainly 
by the antigens that they are directed against, which should be specific to the tumour 
with minimal or no expression in non cancerous tissues. However, in practice, the 
majority of antibodies are not solely specific to the tumour. This means that epitopes to 
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which the antibody binds are also expressed on the surface of non tumour cells, organs 
and tissues (depending on the antigen), although usually in smaller percentages or 
reduced numbers [124]. 
The first radiolabelled monoclonal antibody to be approved by the FDA for the 
diagnostic imaging of cancer was an 111In labelled monoclonal antibody, CYT-103 
(OncoScint OV/CR). CYT-103 is a murine monoclonal antibody (mAb) that binds to 
TAG-72, a cell surface antigen expressed at high levels on the majority of colorectal 
and ovarian adenocarcinomas.  111In CYT-103-mAb imaging in patients with suspected 
recurrent colorectal carcinomas prevents many patients from undergoing unnecessary 
surgery.  
So far, two radiolabelled antibodies have been approved by FDA for the treatment of 
non-Hodgkins lymphoma, 131I-tositumomab (Bexxar) from Corixa Corporation and 90Y- 
tiuxetan-ibritumomab (Zevalin) from Schering corporation [128, 129]. Both are murine 
mAb and target the CD20 antigen expressed on the surface of normal and malignant B 
lymphocytes [128-131]. These radiolabelled antibodies have proved very successful in 
comparison with chemotherapy and unlabelled mAbs [128-131].  
Antibodies can also be conjugated to drugs or toxins to make them more effective.  
For example, a recombinant anti-CD33 monoclonal antibody attached to the cytotoxic 
anti-tumour antibiotic calicheamicin (Mylotarg, Wyeth pharmaceuticals) has recently 
been approved by the FDA  for the treatment of Acute Myeloid Leukemia. After 
binding to the cancer cells, the anti-CD33 antibody- calicheamicin conjugate is 
internalised and the toxin binds to the minorgroove of DNA, causing double strand 
DNA breaks and resulting in inhibition of DNA synthesis, which leads to cell death 
[132-135].  
Although antibody-based therapy has proved successful, some problems have been 
encountered [122, 136]. One problem was the murine origin of most mAbs, which 
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caused the immune systems of patients to recognise them as foreign proteins and 
therefore inactivate them by stimulating host anti murine immune response. This anti 
murine immune responses may induce severe side effects such as nausea, chills, 
diarrhoea, vomiting, headache, seizures and coma. This problem was solved by the 
production of chimeric antibodies, in which mouse framework regions are replaced with 
human sequences [122, 136-138].  
Another problem was the large size of mAbs which prevented them from being 
effectively distributed to certain tumours. It also resulted in them being cleared out at a 
slow rate from the body [122, 136, 137]. This was solved by creating smaller sized 
antibodies containing only the binding site region, Fab. The enzyme papain can be used 
to cleave a whole antibody into Fab fragments [122, 136, 137]. 
Also, variable regions of the heavy and light chains can be fused together by 
recombinant techniques to form a single variable fragment chain (scFv), which is only 
half the size of the Fab fragment but still retains the specificity of the antibody [122, 
136, 137]. 
 
1.15 TSHR as a potential new target for the diagnosis and treatment and of 
radioiodine resistant thyroid cancer 
TSHR ligands can potentially be used as imaging agents for thyroid cancer or to deliver 
drugs to cancer cells expressing TSHRs. TSHR ligands can also be used as probes to 
define the molecular mechanism of TSHR activation, that is, the conformational 
changes that mediate conversion of inactive to active states of TSHR. A number of 
different potential TSHR ligands have been developed, including TSH analogs, 
antibodies and small-molecule compounds.  
While most de-differentiated thyroid carcinoma lose expression of NIS, some  do 
continue to express thyroid hormone stimulating receptor (TSHR) [46, 47]. TSHR is 
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therefore a potential target for the diagnosis and treatment of metastatic recurrent de-
differentiated thyroid carcinoma.  
 
1.16  mab9 monoclonal antibody 
mAb9 anti-TSHR antibody was developed by Gilbert et al. from an experimental 
murine model of hyperthyroid Graves’ disease that exhibit potent thyroid-stimulating 
activity [139]. Graves’ disease is an organ-specific autoimmune disorder characterised 
by a variety of circulating antibodies, including common autoimmune antibodies, as 
well as anti ̶ thyroid peroxidase (anti-TPO) and antithyroglobulin (anti-TG) antibodies. 
The most important autoantibody in Graves disease is thyroid-stimulating 
immunoglobulin (TSI).  These autoimmune stimulatory IgG antibodies  bind and 
activate the TSHR [140, 141], reproducing the same actions of TSH on the thyroid. 
These thyroid-stimulating stimulatory antibodies cause release of thyroid hormone and 
thyroglobulin that is mediated by cyclic AMP, and they also stimulate iodine uptake, 
protein synthesis, and thyroid gland growth.  As a result, iodide trapping by the thyroid 
increases, the synthesis and secretion of both T3 and T4 increase, and the thyroid grows 
in size producing a goiter. If untreated, the affected individual becomes hyperthyroid.   
mAb9 monoclonal antibody was developed by injecting Balb/c mice with a recombinant 
adenovirus expressing the TSHR A-subunit and then selecting antibodies with the 
highest thyroid stimulating activity levels for hybridoma production [139]. 
mAb9 (KSAb1) and another antibody KSAb2 were selected due to their ability to 
inhibit TSH binding. The H and L chain subtypes for mAb9 and KSAb2 were shown to 
be IgG2b and IgG2a, respectively [139].  Both these antibodies were then tested to 
determine their thyroid stimulating activity, their ability to block of TSH-mediated 
stimulation (TSBab) activity, their ability to compete with 125I-TSH for the binding of 
TSHR, as well as their ability to stimulate cAMP [139]. In vivo studies were also carried 
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out to assess the ability of both antibodies to induce hyperthyroidism [139]. The thyroid 
stimulating activity was measured with cAMP assays which determined the ability of 
both antibodies to stimulate cAMP production in CHO cells stably transfected with 
human TSHR (JP09 cells) [139]. Both antibodies showed full agonist activity by 
achieving near maximal cAMP stimulatory responses. The ability of mAb9 and KSAb2 
IgG to block TSH-mediated stimulation of cAMP in TSHR expressed JP09 cells was 
measured [139]. mAb9 showed negligible thyroid stimulating blocking antibody 
(TSBAb) activity. Competition assays using TRAK II DYNO test human kits (tubes 
pre-coated with the TSHR) showed that 100 ng/ml of both antibodies was sufficient to 
inhibit 95% of 125I-TSH binding [139]. Saturation assays performed in the coated tubes 
with 125I radiolabelled mAb9 and KSAb2 were also performed and showed that both 
bound TSHR with high affinities of 4.5 x 1010 litre/mol and 6.25 x 1010 litre/mol [139].  
Passive transfer studies on mAb9 and KSAb2 IgG were also performed in which 10 or 
100 µg of both antibodies were injected i.v into mice, and the induced 
hyperthyroxinemia was measured [139]. This study concluded that these antibodies 
induced rapid hypersecretion of thyroxine, leading to hyperthyroidism with 
considerable morphological changes but with minimal mononuclear cell infiltrate in the 
thyroid glands [139].  Due to these characteristics, and particularly the ability of mAb9 
to bind with high affinity to TSHR, mAb9 was used in this study as a potential 
candidate to target the TSHR. 
 
1.17 4C1 monoclonal antibody 
4C1 is a commercially available IgG2b mouse monoclonal anti-TSHR antibody. 4C1 
cross reacts with human TSHR and it is predicted to also react with rat, pig, sheep, 
mouse, dog and cat TSHR. 4C1 binds to the native TSHR protein and studies showed 
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binding  to residues 378-384 of the human TSHR. 4C1 antibody has been successfully 
used in immunohistochemistry and FACS studies to detect human TSHR [34].  
4C1 was generated with recombinant ECD produced in e.coli [34]. 4C1 antibody 
inhibited the binding of 125I-TSH by an order of 70-80% at 1 µg/ml however it did not 
stimulate cAMP production in human TSHR expressing cell lines. FACS studies also 
determined that 4C1 antibody bound to hTSHR [34]. This antibody was used as a 
positive control anti-TSHR antibody in this study. 
 
1.18 Overview of thyroid cancer and TSHR expressing cell lines used 
Cell lines are important tools to study mechanisms involved in cancer as well as to serve 
as pre-clinical models to assess the efficacy of novel therapies. Cell lines have the 
advantage of growing in cultures for long periods of time and hence being able to 
generate high volumes of research material. They can also be used in genetic 
manipulation studies, and for both in vitro and in vivo (xenografts) studies. Over the 
years, a number of thyroid tumour cell lines derived from different pathologic origins 
have been developed, including  differentiated follicular carcinomas (FTC), papillary 
thyroid carcinomas (PTC) and de-differentiated highly aggressive anaplastic carcinomas 
(ATC). However a disadvantage that is associated with cell lines is that they lose their 
original phenotype. An additional problem is that some cell lines develop different 
phenotypes from cells in the in vivo tumours and current estimates indicate that 18 to 
36% of cell lines are cross-contaminated or misidentified, including cell lines within the 
original supposedly reliable source [142-145].  
 
1.18.1 FTC-133 
The FTC-133 cell line was obtained originally from a lymph node metastasis of a 
differentiated follicular thyroid carcinoma from a 42-year-old male [146]. Their 
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morphology differs from flat polygonal to spindle shaped cells.  These cells could be 
propagated in serum free medium, contained thyroglobulin and EGF receptors, lacked 
any fibroblast contamination, and responded to TSH and local active growth factors 
such as EGF and IGF with a stimulated (3H)thymidine incorporation [146]. They were 
shown to retain differentiated thyrocyte function and responsiveness to TSH.  
TSH was also shown to have the same stimulatory effects on metabolism, DNA 
synthesis and cell growth in FTC-133 cells  as is observed in human endogenous 
thyrocytes.  FTC-133 cells proved therefore to be of particular value in assessing the 
thyrotrophic effects that TSH stimulates in thyroid cells.  Schweppe et al. used standard 
tandom repeat (STR) genetic analysis to compare their obtained profile for a number of 
selected thyroid cancer cell lines to those in cell lines databases (e.g. ECACC) [147]. 
This study found that FTC-133 profile was consistent with that of ECACC database.  It 
also concluded that the FTC-133 cell line is unique and expressed high levels of Pax-8 
and TTF-1 transcription factor mRNA, which confirmed the human thyroid origin. 
Paired box gene 8 (Pax-8) and thyroid transcription factor-1 (TTF-1) are specifically 
involved in thyroid development  and are also involved in the regulation of the 
expression of thyroid-specific genes. Pax-8 and TTF-1 are used as markers of thyroid 
cancer cell lines because they are mainly found in thyroid cancer cells. 
 
1.18.2 TPC-1  
The TPC-1 cell line was obtained originally from a differentiated papillary thyroid 
carcinoma. This cell line was initially shown to retain differentiated thyrocyte function 
and thyrocyte responsiveness to TSH.  Schweppe et al. found TPC-1 cell lines to 
harbour Pax-8 mRNA however unlike FTC-133 cells, TTF-1 mRNA was not detected. 
These results supported that TPC-1 cell lines were of thyroid origin.  In another study 
[148], as was observed with the Schweppe study [147], Pax-8 thyroid transcription 
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factor was also detected in TPC-1 cells lines, however, in contrast with the Schweppe 
study, a small amount of TTF-1 expression was also detected. The cells were also found 
to contain a large number of chromosomal abnormalities, which suggests that this cell 
line although being of thyroid origin has most likely acquired characteristics of fully de-
differentiated thyroid cancer cells.  
 
1.18.3 FRTL5 
The Fischer Rat derived thyroid cell line, FRTL-5, represents one of the best available 
in vitro models for studying thyroid specific proteins in a native thyroid cell line. The 
FRTL-5 cell line is a widely used model for normal thyroid function as these cells show 
responsiveness to TSH over a long period of time and also TSH stimulated iodide 
uptake, thyroglobulin (Tg) iodination and thyroid hormone secretion [149].  FRTL-5 
cells  exhibit a TSH-responsive adenylate cyclase, ion flux and phospholipid metabolic 
shift as well as an absolute growth requirement for TSH. These cells can lose their 
diploid characteristics while retaining functional characteristics, for a period of at least 1 
year. However, after variable time periods, these non-diploid cells can lose 
responsiveness to TSHR autoantibody stimulators. Therefore, the uniformity of the 
FRTL-5 cells needs to be confirmed by monitoring of the thyroid markers. 
FRTL-5 cells are useful in three main assays. Firstly, they are employed to detect 
thyroid stimulating autoantibodies and immugobulin Gs present in the patients with 
Graves’ disease by measuring the increase in cAMP levels [150, 151].  Secondly, they 
have been described to effectively measure the uptake of iodine, and thereby they have 
been used to measure the growth stimulatory or inhibitory activity of IgG preparations 
from patients with autoimmune thyroid disease by determining labeled thymidine 
uptake [150, 151].  
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1.18.4 GPI 
In these cells, TSHR  extracellular domain (ECD) is expressed in isolation on the cell 
surface of CHO cells with the use of a glycosylphosphatidylinositol (GPI) anchor 
sequence [152]. The GPI anchored ECD was recognised by experimental and 
pathological antibodies. Flow cytometry studies showed that the ECD was expressed at 
10-fold higher levels than the highest expressing full length receptor clone [152]. 
Additionally, radioligand studies showed that the anchored ECD bound TSH with a 
high affinity similar to the full length TSHR [152]. This cell line proved to be useful in 
studying structure function relationships of TSHR as well as interactions of TSH, and 
anti-TSHR antibodies and autoantibodies with the TSHR [14, 153, 154]. 
 
1.19 Radiopharmaceuticals and cancer 
Radiopharmaceuticals include any radiolabelled molecules that are used in the diagnosis 
and treatment of diseases. These radiolabelled molecules are designed to deliver 
diagnostic and therapeutic doses of ionising radiation to target sites within the body. 
Radiopharmaceuticals have the ability to kill cells through radiation and to emit 
radiation with sufficient energy and quantity to be detected externally. For this reason, 
radiopharmaceuticals can be useful in the diagnosis and treatment of cancer [155, 156].  
The radionuclides of major interest in nuclear medicine are the ones with short half-
lives.  Several radionuclides are used to diagnose and treat diseases and conventional 
nuclear medicine began with applying 131I (half life of 193 hours), exclusively to study 
the thyroid gland and it was later used in the radiolabelling of a number of 
radiopharmaceuticals. Another commonly used marker is 111In (half life of 67 hours). 
111In allows for sequential imaging to be obtained over a period of a few days as well as 
it plays an important role in the evaluation of inflammatory diseases (such as leucocytes 
with 111In) as well as in imaging with antibodies and peptides. 67Ga (half life of 78 
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hours) is now widely used to trace tumours and infection sites, while 201Tl (half life of 
73 hours), is an agent used in myocardial scintigraphy.  The most used radioisotope in 
nuclear medicine is 99mTc (half life of 6 hours) due to its favourable decay 
characteristics, it easy production in generators and its ability to radiolabel various 
molecules [155, 156].  
 
1.19.1 Radiopharmaceuticals for therapy 
Radiopharmaceuticals used for therapeutic purposes should be able to selectively 
destroy the tissue of interest.  The design and selection criteria for therapeutic 
radiopharmaceuticals include; half-life, the types of emission (α, β, γ, auger or 
conversion electrons), specific activity, chemistry, internal dosimetry, intra-tumour 
distribution, pharmacokinetics of the radiopharmaceutical and size of the tumour [156]. 
In addition to their biological, physical and chemical properties, radiation safety, 
energy, cost of production and availability should also be taken into account when 
selecting suitable radiopharmaceuticals for therapeutic use [156]. The half life of the 
radionuclide should be in a range of hours to days for clinical applications. If the half-
life is too short, there is not enough time to prepare the radiopharmaceutical for 
administration to the patient, as most of the decay will have occurred before the 
compound reaches the target tissue.  On the other hand, if the half-life is too long the 
radiopharmaceutical can be metabolised/excreted, and also the number of 
disintegrations occurring at the target would be too low, which would result in an 
insufficient radiation dose being delivered to the tumour [156]. 
The specific activity of the radionuclide determines the mass of compound needed to 
achieve the desirable activity to perform the study. The molecular weight should be 
ideally be low and the specific activity high. If the specific activity is low only a small 
proportion of the administered molecules will be radioactive [156]. The nature of the 
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particle emission is also important to consider to ensure maximum therapeutic 
effectiveness. β-particles, α-particles and auger electrons all have different effective 
ranges and linear energy transfer (LET) properties. LET describes the rate at which 
energy is transferred from ionising radiations to soft tissue. The unit that quantifies LET 
is kiloelectron volts of energy transferred to soft tissue per micrometer of length 
traveled (keV/µm).  
A β-particle is an electron emitted from the nucleus of a radioactive atom. β-particles 
are most widely used in targeted radiotherapy and have the advantage of relatively low 
homogeneous radiation doses but produce lower ionisation density and high LET [156]. 
The chemical properties of a radionuclide are also very important, because they 
determine if the radionuclide would easily label the molecules. 
Radiation damage can result from direct ionisation of the DNA molecule, or some other 
cellular component critical to the survival of the cell. Such an interaction may affect the 
ability of the cell to reproduce and, thus, survive. If enough atoms are affected such that 
the chromosomes do not replicate properly, or there is a significant alteration in the 
information carried by the DNA molecule, then the cell may be destroyed. However, in 
clinical therapy, damage is most commonly caused by indirect ionisation via free-
radical intermediaries formed from the radiolysis of cellular water. Radiation can also 
affect the processes of the cell cycle necessary for cell growth, cell senescence, and 
apoptosis [156]. 
 
1.19.2 Diagnosis 
Radiopharmaceuticals used in diagnosis should be either gamma emitters or positron 
(B+) emitters, because their decay generates electromagnetic radiation that can penetrate 
the tissues and this radiation can be detected and used to image [156]. The energy of the 
photons should be between 50 and 600 KeV.  
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Photons with very low energy (lower than 50 keV) have a greater chance of interacting 
with the body, and not being detected externally [156].  The radiopharmaceuticals used 
for diagnostic proposes may be classified into perfusion radiopharmaceuticals and 
target-specific radiopharmaceuticals. Perfusion radiopharmaceuticals are transported in 
the blood and reach the target tissue in proportion to blood flow. They do not have 
specific sites of binding and are thought to be distributed according to size and charge. 
Target-specific radiopharmaceutical are directed by biologically active molecules, such 
as antibodies and peptides that bind to cell receptors or are transported into cells [156]. 
 
1.19.2.1 Positron emission tomography (PET) 
PET is a diagnostic technology which produces 3-D and CT images of the distributrion 
of positron emitters in the body. A tumour-targeting radiotracer is intravenously 
injected, and upon targeting the cancer, it emits positrons. A positron is a particle 
equivalent to an electron, however with positive charge. The collision of a positron with 
an electron causes the release of two gamma photons at 180° to each other. This 
coincidence of events can be detected, reconstructed and analysed to determine the 
location and concentration of radiation within the body. The subtracts targeted by the 
radioiosotopes in PET include cellular metabolic substracts, drugs, antibodies, 
neurotransmitters and other biologically active molecules [157, 158]. The images 
obtained provide information on blood flow, glucose metabolism, amino acid transport, 
neuroreceptors, oxygen consumption, amongst others. 
The most common radiotracer in use is fluorine-18 bound to fluorodeoxyglucose [18F]-
(FDG). This tracer is a glucose analogue that is taken up by glucose-using cells 
(elevated in rapidly growing malignant tumours). As a result, FDG-PET can be used for 
diagnosis, staging, and monitoring treatment of cancers, particularly in Hodgkin's 
lymphoma, non-Hodgkin lymphoma, and lung cancer [159]. 
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1.19.2.2 SPECT/CT 
Single photon emission computed tomography (SPECT) has enabled the evaluation of 
disease processes based on functional and metabolic information of organs and cells. In 
SPECT, a single gamma-ray is emitted per nuclear disintegration.  SPECT images are 
produced from multiple 2D projections by rotating one or more gamma cameras around 
the body to achieve complete 360° angular sampling of photons from the body. 
Reconstruction using methods similar to those used in X-ray CT provides 3D data sets 
allowing the tracer biodistribution to be displayed in orthogonal planes [160].  
Because SPECT acquisition is very similar to planar gamma camera imaging, the same 
radiopharmaceuticals may be used. Integration of X-ray computed tomography (CT) 
into SPECT has recently emerged as a useful diagnostic tool in medical imaging, where 
anatomical details may complement functional and metabolic information [160]. 
 SPECT/CT can be used in a range of malignancies such as prostate, lung, brain and 
neuroendocrine tumours as well as bone lesions and infections. In cardiology, SPECT is 
used to assess the viability of the heart muscle to help differentiate between ischaemia 
and infarction. In the brain SPECT is used to measure cerebral blood flow and brain 
patency in patients with stroke and tumour. Liver disease can be imaged using SPECT 
to determine the existence of sarcoma, hepatic tumour, haemangioma, metastases, cysts, 
glycogen storage disease, and Menetrier’s disease. In the lung, radioisotope imaging is 
carried out most commonly to measure the ventilation and perfusion status of the lung.  
PET cameras have the advantage over SPECT cameras of being more sensitive and 
possessing higher resolution. There is also higher flexibility to incorporate positron 
emitters into biomolecules, while PET’s main disadvantage is its higher cost as well as 
the need for a nearby cyclotron. The SPECT system offers significant advantages 
relating to price, smaller size, ease of installation and the application of a large variety 
of procedures performed in nuclear medicine [160]. 
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1.20 SPECT and SPECT/CT in thyroid cancer 
Planar 131I scintigraphy is routinely used to detect radioiodine avid metastases of 
differentiated thyroid carcinoma (DTC). However, the modality has limitations, such as 
low sensitivity and lack of anatomic landmarks. The use of radioiodine-131 (131I) single 
SPECT/CT after thyroidectomy for thyroid cancer offers improvement over planar 
scans in detecting metastases, and can potentially be used to guide disease management. 
SPECT/CT can also avoid additional imaging tests for thyroid cancer evaluation and 
prompt changes in risk classification and treatment management among intermediate- 
and high-risk patients, according to a study [161, 162]. SPECT/CT has also been found 
to be useful in detecting thyroid cancer lymph node metastasis early [163]. Researchers 
were also able to accurately distinguish between cancerous cells in regional lymph 
nodes and normal residual thyroid tissue directly after surgery with SPECT/CT (figure 
1.10) [164]. 
 
Figure 1.10: (A) SPECT/CT in thyroid cancer. The planar scan post-radioiodine ablation of thyroid 
remnants shows radioiodine-avid tissue in the neck of a patient after total thyroidectomy, without the 
possibility of discriminating 131I uptake in remnant normal thyroid parenchyma from possible lymph node 
metastasis. (B) SPECT/CT demonstrates two cervical lymph nodes in this patient (arrows) that cannot be 
differentiated from benign remnant tissue in the planar scan [164]. 
 
1.21 SPECT/CT in small animal research 
Non invasive imaging of molecular events and interactions in living small animal 
models using small animal SPECT/CT has gained increasing importance in researching 
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novel drugs and radiopharmaceuticals. The main advantages of this technology are 
quantitative accuracy independent of location in the subject body, and direct translation 
to human clinical setting. Also, imaging with small animal SEPCT/CT can substantially 
reduce the number of animals needed in order to obtain statistically significant data as 
well as the study in detail the biodistribution/kinetics of 
radiopharmaceuticals/radiotracers in tumour-bearing animal models [165]. 
The NanoSPECT system (Bioscan) uses a patented multiplexed, multipinhole SPECT 
technology that allows the system to operate in the sub-millimeter resolution range 
required to image small animals such as mice [166]. Instead of acquiring images 
through a single pinhole, NanoSPECT acquires images through thirty six or smaller 
pinholes. The use of small pinholes ensures high resolution (<1mm) while the 
projection of images through multiple pinholes simultaneously ensures high detection 
sensitivities [166]. Due to this approach, NanoSPECT manages to produce high 
resolution and high sensitivity images. To help locate tumours in the animal body, 
SPECT can be combined with CT. Numerous animal studies have been performed with 
a wide range of applications using nanoSPECT/CT technologies [165]. Animal studies 
are carried out by injecting an animal (usually mice) with the radiopharmaceutical 
(usually 37 MBq or less), placing it in the SPECT bed then collecting projections 
(typically 16 to 64) with an aim of 2 million total counts. Mice are imaged with a radius 
of rotation near 30 mm. The data acquired can be transferred to images or video 
formats, allowing for visualisation of the behaviour of the ligand in vivo over prolonged 
time points (figure 1.11).  NanoSPEC/CT can be routinely used to image and to 
quantify NIS activity in mouse thyroids. Previous studies used 99mTc and 123I to quantify 
the uptake of iodine via NIS into the thyroid of mice [167].  
In this study SPECT/CT was used for in vivo imaging studies with both radiolabelled 
mAb9 and radiolabelled rhTSH. 
  
 
 
Figure 1.11: NanoSPECT/CT imaging. After administering a radiopharmaceutical or tracer the single 
photon emissions are projected through multi
from [168]. 
 
1.22 Radioiodination of monoclonal antibodies and peptides
A number of methods can be employed in the ra
antibody fragments and peptides. 
Compounds can be directly radiolabelled through electrophilic oxidative substitution 
reactions that are catalysed by either oxidising agents, such as Iodogen or chloroamine 
T, or by enzymes, such as lactoperoxidase
given below. 
Almost all proteins can be radiolabelled with 
which has a half life of 60 days and which emits gamma ra
-pinholes on four detectors surrounding the mouse.
 
dioiodination of proteins, antibodies, 
 
 [169]. An overview of these reactions are 
125I, the radioactive isotope of iodine 
diation of 35 KeV
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The iodination is achieved by substituting a hydrogen atom on the phenyl ring of the 
tyrosine by one atom of oxidised iodine, via the activation of the ortho position of the 
aromatic ring of the tyrosine [169]. Additionally, 125I can also be incorporated 
chemically and enzymatically into lysine, histidine amino acids in proteins or antibodies 
[169]. 
125I is a gamma emitter, and for that reason it can be counted directly in a gamma 
counter without the need for sample preparation in contrast with beta emitting 
radionuclides such as 3H and 14C. For most purposes, it is essential to have the labeled 
species as pure as possible. However most radioiodinated compounds after the 
radioiodination procedure will contain some proportion of components such as 
unlabeled protein, free radioiodine, mineral salts and enzyme (in the case of 
lactoperoxidase). It is therefore important to apply purification methods to the 
radioiodinated compound before using it [169]. 
 
1.22.1 Radioiodination using Chloramine T 
Radioiodination with chloramine T (N-chloro-p-toluene sulphonamide) is rapid and 
efficient. Chloramine T oxidises iodide into iodine, which reacts in turn with tyrosine 
and histidine residues of proteins (figure 1.12) [170]. With chloramine T, the iodination 
reaction is usually stopped by adding free tyrosine and sodium metabisulfite to the 
reaction mixture, which reduces the volatile iodine to iodide. The disadvantage of 
chloramine T is that some proteins may be oxidised in this process. 
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Figure 1.12: Iodination by Chloramine T. Iodide is oxidised to iodine (I2),which reacts with tyrosyl and 
histidyl side chains of proteins. Adapted from [170]. 
 
1.22.2 Iodogen 
Iodogen allows efficient incorporation of iodide and can be used with a great variety of 
proteins producing a stable labelling agent that remains stable for at least  3 months 
[171]. 
In this procedure, the oxidant iodogen (1,3,4,6-tetrachloro-3alpha,6alpha-
diphenylglucoluril) is coated into a reaction vessel. A solution containing iodide and the 
target protein is then added to the vessel. Once added to the vessel, iodogen oxidises the 
iodide in the solution to free iodine (I2) , which in turn reacts with tyrosine and histidine 
residues on the protein  in the solution (Figure 1.13) [171]. 
 In some sensitive proteins this oxidation can decrease the biological activities of the 
protein. However, antibodies are not generally affected by this oxidation, and therefore 
this method is often useful for antibody labelling.  
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Figure 1.13: Iodination by Iodogen. Iodogen oxidises iodide to iodine, which then reacts with tyrosine 
and histidine residues of the protein. Adapted from  [171]. 
 
1.22.3 Lactoperoxidase 
This method, introduced by Marchalonis [172], employs lactoperoxidase in the presence 
of a trace of hydrogen peroxide to oxidise radioactive iodide to produce the reactive 
species I2 or I+. These reactive species substitute mainly into tyrosine residues of the 
protein, although substitution into other amino acid residues can occur under certain 
conditions (figure 1.14). Hydrogen peroxide can be obtained from a chemical stock or 
can be produced enzymatically, usually by using glucose oxidase. The oxidation can be 
stopped by simple dilution. This technique usually results in less denaturation of 
susceptible proteins than the chloramine T method, however it is sometimes technically 
demanding. 
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Figure 1.14: Iodination using Lactoperoxidase. Lactoperoxidase catalyses the oxidation of iodide to 
iodine in the presence of the oxidant hydrogen peroxide (H2O2). Adapted from [172]. 
 
1.23 Radiolabelling by conjugation 
Metallic radioisotopes such as 111In, 90Y, 67Ga do not form strong covalent bonds  with 
protein structures and therefore they cannot be used to directly label the protein.  
Techniques can however be used to indirectly complex these radioisotopes to proteins 
with the use of bifunctional agents [173]. In these techniques, proteins are first tagged 
by conjugating a suitable chelating agent to the protein that has a high affinity for one of 
the aforementioned radioisotopes. 
A number of chelating agents have been developed and their chelating properties 
depend on the structure and lipophilicity that the chelating agents take up after being 
complexed to a protein.  Ideally the chelator must form stable complexes with the 
radioisotope of interest, strong enough so that the complex does not dissociate in 
biological setting in which it will be used. It must also be possible to react the chelator 
with the protein without adversely affecting its chelating properties. 
The first bifunctional  chelating agents to be used were introduced by Sundberg and 
Meares [174]. These agents are EDTA (Ethylenediaminetetraacetic acid) and DTPA 
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(diethylene triamine pentaacetic acid). These compounds have been used extensively 
and form stable complexes with 111In, 67Ga and 90Y. However, administration of some 
DPTA conjugated 90Y radiolabelled monoclonal antibodies to humans has been shown 
to lead to hematopoietic toxicity due to detachment of 90Y from the antibody and 
subsequent absorption of free 90Y into the skeleton [175]. In the late 1990s other 
chelating agents became available, the macrocyclic compounds known as 1,4,7-
triazacyclononane-N,N',N''-triacetic acid (NOTA), tetraazacyclododecanetetraacetic 
acid (DOTA), diethylene triamine pentaacetic acid (modified DTPA) and 1,4,8,11-
tetraazacyclotetradecane (TETA) [176, 177]. 
DOTA  is a bifunctional chelating agent that is commonly used as to conjugate a 
number of different radioisotopes to proteins including  radioisotopes that emit photons 
such as 111In and 67Ga, radioisotopes emitting positrons such as 68Ga, 86Y, 64C and beta 
emitting 90Y. DOTA has previously successfully been used to conjugate a number of 
peptides [178] including octreotide (DOTA-d-Phe(1)-Tyr(3)-octreotide) , lanreotide 
(DOTA-lanreotide), and vapreotide (DOTA- vapreotide).  DOTA complexes are more 
thermodynamically and kinetically stable than the DTPA (diethylenetriaminepentaacetic 
acid) complexes.  However, DOTA has the disadvantage of requiring a degree of 
heating to aid their formation, whereas the less stable DTPA complexes can be formed 
at room temperature. In this project, Scn-Bz-DOTA was conjugated to mAb9 and then 
radiolabelled with 111In (figure 1.15). 
 
  
Figure 1.15: Schematic representation of 
 
1.24 Scope of project
Radioiodine resistant de
treat. Survival rates are poor due to the lack of uptake of radioactive iodine, making it 
impossible to stage and treat the disease with conventional radioactive iodine therapy.
The rationale behind this project was to produce a radiopharmaceutical that would bind 
specifically to the TSHR, which has been shown by some papers to still be expressed in 
a number of de-differentiated thyroid cancers that have lost the ability to take 
radioiodine into the tumour via NIS. 
Ideally this radiolabelled compound would show robust binding to the TSHR, both 
vivo and in vitro, and after an 
thyroid or grafted thyroid tumours, clear 
targeting of the cancer for diagnostic and therapeutic proposes.
111In labelling of ScnBzDota-antibody.
 
-differentiated thyroid cancer remains difficult to diagnose and 
 
i.v injection, bind specifically to TSHR expressed in the 
the circulation rapidly and allow effective 
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The main aims of this project were three fold. The first aim of the project was to 
determine the level of expression of the TSHR in a number of different thyroid cancer 
cell lines in vitro. The second aim was to radiolabel mAb9 monoclonal antibody and 
subsequently rhTSH. The final aim of the project was to determine the binding affinity 
of radiolabelled mAb9 and rhTSH to TSHR expressing cells initially in vitro and then to 
the thyroid of mice, and to thyroid tumours grafted into mice. 
 
1.25 Hypothesis 
The hypothesis behind this project is that de-differentiated thyroid cancer cells continue 
to express TSHR, and therefore that the TSHR can be used to target radioiodine 
resistant thyroid cancer. 
The hypothesis behind the mAb9 antibody chapter is that this high affinity radiolabelled 
anti-TSHR monoclonal antibody will bind to the TSHR in vitro in a number of 
differentiated human thyroid cancer tumours and in vivo in TSHR positive xenografted 
tumours and the thyroid of mice and thus can be of suitable use for the diagnosis and 
treatment of radioiodine resistant de-differentiated thyroid cancer. 
The hypothesis behind the rhTSH chapter is that this well established peptide will bind 
to TSHR both in vitro and in vivo and thus can be potentially used in the diagnosis and 
treatment of radioiodine resistant de-differentiated thyroid cancer. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 MATERIALS 
 
Reagent  
 
Supplier  
0.25% (w/v) Trypsin – 0.53 mM EDTA solution  Cambrex  
10x Tris/Glycine/SDS buffer  electrophoresis grade  National Diagnostics  
2x TY media  Cancer Research UK  
3,3’,5,5’-tetramethylbenzidine (TMB)  Sigma-Aldrich  
4C1 anti-TSHR monoclonal antibody 
A 
Acetone  
Acetonitrile – HPLC grade 
Abcam, UK 
 
VWR 
Aldrich Chemicals Co. 
Agarose Sigma-Aldrich 
Albumin, bovine Sigma-Aldrich  
Ammonium persulfate Sigma-Aldrich 
B  
Beta-mercaptoethanol  
 
VWR  
Brilliant blue R staining  Sigma-Aldrich  
Bovine serum albumin (BSA)  
SuperScript® III first-strand synthesis system  
C 
CHO (Chinese hamster ovary cells)  
F  
Foetal bovine serum  
First strand cDNA synthesis Kit  
FTC-133 cells 
G 
D-(+)-Glucose (>99.5%) 
Glycerol  
Glycine (>99%)  
Goat anti-mouse alexa488 IgG  
GPI cells  
H  
HEPES buffer 
Hydrogen peroxide (30%)  
I [125I]  
ITLC-silica gel 
L  
Sigma-Aldrich  
Invitrogen 
 
Clare Hall, Cancer Research 
 
Invitrogen  
Invitrogen  
Paul Banga, King’s College 
 
Sigma-Aldrich 
VWR  
Sigma-Aldrich  
Invitrogen  
Paul Banga, King’s College  
 
Sigma-Aldrich  
VWR  
Perkin Elmer 
 Pall 
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L-glutamine 
M 
mAB9 anti-TSHR monoclonal antibody 
Marvel milk powder 
Methanol (HPLC grade >99%) 
MKN45 (human gastric adenocarcinoma cells) 
Sigma-Aldrich 
 
Kindly provided by Dr. Paul Banga 
Premier International Food Ltd  
BDH Laboratory  
Clare Hall, Cancer Research 
Monoclonal anti-mouse IgG (whole molecule 
peroxidase)  
Mouse monoclonal anti-human GAPDH control 
Nitrocellulose membrane 
P 
Para-formaldehyde 
Phosphate-buffered saline (PBS) 
Pierce iodination tubes 
Polyacrylamide  
PR1A3 monoclonal antibody 
Precision plus protein standard 
Protease inhibitors cocktail set I  
Protein assay kit  
R 
rhTSH 
S 
Slide-A-lyzer dialysis cassettes 
Sodium [125I]-iodide 
Sigma-Aldrich  
 
Abcam, Cambridge 
BDH Laboratory  
 
Sigma-Aldrich 
Cancer Research  
Pierce 
National Diagnostics Ltd 
Nuclear medicine Barts hospital, London 
BioRad  
Calbiochem  
BioRad  
 
Genzyme, UK 
Pierce  
Perkin Elmer 
T 
Tetramethylethylenediamine (TEMED) 
TPC-1 (thyroid papillary carcinoma cells) 
Taq polymerase  
Triethylamine (>99.5%)  
Trifluoroacetic acid (TFA) (>(99.5)  
Tween 20 
 V 
Versene 
E3MM Blot paper 
 
 
GE Healthcare 
Paul Banga, King’s College London 
Invitrogen  
VWR  
Thermo Scientific  
Sigma-Aldrich 
 
Cancer Research UK 
Whatman International Ltd 
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2.2 Methodology 1 (this methodology relates to the mAb9 results section) 
 
2.2.1 Size Exclusion High Performance Liquid Chromatography (HPLC) 
 to confirm the purity of mAb9 antibody 
10 µl of mAb9 (1 mg/ml) (kindly provided by Dr. Paul Banga, King’s College London). 
was injected into an high performance liquid chromatography (HPLC) system with a 
size exclusion Phenomenex  BioSep-sec-s-2000 column (300 × 7.00 mm, 5 micron, 
Phenomenex) and a Beckman 166 UV detector (Beckman). mAb9 was analysed in Size 
exclusion HPLC (SE-HPLC) using 0.1M phosphate buffer pH 7.2, 10% EtOH and 100 
mM EDTA (as a mobile phase for 30 minutes at a flow rate of 0.5 ml/min using UV 
detection at 168-280 nm. 
10 µl of Bio-Rad’s gel filtration standards (Biorad) were also analysed in SE-HPLC 
using the same settings in order to calibrate the size exclusion column and to determine 
the approximate molecular weight of mAb9.  Bio-Rad’s gel filtration standard is a 
lyophilised mixture of molecular weight markers ranging from 1,350 to 670,000 
daltons. The mixture contains thyroglobulin, γ-globulin, ovalbumin, myoglobin, and 
vitamin B12.  
 
2.2.2 SDS-PAGE electrophoresis of unlabelled mAb9 
10 µg of mAb9 was analysed by SDS-PAGE using 10% homogeneous gels prepared 
from acrylamide in 0.375 M Tris-HCl, pH 8.8, containing 0.1% (w/v) SDS, 0.1% (w/v) 
ammonium persulfate and 0.1% (v/v) tetramethylethylenediamine (TEMED) for 
resolving gels, and in 0.125 M Tris-HCl, pH 6.8, containing 0.1% (w/v) SDS, 0.1% 
(w/v) ammonium persulfate and 0.1% (v/v) TEMED for stacking gels. Samples were 
heated in loading buffer at 95°C for 3 min to linearise proteins, and were run 
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concurrently with a protein standard in 1 x Tris-glycine-SDS buffer, pH 8.3, at 150 V 
and 40 mA per gel for 1.5 h. Gels were stained with Brilliant Blue R (0.5%, w/v) in 
ethanol:acetic acid:water (9:2:9, by vol) for 2 h to visualise bands for determination of 
molecular weights. 
 
2.2.3 Maintenance of CHO, GPI, MKN45, TPC-1, FTC-133 and FRTL5 cell lines 
 
Cell line Description Species 
CHO Chinese hamster ovary cells chinese hamster 
GPI CHO cells stably transfected with 
TSHR 
chinese hamster-transfected 
FTC-133 follicular thyroid carcinoma human 
TPC-1 papillary thyroid carcinoma human 
FRTL-5 fisher rat thyroid glands rat 
MKN45 gastric adenocarcinoma cells human 
Table 2.1: Table of cell lines grown. 
A short description of all cell lines used is given in table 2.1. The human cell lines 
TPC-1, FTC-133 and MKN45 were grown in Dulbecco's Modified Eagle Medium, 
DMEM (Invitrogen) that contained 10% of foetal bovine serum. CHO and GPI cells 
were grown in HAMS-F12 media (Invitrogen) with 10% FBS. FRTL5 cells were gown 
in HAMS-F12 media (Invitrogen) with L-glutamine supplemented with 10% charcoal 
stripped FBS and a mixture of insulin (10 µg/ml), hydrocortisone (3.6 ng/ml), 
transferrin (5 µg/ml), Glycyl-l-lysine acetate (10 ng/ml), somatostatin (0.01 µg/ml), 
bovine TSH (1mU/ml), MEM non essential amino acids (1x), and penicillin-
streptomycin (100 µg/ml). 
The cells were grown at 37°C in a 5% CO2 incubator and were passaged when they 
reached 70-80% confluency. The cells were passaged by removing the media from the 
flask and washing them with 10 ml of autoclaved phosphate buffer saline (PBS). After 
washing, 3 ml of Trypsin/EDTA solution was added in order to detach cells from the 
flask. The majority of the trypsin was quickly aspirated and cells were incubated in a 
film of trypsin solution for 5 minutes before being diluted in a fresh aliquot of complete 
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growth media. The cells were then split into new filter-lidded T75 (75 cm) flasks at a 1 
in 10 dilution. In the case of GPI cells, the antibiotic Geneticin was added every other 
passage. Geneticin antiboiotic is used for the selection of transfected mammalian cells.  
 
2.2.4 Fluorescence activated cell sorting (FACS) analyses to determine levels of 
TSHR in TPC-1, FTC-133 and GPI cells. 
FACS experiments were performed using FTC-133, TPC-1, FRTL-5 and GPI cells and 
with 4C1 (Abcam, Cambridge, UK) and mAb9 antibodies. FACS assays were also 
performed with the following preparations: 
 
mAb9 incubated alone in an Iodogen tube- ‘oxidised mAb9’: in this preparation 10 
µg of mAb9 was added to an Iodogen tube and incubated for 10 minutes. 
mAb9 co-incubated with cold iodine (potassium [127I] iodide-KI) in an Iodogen 
tube – ‘cold labelled’ mAb9: In this preparation 10 µg of mAb9 was mixed with 0.11 
µg of potassium iodide (quantity calculated to give 2 x mol of mAb9 antibody) and then 
added to an Iodogen tube and incubated for 10 minutes. 
 mAb9 mixed with potassium iodide (KI) – ‘mixed mAb9’: In this preparation 10 µg 
of mAb9 was mixed with 0.11 µg of Potassium iodide. 
 
Cells were grown in  2 x T75 culture flasks and then detached from plates using versine 
when the cells reached around 80% confluency. The cells were then collected from the 
flasks into culture medium and centrifuged for 3 minutes at 1200 rpm.  Next, the cells 
were resuspended in 10 ml 0.1% PBS/BSA solution. The cells were centrifuged again 
and the pellet resuspended at a concentration of 4 x 106 cells per ml. 50 µl of cells were 
added to 50 ml falcon tubes and placed on ice. Thereafter, 1, 5, 10 and 20 µg/ml 
concentrations of 4C1 antibody (abcam) and mAb9 were prepared in 0.1%PBS/BSA 
and kept on ice. A negative control isotype antibody was also made to 1, 5, 10 and 20 
µg/ml concentrations in 0.1%PBS/BSA. 50 µl of the primary antibody was added to the 
test tubes and 50 µl of the control isotype was added to the control tubes.  
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The tubes were then incubated for 45-60 minutes on ice. After the incubation, the tubes 
were washed twice with 0.1%PBS/BSA solution by adding 2 ml to each tube and 
centrifuging for 3 minutes at 1200 rpm. After the second wash, the supernatant was 
poured off in order to leave about 50 µl of cell suspension in the tube. 50 µl of diluted 
Goat anti-mouse Alexa Fluor 488  secondary antibody at 8 µg/ml was added to each 
Flacon tube. The tubes were then left on ice in the dark for 30 minutes. Finally, the 
tubes were washed twice in 0.1%PBS/BSA, and the final pellet was resuspended in 400 
µl of 0.1%PBS/BSA solution and kept on ice. 
The samples were read in a flow cytometer LSR 1 (Becton Dickinson, New Jersey, 
USA) equipped with 3 lasers: an argon ion laser emitting at light 488 nm, a HeNe laser 
emitting light at 635 nm and a HeCd UV laser emitting light at 325 nm. 50 µl of 
propidium iodide (5 mg/ml) (Invitrogen, Paisley, UK) a nucleic acid stainer that detects 
cell death was added to the cells prior to the FACS reading. Both propidum iodide and 
Goat anti-mouse Alexa Fluor 488 secondary antibody are excited by the 488 nm laser. 
However, as they emit at different wavelengths, the Alexa Fluor 488 was detected by 
the FL1 detector and the propidium iodide was detected by the FL3 detector. A gate was 
set on a 2 parameter dot plot of forward scatter versus side scatter to exclude debris and 
another was set on a histogram of PI fluorescence intensity to include live cells (PI 
negative). A third gate was created to combine these two gates and events falling within 
this were analysed for expression of the TSHR. Data was analysed using CELLQuest 
software.  
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2.2.5 Immunohistochemistry of FTC-133, TPC-1, GPI and CHO cells 
2.2.5.1 Coating of Glass Coverslips with Poly-D-lysine for Use in Cell Culture 
Experiments 
13 mm glass coverslips were coated with poly-D-lysine (Sigma-adrich). Batches of 
~300 coverslips were immersed and agitated in an 80% ethanol solution for 2 h at RT to 
sterilise the coverslips. The coverslips were then rinsed 3 x with sterile dH20 to remove 
all traces of ethanol. Thereafter, the coverslips were immersed and agitated in a 0.1 
mg/ml poly-D-lysine solution (made up in dH2O) for 3h at RT. The coverslips were 
then again washed 3 x in dH2O, this time to remove any unbound poly-D-lysine. The 
poly-D-lysine coated coverslips were then stored in dH2O in a sealed sterile container 
kept in the fridge.   
 
2.2.5.2 Visualisation of Staining using the HRP/DAB ABC Method  
FTC-133, TPC-1, CHO and GPI cells were paraformaldehyde (PFA) fixed. After 
growing the cells as described in section 2.3.2, media was removed from the cultures, 
after which the cultures were washed with PBS, and then fixed by incubating the 
cultures in ice cold 4% PFA (dissolved in D-PBS, pH7.6) for 10 minutes at RT. The 
PFA-fixed cell cultures were washed with TBS (10 x TBS stock: 12.1g Tris (base), 
40.0g NaCl, water adjusted to 500 ml, pH 7.6) and the cultures then incubated for 10 
minutes in a 3% hydrogen peroxide solution (dissolved in H2O) to inactivate any 
endogenous peroxidise activity. Thereafter, cultures were washed with PBS, and 
incubated for 10 minutes with blocking buffer (1% BSA and 10% NaAz dissolved in 
0.5 M TBS, pH 7.6) to block non-specific binding sites. To detect TSHR, cells were 
then incubated with either mAb9 or 4C1 primary antibodies overnight at RT. In all 
cases, cultures were then incubated with a goat anti-human biotinylated secondary 
antibody (for 1 h at RT). 
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An avidin-biotin-HRP complex was freshly prepared using a Vectorlabs ABC kit 
solution (Vectorlabs). This was done by mixing/diluting solution A (Avidin-OH) with 
solution B (biotinylated HRP) in an appropriate ratio in TBS (10 µl of solution A and B 
was added to every 1 ml of 0.5 M pH 7.6 TBS solution. Sections were washed for 10 
minutes in TBS to remove any excess unbound secondary antibody, and then incubated 
for 1 hour in the freshly prepared avidin-biotin-HRP complex to allow the complex to 
conjugate to the biotinylated secondary antibody bound in the sections. Sections were 
washed in TBS to remove any excess unbound avidin-biotin-HRP complexes. Finally, 
antigen localisation was visualised by incubating the sections in a 0.05% 
diaminobenzidine (DAB)/0.03%H2O2 solution dissolved in TBS (0.1 M TBS, pH 7.6) 
for 10 minutes. This results in a brown coloured stain developing in the close vicinity of 
the antibody-localised antigen, as the HRP enzyme converts DAB into a brown 
coloured water insoluble precipitate in the presence of hydrogen peroxide. Following 
this, sections were removed from the DAB solution and thoroughly washed in dH2O to 
remove any remaining DAB solution from the slides. Sections were subsequently 
counterstained with haematoxylin to visualise cell nuclei. The sections were immersed 
in a Mayer’s haematoxylin solution (0.1% haematoxylin, 5% alum, 0.02% sodium 
iodate, 2% acetic acid, dissolved in dH2O) for ~ 90 seconds, and thereafter, the sections 
were thoroughly washed with dH2O, and staining differentiated by immersing in a 
differentiation solution (0.5% HCl dissolved in 70% industrial methylated spirits (IMS) 
for ~60 sec.  Thereafter, sections were firstly dehydrated by immersing them in 100% 
IMS for 4x 2 minute time-periods, and then subsequently cleared by immersing them in 
100% xylene for 2 x 5 minute time-periods, with solution changes separating each 
immersion period. Glass coverslips were then finally mounted on top of the 
immunohistochemically stained sections using the hydrophobic mountant, dibutyl 
phthalate in xylene (DPX). Images of the HRP/DAB stained sections were acquired 
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using a standard Zeiss bright field microscope fitted with an Axiocam colour camera 
and using Axiovision image analysis software. 
 
2.2.6 RT-PCR 
There are two types of RT-PCR; absolute quantification and relative quantification. In 
the experiments carried out in this study, relative quantification was used. Relative 
quantification determines the change in expression of a nucleic acid sequence (target) in 
a test sample relative to the same sequence in a calibrator sample, which was a non-
TSHR-expressing cell line, CHO. In addition an endogenous control housekeeping 
gene, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was also run in parallel. 
GAPDH is expressed in all the samples at consistent levels and due to this its frequently 
used as a reference gene in RT-PCR reactions. The GAPDH endogenous control is used 
to normalise the quantification of the cDNA target for differences in the amount of 
cDNA added to each reaction.  A two-step reaction was performed, in which total RNA 
was first transcribed into cDNA, and then amplified by PCR.  
 
2.1.6.1 RNA Isolation  
Cells were detached from flasks using Versene instead of 0.25% (w/v) Trypsin / 0.53 
mM EDTA solution, to eliminate any possibility of the expressed receptor being 
cleaved. Detached cells were washed twice in PBS and the pellet was taken forward for 
RNA isolation using the RNeasy Mini Kit (Qiagen) as per manufacturer’s instructions. 
A negative TSHR cell-line, CHO, served as the control. The kit comprises a spin 
column which allows up to 100 µg of total RNA of minimum length at 200 bases 
(mainly mRNA) to bind to a silica-gel membrane, with the aid of a specialised high-salt 
buffer. The addition of ethanol ensures the binding of total RNA to the column 
membrane, and contaminants are efficiently washed away.  
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The pellet, comprising approximately 5x106 cells, (counted using a haemocytometer) 
was homogenised in 350 µl of lysis buffer containing guanidine thiocyanate, and β-
mercaptoethanol (10% of final volume) to inactivate RNase. Thorough mixture of cells 
and buffer was achieved by pipetting followed by vortexing for 1 minute. To the 
homogenised lysate, 350 µl of 70% (v/v) ethanol was added and mixed well, before 
transferring all the lysate, including any precipitate that formed, to an RNeasy mini-
column equipped with a 2 ml collection tube, and centrifuging for 15 s at 8000 g. The 
flow-through was discarded, and the column was washed. DNase I was applied to the 
column membrane and incubated at room temperature for 15 minutes, followed by wash 
buffer (350 µl). The column was re-centrifuged, again discarding the flow-through, then 
washed again twice with the appropriate buffer before being transferred to a new 
collection tube. RNase free-water (50 µl) was applied directly onto the membrane and 
the column was centrifuged for 1 min at 8000 g to recover the eluted RNA. RNA yield 
and purity was determined spectrophotometrically using a NanoDrop spectrophotometer 
(Thermo scientific) at 260 and 280 nm. Recovered total RNA gave A260/A280 >1.9. 
Samples were stored at -80°C until needed or used for cDNA synthesis. 
 
2.2.6.2 cDNA Synthesis  
cDNA synthesis was performed using a cDNA synthesis kit (SuperScript® III first-
strand synthesis system, Invitrogen) as per manufacturer’s instructions. Defrosted RNA 
samples were placed on ice with other kit components. The concentration of RNA was 
measured again to ensure that the freeze-thawing process had not damaged it. In a 0.5 
ml tube, the following components (table 2.2) were mixed together to generate the 
RNA/primer mixture:  
 
 
  
Table 2.2: RNA/primer mixture
 
Random hexamers are a mixture of oligonucleotides representing all possible sequences 
for a hexamer.  
After mixture, samples were incubated at 65 °C for 5 min
minimum of 1 min
component in the order shown in 
 
Table 2.3: cDNA synthesis mixture.
 
RT Buffer comprised of 200 m
against degradation of target RNA due to ribonuclease contamination and SuperScript 
III RT is used to synthesise first
mixed gently with the RNA/primer mixture, then incubated on the thermo
(BioRad) at 25°C for 10 min
5 minutes, after which samples were chilled on ice. In parallel, a reverse
control without RNA was also prepared. Brief centrifugation ensured collection of each 
sample without any air bubbles before
tube and incubation at 37°C for 20 min
stored at -20°C in aliquots to minimise repeat freeze
 
 
. 
utes, then placed on ice 
ute. A cDNA synthesis mixture was prepared, adding each 
table 2.3.  
 
 
M Tris-HCl, pH 8.4 / 500 mM KCl. RNaseOUT protects
-strand cDNA. cDNA synthesis mixture (10 
utes, followed by 50°C for 50 minutes
 the addition of 1 µl of RNase H solution to each 
utes. Samples were used for PCR immediately or 
-thaw cycles. 
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µl) was 
-cycler 
, and finally 85°C for 
-transcriptase 
  
2.2.6.3 Real-Time PCR 
RT-PCR was performed by setting up 
the tested gene and the endogenous (
Table 2.4: PCR master mix
 
The PCR master mixture was 
plate at room temperature. To this, 4 
pipetting. The plate was briefly centrifuged to collect the contents at the bottoms of the 
wells, then stored on ice u
The plate was placed in the RT
Applied Biosystems) 
Table 2.5: RT-PCR Instrument Settings
 
An amplification plot for each sample was 
on the threshold cycle (Ct
– Experimental Protocol  
a PCR master mix for a 20 
GAPDH) control (table 2.4) 
 
. 
distributed in 16 µl aliquots into the wells of a RT
µl of cDNA template was added and mixed by 
ntil used.  
-PCR instrument (7900HT Fast real
and incubated, using the following settings (
 
 
obtained and further analysis was perf
) values acquired.  
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µl reaction, for both 
-PCR 
-time PCR system, 
table 2.5). 
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The Ct values obtained were quantified and compared with those derived from a 
calibrator, here the non-TSHR expressing cell line, CHO. Results were expressed in 
terms of the ratio of the level of expression of the base sequence in a given cell line to 
that found in the calibrator.  
The comparative Ct method is also known as the 2–∆∆Ct method, where: 
 
 
 
∆Ctsample is the Ct value for the tested cell line normalised to the endogenous 
housekeeping gene and ∆Ct, reference is the Ct value for the calibrator also normalised 
to the endogenous housekeeping gene. 
For the ∆∆Ct calculation to be valid, the amplification efficiencies of the target and the 
endogenous reference must be approximately equal. This was established by observing 
how ∆Ct varied with template dilution 
 
2.2.7 Western blot analysis with FTC-133, TPC-1 and GPI cells 
FTC-133, TPC-1, CHO and GPI cells grown in T75 flasks were lysed with 0.5 ml ice-
cold NP40 lysis buffer containing 10% protease cocktail inhibitor (Sigma aldrich). 
Lysed FTC-133, TPC-1, CHO and GPI cells protein concentrations were determined by 
the Bradford assay (Biorad). 50 µg of Protein lysates  containing ¼ volume of 5 x SDS 
loading buffer (20 ml: 7.5 ml water, 2.5 ml 1 M Tris HCl. pH 6.8, 6 ml glycerol, 0.04 g 
0.5% (w/v) Bromephenol blue, 4 ml SDS (10% w/v)) and rainbow molecular weight 
markers (GE Healthcare) were then run on a denaturing SDS-PAGE gel (10% 
polyacrilamide) at 150 V for approximately one and a half hour. The gel, together with 
two fibre pads and two pieces of Whatman 3MM paper, was then blotted onto a PVDF 
membrane (Millipore, Watford, United Kingdom) for 1 hour at 190 mA. This blotting 
was assembled in 1 X WB transfer buffer (100 ml methanol, 400 ml 1 x TRIS-glycine, 
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SDS buffer). Once blotted, the membrane was blocked with 5% non fat milk in TBST 
(100 ml 10 X TBS stock, 900 ml water, 1 ml Tween-20) for 2 hours and rinsed with 
TBST 4 times for 5 minutes. The membrane was then incubated at 4ºC overnight with 
either 4C1 primary antibody (1:2000 dilution) or mAb9 antibody (1:2000 dilution) 
together with mouse monoclonal anti human GAPDH control antibody (1:10,000 
dilution). After the overnight incubation, the membrane was rinsed with TBST and 
washed 4 times for 5 minutes. Thereafter, Goat anti mouse secondary antibody 
conjugated to HRP (1:2000 dilution) was added to the membrane and left to incubate 
for 30 minutes. The membrane was then rinsed with TBST and washed 4 times for 5 
minutes. Proteins were visualised by ECL™ Western Blotting Detection Reagent (GE 
healthcare) as per manufacturer’s instructions. 
 
2.2.8 Radioiodination of mAB9 antibody with Sodium [125I]-Iodide using Iodogen  
All radiolabelling procedures were performed according to good radiation safety 
practice. Radioiodinations were performed in a well-ventilated fume hood and all 
containers were shielded by keeping them in small lead pots. Iodine-125 (125I) is used to 
radiolabel antibody fragments, reacting with tyrosine and some histidine residues in 
proteins or peptides by electrophilic substitution [171]. Na 125I was purchased from 
IMS30 Amersham at a concentration of 3.7 GBq/ml. This procedure is adapted from 
Fraker PJ and Speck JC Jr. [179].  
 
2.2.8.1 Radiolabelling of mAb9 for in vitro experiments 
For efficient labelling of mAb9 antibody, iodinations were conducted in glass tubes (12 
x 75 mm) coated at the bottom with the oxidant Iodogen (1,3,4,6-tetrachloro-3α, 6α-
diphenylglycoluril) (Perbio, UK. Part of Thermo Fisher Scientific) for the activation of 
125I. 5 µg, 10 µg or 100 µg of mAb9 antibody were added to the Iodogen tube together 
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with 4 MBq of Na 125I. This was then mixed gently and incubated for 10 minutes. Next, 
PBS was added to make up the volume to 100 µl and the sample was transferred to a 
clean 1.5 ml eppendorf tube and kept at 4°C until used. 
 
2.2.8.2 Radioiodination of mAB9 for imaging experiment 
To radiolabelling of mAb9 for imaging experiments the same method was used as for 
the in vitro experiments (2.2.8.1). However, instead of 4 MBq of 125I, 40 MBq was 
used. Also, an additional purification step was performed by running the samples 
through a Nap5 column (GE healthcare). This additional purification step was 
performed to ensure that radioiodinated mAb9 injected into mice was of a maximum 
purity. Thereafter 5 ml tubes were labelled 1 to 10 and the radiolabelled antibody was 
inserted into the Nap5 column, 550 µl of 0.1% PBS/BSA was added to the column and 
the solution allowed to elute into tube 1. Fractions of 250 µl 0.1% PBS/BSA were 
eluted into tubes 2-6 and fractions of 1 ml 0.1% PBS/BSA were eluted into tubes 7,8,9 
and 10. The radioactivity in tubes 1 to 10 was then measured. The radiolabelled samples 
in the tube with the greatest activity were then used in imaging experiments. 
Confirmation of successful labelling was achieved by Instant Thin Layer 
Chromatography (ITLC) and radio-HPLC of the samples, as explained in 2.2.9. 
 
2.2.9 Determination of purity and labelling efficiency of mAb9 
2.2.9.1 Instant thin layer chromatography (ITLC) 
Samples on ITLC-Silica Gel (ITLC-SG) strips (1 x 8 cm) were developed in duplicate, 
in 85% methanol. A 1 µl fraction of labelled mAb9 was spotted onto strips, which were 
developed to within 1 cm of the top. Strips were removed from the solvent tank, dried, 
and the labelled antibody fragments were visualised using a phosphor imager.  
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2.2.9.2 Radio-High Performance Liquid Chromatography (radio-HPLC)  
A Beckman System Gold running 24 Karat proprietary software was used for radio 
HPLC analysis with a size exclusion Phenomenex BioSep-sec-s-2000 column, 300 × 
7.00mm 5 micron (Phenomenex), and a Beckman 166 UV detector in series with a 
GABI sodium iodide radioactivity monitor (Raytest). HPLC was run using 0.1M 
phosphate pH 7.2, 10% EtOH 100 mM EDTA  as a mobile phase for 30 minutes at a 
flow rate of 0.5 ml/min and UV detection at 168-280nm. 
 
2.2.9.3 SDS-PAGE gel electrophoresis and phosphor imaging system to determine 
molecular weight and purity of 125I-mAb9 
Electrophoresis of 125I-mAb9 was performed on a PHAST system® (GE healthcare, 
Bucks, United Kingdom) using 15% gradient SDS-PAGE. The PHAST system® 
automatically separates and stains proteins under controlled energy and temperature 
conditions. The PHAST system® assures reproducibility with quality-tested precast 
gels, buffer strips, and staining kits. A 7.5% SDS Phast gel (GE healthcare, Bucks, 
United Kingdom) was used. The Phast gel was inserted into the gel bed in the machine 
and next the transfer buffer strips (GE healthcare, United Kingdom) were inserted into 
the Phastgel. 10 µl of Tris buffer was added to the 125I-mAb9 sample. Molecular weight 
standards (supplied by GE healthcare, Bucks, United Kingdom) already contained Tris 
buffer. The samples were then heated to 95°C for 5-10 minutes. 6 µl of samples were 
then aligned in a piece of parafilm and then the samples were aspirated with a plastic 
capillary applicator and then inserted into the PHAST system machine. The machine 
was set on a programme appropriate to the 7.5% Phast gel. 
When the run was finished, the gel was placed in a container filled with fixing and 
staining solution and left to incubate overnight. The next day the gel was destained with 
destaining solution and allowed to dry overnight. The gel was then analysed by digital 
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autoradiography using  a Packard Cyclone phosphor imaging system using OptiQuant 
version 3.00 (Perkin-Elmer, Ohio, USA).  
 
2.2.10 TSHR Binding assays 
2.2.10.1 Coated tube assay for the measurement of TSHR binding to mAb9 
This assay was obtained from B-R-A-H-M-S Aktiengesellschaft (Hennigsdorf, 
Germany). 
200 µl of buffer B (supplied with the kit) was added to the coated tubes. Next, 100 µl of 
unlabelled mAb9 radiolabelled with a lower (10 µg mAb9 with 5 MBq125I) and higher 
(5 µg mAb9 with 10 MBq 125I) specific activity, and PR1A3 (murine monoclonal 
antibody against the carcinoembryonic antigen, Nuclear Medicine Barts Hospital, 
London, UK) were added at 5 different concentrations: 3000 ng/ml, 1000 ng/ml, 300 
ng/ml, 100 ng/ml, 30 ng/ml. Thereafter the tubes were incubated for 2 hours at room 
temperature while shaking at 300 rpm. The coated tubes were washed twice with 2 ml 
of washing solution (provided by the kit) and then allowed to dry in a blotting paper for 
10 minutes. Next, either 200 µl 125I radiolabelled TSH (supplied by the kit) or 200 µl 
125I-mAb9 (50 ng/ml) was pipetted into the tubes. The tubes were then incubated for 1 
hour at room temperature while shaking (300 rpm). Following the 1 hour incubation 
time, the coated tubes were washed twice with 2 ml of washing solution and dried on a 
blotting paper for 30 minutes before being read in a gamma counter.  
The oxidation and labelling effect of iodine was also tested in the coated tube assay in 
which ‘oxidised mAb9’ ‘cold labelled’ mAb9 (prepared as in section 2.2.4) were used 
in the coated tubes as explained above. 
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2.2.11 Cell binding assays 
2.2.11.1 Effect of temperature and time on TSHR binding  
20 nM of 125I-mAb9 was added to FTC-133, TPC-1 and GPI cells previously plated in 6 
well plates and incubated for 2 hours at 4ºC, room temperature and 37ºC. The medium 
was then aspirated carefully to avoid disrupting the cells, which were washed twice with 
PBS. The cells were then lysed with NaOH for a period of 10 minutes and the 
radioactivity read in the gamma counter. The bound percentage was calculated. 
A TCA precipitation assay was performed over a 6 hour period to find out if the 
antibody remained bound to 125I and did not dissociate. The supernatants were collected 
and 20% trichloroacetic acid (TCA) was added to each sample fraction to form a final 
solution of 10% TCA as to precipitate the protein in solution. After centrifuging the 
protein into a pellet, the supernatant was removed and both fractions were counted 
using the gamma counter. Both the supernatant and the pellet were analysed 
 
2.2.11.2 Effect of media in binding assay: 
125I-mAb9 was made up in different buffers –DMEM, HBSS, Krebs and PBS/0.1BSA 
(all with 10% FBS and 0.04% sodium azide and pH 7). They were added to GPI cells 
plated in 6 well plates and incubated for 2 hours at RT. The cells were then lysed with 
1M NaOH and read in the gamma counter and the % of antibody bound to the cells 
calculated.  
 
2.2.11.3 Assessment of the binding of 125I-mAb9 to TSHR in cells using the 
immunoreactive fraction assay. 
The immunoreactive fraction assay has been adapted from a method published by 
Lindmo  [180]. 15 x 106 FTC-133 cells, TPC-1 cells and GPI cells were harvested. Cells 
were detached from the tissue culture flasks using versine/EDTA and the cell 
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concentrations counted using a haemocytometer. The final concentration was diluted to 
4x106 cells/ml in cold 0.1% BSA/PBS. 0.5 ml of cell suspension was pipetted into two 
eppendorf tubes and a series of 5 one in two dilutions were made. Next, 200 µg of 
unlabelled antibody was added to two additional tubes containing 0.5 ml of cell 
suspension. 50 to 100 ng of 125I-mAb9 was then added to all the tubes including the 
empty tubes. Thereafter the tubes were incubated for 2 hours at room temperature in a 
mechanical shaker. The tubes were left in ice for 10 minutes to cool and then 
centrifuged at high speed (>1000rpm) for 2 minutes. The supernatant was carefully 
removed and discarded and another 0.5 ml of cold 0.1%BSA/PBS was added. The tubes 
were again centrifuged, their supernatant discarded after which they were ready to be 
read in the gamma counter. The data obtained from the gamma counter was analysed by 
dividing the counts in the tubes containing cells and 125I-mAb9 (bound counts) by an 
average of the counts in tubes containing just 125I-mAb9 (total counts). This allowed for 
the fraction of counts bound to the cells to be calculated for each cell concentration.  
 
2.2.11.4 Saturation binding assays 
Saturation binding assays were carried out using GPI, FTC-133, TPC-1 and FRTL5 
cells. Forty-eight hours prior to the experiment, adherent cells (1x106 per well), in 2 ml 
of cell growth medium (HAMSF12 or DMEM 10% FBS) per well, were seeded in a 6-
well plate. One plate was prepared for each of the following concentrations of 
radioligand: 25, 10, 7.5, 5, 2.5, 1 and 0.1 nM.  
Prior to experimentation, cells in the plates were checked to ensure they had fully 
adhered to the wells and were not over-confluent. The medium was aspirated carefully 
to avoid disturbing the cells, which were washed twice in PBS to remove any that were 
not adhering. Fresh medium (1.2 ml/well) containing 1% (w/v) FBS and 0.1% (w/v) 
80 
 
 
sodium azide was added and plates were returned to the incubator until needed. The 
remaining medium was kept at 4°C.  
mAb9 and 4C1 were radiolabelled to produce 125I-mAb9 and 125I-4C1 and the 
radiochemical purity determined (section 2.2.8 and 2.2.9). The radiolabelled antibodies 
were prepared at 10 x the concentration ultimately required. Assays were performed in 
triplicate, and for each concentration of radiolabelled peptide, a duplicate well 
containing unlabelled competitor was set up. Competitor wells received, in 1% PBS-
BSA, 150 µl of unlabelled mAb9 and 4C1 at a final concentration of 1 mM. The 
corresponding non-competitor wells received 150 µl 1% PBS-BSA to bring the protein 
concentration and volume to the same values. All wells received 150 µl of the 
appropriate concentration of labelled mAb9 and 4C1, added dropwise to the contents of 
each well, avoiding contact with the walls to prevent non-specific binding to the plastic. 
Plates were gently swirled to ensure even dispersion of the radioligand, then incubated 
at 37°C under 5% (v/v) CO2/air for 90 minutes. 
After incubation, the medium was aspirated and the cells washed twice in 1% FBS, then 
in medium containing 0.1% (w/v) sodium azide, and finally in ice cold PBS, taking care 
not to disturb the cells. To each well, 1 ml of 1 M NaOH was added to lyse the cells and 
left until lysis became apparent (10 min). Thereafter, three 5 µl aliquots per well were 
transferred to a 96-well plate for determination of protein concentration. Protein was 
assayed using the Bio-Rad Protein Assay Kit (Bio-Rad), as per manufacturer’s 
instructions, and the plate was measured in the plate reader at 595 nm. The remaining 
supernatant samples were transferred into scintillation tubes, together with the washings 
from two 1 ml fractions of PBS for each well, and the tubes were then counted on the 
gamma counter. This experiment was performed three separate times for each cell line. 
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2.2.12 Assessing the in vivo binding of 125I radiolabelled mAb9 to TSHRs in the 
mouse thyroid using SPECT/CT imaging and biodistribution 
All animal procedures were undertaken in accordance with the UK Animals (Scientific 
Procedures) Act 1986.  
Four groups of C57 mice (n=2) (Charles River Research Animal Diagnostic Services, 
London) were used in imaging experiments.  Because 125I is also taken up by the thyroid 
gland, all mice were given potassium iodide for 3 days prior to imaging. The 4 groups 
received the following treatments: 
 
Group A (mouse 1 and 2): 125I radiolabelled mAb9 (2 MBq i.v) 
Group B (mouse 3 and 4): Sodium perchlorate (5 mg i.p) followed 30 minutes later by 
125I radiolabelled mAb9 (i.v). 
Group C (mouse 5 and 6): 125I-iodide (2 MBq i.v) 
Group D (mouse 7 and 8): Sodium perchlorate (5 mg i.p) followed 30 minutes later by 
125I-iodide (i.v). 
 
A SPECT/CT scanner (Bioscan, UK) was used to image the area around the neck (CT 
was used to focus the scan) at time points of 4 hours and 24 hours post i.v injection of 
125I-iodide (125I) and 125I-mAb9. The injections were staggered by 30 minutes since the 
total imaging (SPECT scan = 20 minutes, CT= 3 minutes) and set up times were 
approximately 30 minutes. Approximately 2 MBq of 125I-mAb9 and 125I were injected 
into each mouse.  A 4-head small animal NanoSPECT/CT (Bioscan Inc., Washington 
DC) imaging camera with 1.4mm pinhole apertures was used to image the thyroid of the 
mice. The mice were anaesthetised using isoflurane (Induction – 4% Isoflurane, 0.5-
1L/min O2; Maintenance – 2% Isoflurane, 0.5-1L/min O2) and placed on a heated 
animal bed. A topogram was acquired to focus the scan on the neck area.  
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A CT scan was acquired with the following parameters: 
No of projections = 180 projections  
Frame resolution = Standard 
Exposure time = 1000ms  
Tube Voltage = 45kVp  
Duration = 3 minutes. 
Scan range = approx 20mm. 
SPECT scans were acquired with following parameters: 
No of projections = 16 projections  
Time per projection =  ranged from 300-400ms  
Duration of 20mins/scan (4hours) and 26mins/scan (24hours) 
Scan range = same as CT. 
 
Images were reconstructed in a 256 x 256 matrix using HiSPECT (Scivis GmbH), a 
reconstruction software package, and images were fused using Bioscan InVivoScope 
(IVS) software.  
For biodistribution studies, the mice used for imaging were removed from the 
SPECT/CT camera after the 24 hour time point scan and were immediately culled by 
CO2 anaesthesia and the thyroids were dissected and counted. 
Empty scintillation tubes were weighed with their lids prior to the experiment, and 
reweighed after filling to obtain the weights of the excised  thyroid tissue. The thyroid, 
(within the scintillation tubes) was then counted in the gamma counter. As a control to 
standardise the experiment, a 100-µL dose (assuming an injected dose of that volume) was 
dispensed into a polypropylene 15-mL falcon tube containing 9.9 mL of 1% PBS-BSA. 
Three 1-mL fractions from the 10-mL control sample, neat and after dilution (1:10 and 
1:100) were also read in the gamma counter. The counts obtained from the counted 
tissues were compared with counts obtained from the control standards which were 
corrected for dilution to obtain CPM per mL and the percentage of injected dose per 
gram of tissue was calculated.  
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2.2.13 Radiolabelling of mAb9 with  111In  
111In does not form strong interactions directly with antibodies but can form highly 
stable complexes with a number of bifunctional chelating agents which have a 
chemically active group that can bind covalently to the antibody. 
 
 2.2.13.1 Conjugation of mAb9 with Bz-Scn-DOTA 
Conjugation was achieved by using mini dialysis cassettes (Slide-A-lyzer mini dialysis 
cassettes, Pierce). mAb9 antibody was added to the dialysis cassette and placed in 
Hepes buffer pH 8 overnight at 4°C. The antibody was then removed from the dialysis 
cassette and its concentration was calculated by measuring the absorbance of the sample 
at 280 nm in a UV spectrophotometer (protein concentration = absorbance/1.4=mg/ml). 
8 times molar excess of ScnBzDOTA was calculated and added to mAb9. ScnBzDOTA 
mAB9 was then placed in the cassette and in Hepes buffer pH 6 for two days. After two 
days, the final concentration of ScnBzDOTA-mAb9 was calculated as well as the pH 
checked. After conjugation it was necessary to go through a purification step to remove 
the free chelate before the radioisotope is added. For the purification step, 
ScnBzDOTA-mAb9 was added to a new dialysis cassette with a syringe and placed in a 
metal free plastic container with 1 litre of newly made 0.1M ammonium  acetate pH 
5.5-6.0 in metal free water. The 0.1M ammonium acetate pH 5.5-6.0 buffer was 
exchanged for 6 x 3 hour periods and for a 1 x 12 hour period. Thereafter, the contents 
of the dialysis cassette were transferred to a metal-free plastic test tube with a syringe. 
The final protein concentration was measured in a UV spectrophotometer at 280nm. 
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2.2.13.2 Assessing the purity and integrity of ScnBzDOTA-mAB9 complex with 
SE-HPLC. 
SE-HPLC was used to assess the purity of the ScnBzDOTAmAB9. 10 µg of 
ScnBzDOTAmAB9 was injected into a SE-HPLC column using the same methodology 
and equipment as explained in detail in section 2.2.1. 
 
2.2.13.3 FACS analysis to assess the binding of SCNBzDota-mAb9 to the TSHR in 
cells 
1 and 10 µg of SCNBzDota-mAb9 were used in GPI cells for the FACS experiment 
using the same methodology, equipement and materials as detailed in section 2.2.4. 
 
2.2.13.4 Coated tube assay to assess the binding of SCNBzDota-mAb9 to the TSHR 
in cells 
A TSHR coated tube assay was carried out with increasing concentrations of cold 
SCNBzDota-mAb9 and 125I-TSH supplied by the kit using the same methodology 
detailed in section 2.2.10.1. 
 
2.2.14 111In binding to BzScnDOTA mAb9 
For the labeling reaction, 5 MBq of 111In (Covidien-Petten, Netherlands) was added to 
50 µg SCNBzDOTA-mAb9. 1 M ammonium acetate buffer, pH 6, was also added to the 
reaction to maintain the pH in this range (pH 6). The reaction was then incubated for 1 h 
at 37 °C and thereafter quenched by 10% (vol/vol) 0.1 M ammonium acetate buffer, pH 
6, containing 50 mM EDTA. Thereafter the reaction was mixed well and left for 5 min 
at room temperature. 
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2.2.14.1 Assessing labelling efficiency of 111In-mAb9 
ScnBzDOTA-mAb9111In (111In-mAb9) labelling efficacy was confirmed by Size 
exclusion HPLC (SE-HPLC) and ITLC using the same methodology as explained in 
section 2.2.1 
 
2.2.14.1.1  TSHR Pre-coated tube assay with 111In-mAb9 
111In-mAb9 was used with increasing concentrations of cold mAb9 in the TSHR coated 
tube assay and the assay was performed as previously described in section 2.2.10.1.  
 
2.2.14.1.2 111In-mAb9 saturation cell binding assays 
This saturation assay was carried out exactly as described in section 2.2.11.4 but instead 
using 111In-mAb9 with GPI, FRTL5, TPC-1 and FTC-133 cells. 
 
2.2.14.2 SPECT/CT imaging of 111In mAb9 in mice  
Thus, this experiment was performed in order to assess the binding of 111In-mAb9 to the 
TSHR expressed in the normal thyroid of mice. Because it was set up as a preliminary 
experiment, only two mice were used initially. 
Two C57 (Charles River Research Animal Diagnostic Services, London) mice were 
injected i.v. with 200 µl (5.5 MBq) of the radiolabelled antibody and imaged in the 
NanoSPECT at 4 hours, 24 hours and 48 hours time point so that the levels of thyroid  
uptake could be determined. In one mouse the whole body was imaged while in the 
other mouse the neck region was imaged. The two imaging mice were also 
biodistributed at 48 hours. Imaging uptake was quantified using In-vivoscope software. 
A SPECT/CT scanner (Bioscan, UK) was used to image the area around the neck of one 
mouse (CT was used to focus the scan) and the whole body of another mouse at 4 hour, 
24 hour and 48 hour time points post i.v. injection of 111In-mAb9. The injections were 
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staggered by 30 minutes since the total imaging (SPECT scan = 20 minutes, CT= 3 
minutes) and set up times were approximately 30 minutes. Approximately 2 MBq were 
injected into each mouse.  A 4-head small animal NanoSPECT/CT (Bioscan Inc., 
Washington DC) imaging camera with 1.4mm pinhole apertures was used to image the 
thyroid and other organs of the mice. The mice were anaesthetised using isoflurane 
(Induction – 4% Isoflurane, 0.5-1L/min O2; Maintenance – 2% Isoflurane, 0.5-1L/min 
O2) and placed on a heated animal bed.  
After 48 hours, mice used for imaging were removed from the SPECT/CT camera and 
culled with CO2 anaesthesia.  
For biodistribution studies, the pancreas intestine, spleen, stomach, kidney, liver, heart, 
lungs, blood, muscle, tail and the thyroid were excised from the mice and processed and 
counted as previously described in section 2.2.12.  
 
A CT scan was acquired with the following parameters: 
No of projections = 180 projections  
Frame resolution = Standard 
Exposure time = 1000ms  
Tube Voltage = 45kVp  
Duration = 3 minutes. 
Scan range = approx 20mm. 
SPECT scans were acquired with following parameters: 
No of projections = 16 projections  
Time per projection = ranged from 300-400ms  
 
Duration of thyroid 20mins/scan (4hours), 26mins/scan (24hours) and 23 mins/scan (48 
hour) 
Scan range = same as CT. 
Images were reconstructed in a 256 x 256 matrix using HiSPECT (Scivis GmbH), a 
reconstruction software package, and images were fused using proprietary Bioscan 
InVivoScope (IVS) software. 
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2.2.14.2.1 Blood/Plasma stability study of 111In-mAb9 
Three mice were injected i.v. with 5 MBq 111In-mAb9.  One mouse was used for ex vivo 
blood studies and two mice were used for in vivo blood studies. 
In the ex vivo study, the mouse was terminally anaesthesised and intracardially bled in 
situ 6 hours post-injection of 111In-mAb9.  Around 700 µl of blood was collected and 
200 µl of 111In-mAb9 (5MBq) was added to the blood sample and the sample was 
incubated for 6 hours at 37ºC.  
In the in vivo study, 5 mice were culled 6 hours post 111In-mAB9 i.v injection and the 
blood was collected using the same method as abovementioned. 
1 µl of blood from the in vivo and ex vivo studies were then analysed by PHAST page 
SDS-PAGE electrophoresis together with a control 111In-mAb9 sample that was 
incubated for 6 hours at 37ºC in PBS. See section 2.2.9.3 for a description of the 
methodology for phast page gel electrophoresis. 
 
2.3 Methodology 2 (this methodology relates to the results section in chapter 4) 
2.3.1 Radioiodination of rhTSH using enzymatic substitution 
The lactoperoxidase enzymatic substitutiuon labelling method was adapted from 
Corsetti et al. [181]. The reaction was carried out at both pH 5.4 and pH 7 and the 
following concentrations and reagents were used (table 2.6). 
Reagent Quantity 
rhTSH 1 µg 
0.5 M sodium phosphate pH 5.4 or pH 7 2.5 µl 
glucose oxidase  0.5 µl (0.01 mg/ml) 
lactoperoxidase  0.5 µl (1mg/ml) 
D-glucose 1  µl (10mg/ml) 
125I 3.7 MBq 
Table 2. 6: concentrations used for the lactoperoxidase radioiodination method. 
 
The reaction was scaled down or up depending on the quantity of 125I-rhTSH needed. 
The reaction was stopped using sodium metabisulfate. 
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2.3.1.2 ITLC and SDS-PAGE to check purity of radiolabelled rhTSH 
ITLC and SDS-PAGE electrophoresis were carried out to confirm the purity of 125I 
radiolabelled rhTSH. The procedures were carried out as detailed in sections 2.2.9.1 and 
2.2.9.3, respectively. 
 
2.3.2 Effect of glucose oxidase and lactoperoxidase on 125I-rhTSH labeling 
efficiency. 
0.5, 0.05, 0.005 and 0.0005 µg of lactoperoxidase and  0.005, 0.0005, 0.00005 and 
0.000005 µg of glucose oxidase were added to constant amounts of the other labeling 
components separately as in table 2.5 (exept 125I). An ITLC was then carried out as 
detailed in section 2.2.9.1 to calculate the labeling efficiency.  
 
2.3.3 SE-HPLC with rhTSH and 125I-rhTSH 
10 µg of rhTSH and 125I-rhTSH were run on a size exclusion HPLC with 0.5 M 
phosphate buffer pH 7.0 with 20 mM EDTA used as a mobile phase. A YMC Pack™ 
Pro™column was used (Waters) 10 µl of a full length biosep molecular weight standard 
was also analysed in SE-HPLC in order to estimate the molecular weight of rhTSH.  
10 µl of 1 mg/ml Carbonic anhydrase and 10 µl of 1mg/ml lysosyme were analysed in 
SE-HPLC using the same methodology as above. Carbonic anydrase and lysosyme have 
known molecular weights of approximately 29 kDa and 14.7 kDa respectively. 
Carbonic anydrase molecular weight corresponds to the approximate molecular weight 
of intact rhTSH (29-30 kDa) and lysosyme corresponds to the approximate molecular 
weight of TSH α subunit (14 kDa). 
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2.3.4 Reverse phasse HPLC 
rhTSH was analysed in RP-HPLC using C18ODS reverse phase column, and a gradient 
of aqueous 0.1%  (v/v) trifluoroacetic acid (TFA) (Solvent A) and acetonitrile 
(ACN)/TFA (pH 2.5). UV detection was performed at 160-280 nm and radioactivity 
was detected using an in-line gamma-detector. The flow rate was 1 mL/min. Solvent A 
was passed through the column for ten minutes between injections to allow re-
equilibration. The radiolabelled peptide was diluted 1:1 in PBS before injecting 20 - 30 
µl samples. The initial gradient system used for analysis was as follows: 5% A : 50% B 
for 35 minutes, then B was increased linearly to 100% over the next 10 minutes to elute 
lipophilic impurities, and reduced to 5% (i.e. A was increased to 100%) linearly 
thereafter over 5 minutes.  rhTSH and 125I-rhTSH were then analysed with the following 
gradient: 5% A : 20% B for 30 minutes, then B was increased from 20% to 35% over 30 
minutes followed by a linear increase of B from 35% to 100% over the next 10 minutes 
to elute lipophilic impurities, and reduced to 5% (i.e. A was increased to 100%) linearly 
thereafter over 5 minutes. 
 
2.3.4.1 SDS-PAGE electrophoresis with 125I-rhTSH treated with either pH 2.5 or 
pH 7  
rhTSH was treated with both pH 7 and pH 2.5 by incubating in 0.1M TEAA (pH 7) and 
0.1%TFA/water (pH 2.5) for a period of an hour and after analysed in a phast-page 
SDS-PAGE gel as described in  section 2.2.9.3 
 
2.3.5 Ion pairing RP-HPLC 
rhTSH and 125I-rhTSH were analysed in RP-HPLC using a C18ODS reverse phase 
column, using a gradient of aqueous 0.01 M Triethylammonium acetate (TEAA) pH 5.5 
and 0.1M TEAA pH7 (Solvent A) and acetonitrile(ACN) as a mobile phase. UV 
  
detection was performed at 160
gamma-detector. The flow rate
for ten minutes between injections to allow re
was diluted 1:1 in PBS before injecting 20 
TEAA pH7 (Solvent A) and aceton
The initial gradient system used for analysis was as follows: 25% A : 60% B for 20 
minutes, then B was increased linearly to 100% over the next 10 min
lipophilic impurities, and reduced to 25% (i.e. A was increased to 100%) linearl
thereafter over 5 minutes.
 
2.3.5.1 Ion pairing HPLC with o
Glucose oxidase and lactoperoxidase we
oxidation step. A ‘cold labelled
2.6). Both ‘oxidised’ and ‘cold labelled’ rhTSH were analysed in RP
reverse-phase column, C
TEAA pH7 (Solvent A) and acetonitrile(ACN). Radioactivity was detected using an in
line gamma-detector. The flow rate was 1 ml
the previously used with rhTSH and 
Table 2.7: Preparation of ‘oxidised rhTSH’ and ‘cold labelled rhTSH’ reaction mixtures.
 
-280 nm and radioactivity was detected using an in
 was 1 ml/min. Solvent A was passed through the column 
-equilibration. The radiolabelled peptide 
- 30 µl samples and analysed with 0.1M 
itrile(ACN) 
 
xidised TSH and cold labelled TSH 
re added to rhTSH- ‘oxidised’
’ rhTSH was created by adding NaI to
18ODS (Phenomenex), using a gradient of aqueous 0.1M 
/min. The gradient used was the same as 
125I-rhTSH in section 2.3.3. 
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2.3.6 125I-rhTSH binding assays 
Constant amounts of 125I-rhTSH made up in different binding buffers – HAMS-F12, 
HBSS, Krebs and PBS/0.1BSA (all with 10% FBS and 0.04% sodium azide and pH 
7),were added to GPI cells plated in 6 well plates and incubated for 2 hours at room 
temperature. Thereafter, the cells were lysed with 1 M NaOH and the radioactive signal 
read in the gamma counter. 
 
2.3.6.1 Coated tube assay with 125I-rhTSH cold rhTSH 
In this assay a constant amount of 125I-rhTSH was added to increasing concentrations of 
cold rhTSH. This assay was performed as described previously in section 2.2.10.1. 
 
2.3.6.2 Saturation assay of 125I-rhTSH in GPI cells 
Saturation binding assays were performed with 125I-rhTSH in GPI, TPC-1 and FTC-133 
cells as previously described in section 2.2.11.4.  
 
2.3.6.3 Competition assay with 125I-rhTSH and cold rhTSH in GPI cells. 
GPI cells were seeded at a density of 1x106 cells per well in six-well plates and grown 
at 37°C for 48 hours. Dilutions of unlabelled rhTSH (competitor) corresponding to 0.01, 
0.1, 0.3, 1, 3, 10, 100, 1000, 10000 nM in final (1.5ml) plate volume were made up in 
1% PBS/BSA.  After 48 hours incubation time, the cells were washed by  adding 1 ml 
1% FCS Media to each well and then 1.2 ml of HAMSF12 media with 1% FBS was 
added to each well. 150 µl of each concentration of competitor was then added in 
triplicate to the cells. 125I-rhTSH diluted in 0.1% PBS/BSA was then added to the cells. 
The plates were then mixed gently and incubated for 2 hours at room temperature. 
Thereafter, the media was removed and the plates were washed 2 x with 1 ml PBS per 
well. 1 ml of 1M NaOH was then added to each well in order to lyse the cells during 15 
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minutes. The radioactivity was then counted in a gamma counter and results plotted on 
graphPrism software and IC50 values calculated. 
 
 
2.3.7 125I-rhTSH internalisation and externalisation assays 
2.3.7.1 Internalisation assays 
For internalisation experiments, GPI cells were seeded at a density of 1x106 cells per 
well in six-well plates (Corning,USA) and grown at 37°C for 48 hours. On the day of 
the experiment, cells were washed twice with ice cold internalisation medium (HAMS-
F12 supplemented with 1 % (v/v) FBS), followed by incubation for 2 hours at 37°C in 
fresh medium (1.2 ml per well). Approximately 3 pmol of 125I-rhTSH in 150 µl 
PBS/1%BSA was added to each well, along with either 150 µl PBS/1%BSA (for 
determining total binding) or 1.5 nmol unlabelled rhTSH in 150 µl PBS/1%BSA (for 
determining non-specific binding). The cells were incubated at 37°C for 10, 30, 60, 90 
and 120 minutes. At each time point the medium was removed and the internalisation 
halted by rinsing the cells twice with ice cold internalisation medium. Thereafter, the 
cells were washed twice for 5 min in ice cold 50 mM glycine, pH 2.8, 0.1 MNaCl 
(glycine/NaCl), followed by a rapid rinse in the same buffer. The two resulting acid 
wash supernatants in each case were pooled and retained as the surface-associated 
fraction. The cells were lysed with 1 M NaOH and collected as the internalised 
radioligand fraction. Each fraction was prepared in triplicate and all fractions were 
counted in a gamma-counter (LKB-1282 Compugamma system). The protein 
concentrations in the lysates were determined using the DC protein assay (BioRad). The 
internalised radioligand fraction was expressed either as a percentage of the total 
activity added per mg cell protein, or as a percentage of the total cell associated activity 
(i.e.surface associated plus internalised activity). 
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2.3.7.2 Externalisation assay 
GPI cells were seeded at a density of 1x106 cells per well in six-well plates 48h prior to 
the experiment. Cells were incubated at 37°C for 120 minutes with approximately 3 
pmol 125I-rhTSH in a total volume of 1.5 ml, in the presence or absence of excess 
competitor (1.5 nmol cold peptide). Incubation was terminated by washing each well 
with 2 x 1 ml ice cold PBS/1%BSA. Membrane bound ligand was removed by 
incubating the cells twice for 5 minutes in 1 ml ice cold glycine buffer (pH2.8) per well 
at room temperature, followed by a rapid rinse in the same buffer. The supernatant was 
discarded, and 1.5 ml assay medium (HAMS-F12 1640/1%FBSpre- warmed to 37°C) 
with or without excess competitor (1.5nmol cold peptide) was added, followed by 
incubation at 37°C for 10, 30, 60, 90 and 120 min. Following incubation, the medium 
was removed and retained for analysis (externalised fraction).The cells were lysed with 
1ml of 1MNaOH and collected (cell associated fraction). The externalised and cell 
associated fractions were counted in a gamma counter and expressed as a percentage of 
the total activity added per milligram of cell protein (as determined using a BioRadDC 
protein assay). Externalisation experiments were performed in triplicate. 
TCA precipitation of the supernatant was performed to ensure that the majority of the 
radioiodine remained in a protein-bound form with minimal free iodide. The 
supernatants were collected and 20% trichloacetic acid (TCA) was added to each 
sample fraction to form a final solution of 10% TCA as to precipitate the protein in 
solution. After centrifuging the protein into a pellet, the supernatant was removed and 
both fractions were counted using the gamma counter. Both the supernatant and the 
pellet were analysed. 
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2.3.8 125I-rhTSH in vivo studies 
2.3.8.1 125I-rhTSH SPECT/CT imaging and biodistribution studies 
Biodistribution and imaging studies were carried out to investigate the binding of 125I-
rhTSH to the thyroid and FRTL5 grafted subcutaneously in mice. 4 weeks prior to the 
experiment, 10 male SCID beige mice (Charles River research animal diagnostic 
services, London) were injected subcutaneously with 5 million FRTL5 cells in the left 
shoulder and left to grow until tumours became visible under the skin. In the SPECT/CT 
imaging, a blocking control using excess rhTSH was used together with 125I-rhTSH. All 
mice were given water with potassium iodide 3 days prior to imaging/biodistribution in 
order to saturate NIS and block the uptake of 125I via this transporter. Sodium 
perchlorate was also injected (i.p) half an hour previous to imaging/biodistribution 
experiments. Sodium perchlorate acts by blocking the uptake of 125I via NIS. For 
imaging studies, radiolabelled rhTSH and the blocking control were administered by 
intravenous tail injections and for biodistribution studies 125I-rhTSH and 125I-TI were 
also administered by intravenous tail injections. 
Trypsin inhibitor was radiolabelled with 125I-iodide and 125I-TI was selected for to be 
used as a control for the initial biodistribution due to its similar molecular weight to the 
rhTSH- 23 kDa. 
 The biodistributed animals were culled 2 hours after 125I-rhTH and 125I-TI injections 
and their tumour, pancreas, intestines, spleen, stomach, kidney, liver, heart, lungs, 
blood, muscle, tail and the thyroid, removed and biodistributed.  Biodistribution studies 
were carried out as described previously in section 2.2.12. 
The imaging animals were scanned using SPECT/CT (Bioscan, UK) at several times 
post i.v injection: 1h, 2h, 2.5h, 3h, 4h, 5h, 6h. These times were chosen to allow 
monitoring of the distribution and both specific and non-specific uptake of the 
radioligand. The injections were staggered by 30 minutes since the total imaging 
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(SPECT scan = 48 minutes, CT= 3 minutes) and set up times were approximately 30 
minutes. Approximately 5 MBq were injected into each mouse.  A 4-head small animal 
NanoSPECT/CT (Bioscan Inc., Washington DC) imaging camera with 1.4 mm pinhole 
apertures was used to image the thyroid of the mice. The mice were anaesthetised using 
isoflurane (Induction – 4% Isoflurane, 0.5-1L/min O2; Maintenance – 2% Isoflurane, 
0.5-1L/min O2) and placed on a heated animal bed.  
 
A CT scan was acquired with the following parameters: 
No of projections = 180 projections  
Frame resolution = Standard 
Exposure time = 500 ms  
Tube Voltage = 45kVp  
Duration = 3.45 minutes. 
Scan range = approx 60 mm. 
 
SPECT scans were acquired with following parameters: 
No of projections = 16 projections  
Time per projection =  ranged from 300-400ms  
Duration of 48 mins/scan (1hour), 48 mins/scan (3hours) and 48 mins/scan (6 hours) 
Scan range = same as CT. 
Images were obtained as described in section 2.2.12 
 
2.3.8.1.1 Quantification 
The tumour region of mice was quantified using IVS software. Elliptical regions of 
interest (ROIs) were manually drawn around target tumour from imaged mice. The ROI 
was manually drawn around the tumour, although all views were used to locate the 
tissue of interest. Data obtained from the ROIs drawn was expressed in terms of 
MBq/mm3, and the percentage of the injected dose in the total ROI was calculated by 
dividing this by the total radioactivity of 125I injected. 
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2.3.8.1.2 Blood stability studies 
Blood was collected from biodistributed mice 2 hours post 125I-rhTSH and 125I-TI 
injections. A TCA precipitation was carried out by adding 20%TCA to the same volume 
of 125I-rhTSH/blood and 125I-TI/blood to form a final solution of 10% TCA as to 
precipitate the protein in solution. After centrifuging the protein into a pellet, the 
supernatant was removed and both fractions were counted using the gamma counter. 
Both the supernatant and the pellet were analysed 
SDS-PAGE electrophoresis using PHASTgel was also carried out to confirm the 
stability of 125I-rhTSH and 125I-TI conjugate in the blood.  1 µl of blood was collected 
from biodistributed animals at 2 hours post injection of 125I-rhTSH and 125I-TI. The 
collected 1 µl was loaded into a Phastgel SDS-GEL electrophoresis and a reduced and 
non-reduced gel was run together with a control radiolabelled 125I-rhTSH and 125I-TI 
incubated at 37°C in PBS for the same amount of time. 
A detailed description of phastpage gel electrophoresis is pointed in section 2.2.9.3. 
 
2.3.8.2 Final biodistribution studies with 125I-rhTSH and 125I-CA 
Four weeks prior to the experiment, 10 male SCID beige mice were injected 
subcutaneously with 5 million FRTL5 cells in the left shoulder and the cells left to grow 
until tumours became visible under the skin. All mice were given water with potassium 
iodide 3 days prior to imaging/biodistribution in order to saturate NIS and block the 
uptake of 125I via this transporter. Sodium perchlorate was also injected (i.p) half an 
hour previous to imaging/biodistribution results.  
4 mice were injected with 125I-rhTSH, 3 mice were injected with control 125I 
radiolabelled  carbonic anydrase and 3 mice were injected with excess rhTSH together 
with 125I-rhTSH for the blocking control.  
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Carbonic anydrase (CA) was selected due to its non specific binding to TSHR as well as 
identical size to rhTSH of approximately 29 kDa. Mice were biodistributed at 3 hour 
time point post 125I-rhTSH and 125I-CA injections. Biodistribution studies were carried 
out as previously described in section 2.2.12.  
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CHAPTER 3. MAB9 STUDY 
In recent years, monoclonal antibodies have become useful tools in the management of 
cancer including its diagnosis, monitoring and treatment [182-186].  
Antibodies have the capacity to recognise and bind with high specificity and affinity to 
cell surface receptors that are expressed in a wide variety of malignant tissues. This 
property can allow radiolabelled antibodies to offer more precise diagnostic imaging 
and can also increase the effectiveness and decrease the potential side effects of 
radiotherapy [121, 127, 183, 187, 188].  
Most thyroid cancers are usually treated with radioactive iodine (RAI) which is taken up 
by the thyroid via NIS. However, some thyroid cancers can de-differentiate into an 
aggressive form that loses the expression of NIS and thus becomes resistant to 
radioiodine therapy [78-81, 86]. 
TSHR is a G protein coupled receptor expressed in at least some radioiodine resistant 
de-differentiated thyroid cancers [11, 27]. A monoclonal antibody (mAb9) against 
TSHR was investigated for its use in pre-clinical targeting of radioiodine resistant de-
differentiated thyroid cancer. 
Aims:  
• Assess the integrity and purity of unlabelled mAb9 with HPLC and SDS-PAGE 
electrophoresis. 
• Study the binding of unlabelled mAb9 to the TSHR in coated tubes and in a 
range of thyroid cancer cells using FACS and Western blot. 
• Determine the expression of TSHR in a range of thyroid cancer cell lines with 
RT-PCR, FACS and Western blot. 
• Label mAb9 with 125I and 111In radioisotopes. 
• Test the ability of radiolabelled mAb9 to bind to TSHR in thyroid cancer cell 
lines, TSHR transfected cells and pre-coated tubes in vitro. 
• Investigate the binding of radiolabelled mAb9 to the TSHR in the mouse thyroid  
in vivo. 
  
3.1.1 Confirmation of the integrity and purity of unlabelled mAb9
3.1.1.1  Size Exclusion HPLC
The first step was to perform size exclusion HPLC in order to determine the integrity 
and purity of mAb9. The method for these studies is detailed in 
The Size exclusion HPLC
retention time of 13.4 minutes with a very small degree of shouldering at retention time 
12.35 minutes which 
percentage for the intact antibody is
shouldering peak is 2.52.  The purity and integrity of mAb9 was shown to be relatively 
high due to the lack of major alternative peaks
Bio-Rad gel filtration standards were  also analysed in the SE
calibrate the size exclusion column (
A table with the Bio-Rad’s gel filtration components respective molecular weights and 
the retention times obtained with Biosep 2000 column in size exclusion HPLC is shown 
(Table 3.1). 
Figure 3.1:  UV chromatogram (280nm) of mAb9
a main peak at retention time 13.4 that corresponds to mAb9. 
 
3.1 mAb9 study results 
 
 
2.2.1
 chromatogram (figure 3.1) showed a single defined
most likely represents antibody aggregates. The surface area 
 97.5 while the surface area percentage for the 
. 
-HPLC in order to 
figure 3.2).  
 using size exclusion HPLC. The chromatogram shows 
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Figure 3.2: UV chromatogram of Biorad gel filtration standards (280nm). 
670,000Da) at retention time (RT) 11.43, 
at RT 15.12, Myoglobin (17,000 Da) at RT 16.72 and Vitamin
shown. 
 
The approximate size of proteins/antibodies can be determined by extrapolating their 
retention times from a graph of known Log 
 
Component   
 
Thyroglobulin (bovine)
γ-globulin (bovine) 
Ovalbumin (chicken) 
Myoglobin (horse)  
Vitamin B12   
 
Table 3.1: Biorad gel filtration molecular weight standards
corresponding to the retention time obtained with size exclusion HPLC.
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γ-globulin (Mwt 158,000) at RT 12.97, Ovalbumin (44,000 Da) 
 B12 (Mwt 1,350 Da) at RT 20.40 are 
molecular weight gel (figure 3.4
 Molecular Weight (Da) Retention Time
  670,000   11.43 
  158,000    12.97 
  44,000    15.12 
 17,000    16.72 
 1,350     20.40 
. The table shows t
 
4 6 8
y = -3.406 +31.015
R2: 0.9958
 
on time obtained in SE-HPLC with BioRad standards
 of Biorad’s components. 
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The approximate molecular weight of mAb9 was calculated by using the formula, Log 
(molecular weight) = RT-B/A. taken from the equation of the graph: Y = A*x + B.  A 
retention time of 13.4 minutes corresponds to 148,970 Da. This correlates with the 
generally accepted molecular weight of IgG antibodies and mAb9 antibody of 150,000 
Da. 
 
3.1.1.2 SDS-PAGE electrophoresis of unlabelled mAb9 
SDS-PAGE electrophoresis was performed as an additional means of confirming the 
integrity and purity of mAb9. See section 2.2.2 for a detailed methodology. 
 
 
Figure 3.5: SDS page electrophoresis analysis of mAb9. Showing mAb9 heavy chain (53 kDa) and light 
chain (22 kDa). 
 
Two main bands of approximately 53 kDa and 22 kDa were detected (figure 3.5). These 
molecular weights correspond to the antibody heavy and light chain respectively. The 
heavy chain band had two very close bands, one fainter than the other. The most likely 
explanation for the fainter band is the heterogeneity in the glycosylation of the heavy 
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chain of the IgG antibody. SDS electrophoresis thus confirmed the integrity and purity 
of mAb9. 
 
3.1.2 Binding of mAb9 to the TSHR in pre-coated tubes and cells 
3.1.2.1 Coated tube assay for the measurement of mAb9 binding to TSHR 
The next step was to determine the binding of mAb9 to the TSHR, which was 
investigated by using TSHR pre-coated tubes. In this assay, the binding of mAb9 to 
TSHR was investigated by assessing the ability of increasing concentrations of 
cold/unlabelled mAb9 to inhibit the binding of 125I-radiolabelled TSH (125I-rhTSH) to 
TSHR coated in the tubes. See section 2.2.10.1 for a detailed prototcol. 
The first experiment with this assay was to look at the competition of increasing 
concentrations of mAb9 and PR1A3 control antibody with 125I-TSH . This was in order 
to determine if unlabelled mAB9 bound to the TSHR coated on the tubes (figure 3.6).  
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Figure 3.6 Competition assay of 125I-TSH with unlabelled mAb9 in TSHR pre coated tubes. Increasing 
concentrations of cold mAb9 inhibited the binding of 125I-TSH by about 97%. mAb9 bound to the TSHR 
in the tubes with an IC50 of 0.43 nM. Values are the mean of triplicate  determinations +- SEM. 
 
Increasing concentrations of unlabelled mAb9 competed with 125I-TSH for the binding 
of TSHR coated in the tubes, as it inhibited the binding of 125I-TSH in a concentration 
dependent manner with the highest concentration inhibiting 96% of the binding. (figure 
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3.6). These results also indicate that mAb9 bound to the TSHR with an apparent affinity 
of 0.43 nM. The control antibody PR1A3 showed no competition for 125I-TSH binding. 
 
 
3.1.2.2 Binding of unlabelled mAb9 to cells 
3.1.2.2.1 Fluorescence activated cell sorting (FACS) to measure the binding of 
mAb9 to TSHR in TPC-1, FTC-133 and GPI cells.  
After confirming the integrity and purity of the mAb9 preparation and confirming the 
ability of mAb9 to bind to TSHR pre-coated in tubes, the next step was to carry out 
FACS experiments in order to assess the binding of both mAb9 and 4C1 monoclonal 
antibodies to the TSHR in a range of cell lines. Cell lines used included FTC-133 and 
TPC-1, GPI and two control cell lines: CHO and MKN45. See section 2.2.4 for a 
detailed methodology. 
 
FACS using GPI cells and 4C1 and mAb9 as primary antibodies 
mAb9, 1 µg/ml mAb9, 10 µg/ml
4C1, 10 µg/ml4C1, 1 µg/ml
 
Figure 3.7: FACS analysis of TSHR expression in GPI (green) and CHO cells (dark blue). A significant 
shift is seen with 4C1 and mAb9 antibodies when compared with control cell lines.  An isotype-matched 
control antibody was used as a negative control (data not shown).  
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Both 4C1 (commercial anti-TSHR monoclonal antibody) and mAb9 antibodies induced 
a substantial positive shift in GPI cells when compared with control cell lines (figure 
3.7). FACS with GPI cells showed a very broad peak. This suggests that expression of 
TSHR in GPI cells is heterogeneous, with some cells expressing THSR in high 
quantities, and others in lower amounts. 
 
FACS using TPC-1 cells and 4C1 and mAb9 as primary antibodies 
4C1, 1 µg/ml 4C1 , 10 µg/ml
mAb9, 1 µg/ml mAb9, 10 µg/ml
 
Figure 3.8:  FACS analysis of TSHR expressed in TPC-1(light blue) and MKN45 (dark blue) cells. At 10 
µg/ml of 4C1, a moderate positive shift is seen in TPC-1 cells. With mAb9 at both 1 µg/ml and 10 µg/ml 
no shift was seen. An isotype-matched control antibody was used as a negative control (data not shown).  
 
4C1 (10 µg/ml) antibody induced a marginal positive in TPC-1 cells shift when 
compared to controls. (figure 3.8). This suggests that 4C1 is binding to low levels of 
TSHR in TPC-1 cells. mAb9 however did not induce a shift when compared to controls.  
This indicates that mAb9 is not binding to the low levels of TSHR in TPC-1 cells. 
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FACS with FTC-133 cells and 4C1 and mAb9 as primary antibodies 
4C1, 1 µg/ml 4C1, 10 µg/ml
mAb9, 1 µg/ml mAb9, 10 µg/ml
Figure 3.9: FACS analysis of TSHR expressed in FTC-133(pink) and MKN45 cells (dark blue). At 10 
µg/ml of 4C1, a moderate positive shift was seen in FTC-133 cells, when compared with control cell 
lines. With mAb9 at both 1 µg/ml and 10 µg/ml no shift was seen. An isotype-matched control antibody 
was used as a negative control (data not shown).  
 
A moderate positive shift was again observed with 10 µg/ml of 4C1 antibody in FTC-
133 cells (figure 3.9). This suggests that 4C1 binds to the TSHR in FTC-133 cells. 
However mAb9 did not induce a positive shift in FTC-133 cells again indicating that 
mAb9 is not binding to the low levels of TSHR expressed in FTC-133 cells. 
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FACS using FRTL5 cells and 4C1 and mAb9 as primary antibodies 
4C1, 1 µg/ml 4C1, 10 µg/ml
mAb9, 1 µg/ml mAb9, 10 µg/ml
 
Figure 3.10: FACS analysis of TSHR expressed in FRTL5 (pink) and CHO cells (dark blue). At 1 µg/ml 
and 10 µg/ml of 4C1, a moderate positive shift was seen in FRTL5 cells, when compared with control cell 
lines. With mAb9 at both 1 µg/ml and 10 µg/ml no shift was seen. An isotype-matched control antibody 
was used as a negative control (data not shown).  
 
A moderate positive shift was observed with 4C1 antibody (figure 3.10) suggesting that 
4C1 binds to TSHR in FRTL5 cells. However, once again, mAb9 did not induce a 
positive shift in FRTL5 cells indicating that mAb9 did not bind to the TSHR expressed 
in FRTL5 cells.  
A graph summarising and comparing MFU values obtained in FACS is shown in figure 
3.11. 
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Figure 3.11: Comparison of mean fluorescent units (MFUs) of performed FACS with both 4C1 and 
mAb9 at 1 µg /ml and 10 µg /ml. Both mAb9 and 4C1 antibodies induced significant differences in the 
MFUs of GPI cells. *** P < 0.001. Values are the Mean+-SEM, n = 3. A One way ANOVA with 
Dunnetts post hoc test was used to compare all the cell lines used.  
 
In summary, FACS experiments showed that 4C1 and mAb9 antibodies are able to bind 
significantly to the TSHR in GPI cells. mAb9 did not bind to any of the other cell lines 
studied. 4C1 bound moderately to FTC-133 and FRTL5 cells, however, the binding 
shown was however not statistically significant when compared with the control cell 
line.  
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3.1.2.2.2 Immunohistochemitry characterisation of TSHR expressed in FTC-133, 
TPC-1 and GPI cells 
Immunohistochemical staining of FTC-133, TPC-1 and GPI cells was carried out with 
the purpose to further verify FACS results.  Detailed methodology of 
immunohistochemistry can be found in section 2.2.5. 
Images of representative sections of the immunofluorescent staining are shown in 
figures 3.12, 3.13, 3.14 and 3.15. 
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4C1 and mAb9, CHO cells 
 
 
 
50 uM 
Figure 3.12: Immunohistochemistry performed on CHO cells to investigate TSHR expression
Blue staining shows haematoxylin stained nuclei. TSHR staining is shown in brown. No
specific binding was shown in CHO cells with both 4C1 and mAb9 antibodies. Images were taken 
at  20x magnification
4C1
mAb9 
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4C1 and mAb9, FTC-133 cells 
 
 
mAb9
4C1 
Figure 3.13Immunohistochemistry performed on FTC-133 cells to investigate TSHR expression. TSHR 
staining is shown in brown. Blue staining shows haematoxylin stained nuclei. No specific binding was 
shown in FTC-133 with both 4C1 and mAb9 antibodies. Images were taken at 20 x magnification.
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4C1 and mAb9, TPC-1 cells 
 
 
50 uM
Figure 3.14: Immunohistochemistry performed on TPC-1 cells to investigate TSHR expression 
Blue staining shows haematoxylin stained nuclei. TSHR staining is shown in brown. No 
specific binding was shown in TPC-1 cells with both 4C1 and mAb9 antibodies. Images were taken 
20 x magnification. 
4C1
mAb9 
50 M
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4C1 and mAb9, GPI cells 
 
4C1
mAb9
50 uM
50 uM
 
Figure 3.15: Immunohistochemistry performed on GPI cells to investigate TSHR expression.  TSHR 
staining is shown in brown. Blue staining shows haematoxylin stained nuclei. TSHR positive staining was 
shown with mAb9 and 4C1 antibody. The black arrow is pointing at TSHR expressed in the nucleus and 
the red arrow is pointing at TSHR expressed in the cell membrane. Images were taken at 20 x 
magnification.  
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No staining was observed with 4C1 in the negative control cell line, CHO, as well as in 
FTC-133 and TPC-1 cells. 4C1 and mAb9 antibodies stained GPI cells in the nucleus as 
well as in the cell membrane. 
Both FACS and immunohistochemistry results showed varying patterns of expression 
of TSHR in GPI cells. Some GPI cells expressed/stained high numbers of TSHR while 
other GPI cells expressed/stained lower levels of TSHR. Also, in 
immunohistochemistry studies, some GPI cells TSHR stained mainly in the nucleus 
while in other GPI cells mainly in the cell membrane.   
No staining was observed with mAb9 in CHO, FTC-133 and TPC-1 cells however some 
degree of staining was observed with mAb9 in GPI cells. This could be due to these 
cells not expressing TSHR at high enough levels in order for it to be detected.  To study 
this further, a Real-Time PCR study was performed. 
 
 3.1.3 Characterising TSHR in cell lines 
3.1.3.1 RT-PCR relative quantification 
In order to determine and compare the mRNA expression levels of TSHR in TPC-1, 
FTC-133 and GPI cells a quantitative RT-PCR assay was conducted.  
Relative quantification can be achieved by analysing the Ct value obtained. The Ct 
value is the number of cycles required for the fluorescent signal to cross a threshold. 
To quantify the RT-PCR results the comparative Ct method was used. In this method, 
the Ct values of the samples are compared with the Ct values of a negative control i.e. 
the calibrator. The Ct values of both calibrator and samples are normalised against a 
suitable endogenous housekeeping gene, in this case GAPDH. See section 2.2.6 for a 
detailed methodology.  
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Relative quantification was performed in FTC-133, TPC-1 and GPI cell lines and TSHR 
expression was compared with that from the calibrator, the non TSHR expressing cell 
line, CHO (figure 3.16).  
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Figure 3.16: Quantitative RT-PCR to determine TSHR expression over CHO  (calibrator) in all thyroid 
cell lines.  GPI cells are shown to have high expression of TSHR when compared with the calibrator cell 
line. FTC-133 and TPC-1 did not show significant expression of TSHR. Values are mean ± SEM (n=3). 
ANOVA, * P <0.05 with a Dunnett post-hoc test. 
 
TSHR mRNA was expressed at significantly higher levels in GPI cells when compared 
to the calibrator cell line, CHO (figure 3.16). FTC-133 cells showed some expression of 
TSHR mRNA when compared with the calibrator cell line, CHO, but this was not 
statistically significant. There was no apparent expression of TSHR mRNA in TPC-1 
cells. 
 
3.1.3.2 Western blot experiments 
Western blot experiments were carried out to measure TSHR protein levels in FTC-133, 
GPI and TPC-1 cell lines. See chapter 2.2.7 for a detailed methodology.  
  
Figure 3.17 Western blot analysis of cell lysates with 4C1 and mAb9 antibodies in GPI cells. With 4C1 a 
band at 67 kDa was shown but mAb9 did not show any band. The 67
GPI cells.   
 
Western blot analysis with 4C1 in GPI cells (
protein at a molecular weight
weight of TSHR in GPI cells. No band was observed in CHO, TPC
cells. These results support 
be expressed in TPC-
The Western blot analysis with mAb9 in GPI cells 
 
3.1.4 Radiolabelling of mAb9 with 
mAb9 was radiolabelled with 
high (10 MBq/5 µg) specific activity.
After the radiolabelling using the Iodogen method three experiments were conducted in 
order to confirm the labelling efficiency of 
chromatography (ITLC) was carried out in order to determine the labelling efficiency of 
the radiolabelled monoclonal antibody. Secondly, Radio
chromatography (Radio
and also to test the integrity of the radiolabelled mAb9. Lastly, SDS
electrophoresis was also carried out to determine the size of the radiolabelled antibody 
and also to test for the presence of any degradation or aggregates. 
 
 kDa band represents the TSHR in 
figure 3.17) detected a single band of 
 of 67 kDa. This corresponds to the expected mol
the RT-PCR results, where TSHR mRNA 
1 and FTC-133 cells.  
detected no band
125I  
125I using the Iodogen method at low (10 MBq/20 µg) and 
 See section 2.2.8 for a detailed methodology.
125I-mAb9. First, instant thin layer 
-High performance liquid 
-HPLC) was carried out to confirm the results obtained by ITLC 
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3.1.4.1 Determination of the purity and radiolabelling efficiency of radiolabelled 
mAb9 
3.1.4.1.1 Instant Thin Layer Chromatography (ITLC) 
ITLC was performed in order to determine the radiolabelling efficiency of 125I-mAb9. 
See section 2.2.9.1 for a detailed methodology. ITLC results showed most of the 
activity in the origin of the strip, indicating that 125I-mAb9 had high labelling efficiency 
ranging from 94% to close to 100% (figure 3.18 and table 3.2). 
 
Figure 3.18: Analysis of the radiolabelled product using ITLC-SG strips run in 85% methanol. The 
origin represents the labelled compound whereas the solvent front represents free 125I. 
 
Labelling experiment CPM Origin CPM Solvent %labelling 
1 1577646 36046 98 
2 2822337 17414 99.8 
3 393839 28041 94.4 
4 574026 36716 93.9 
5 555450 29883 94.9 
6 326520 18365 94.7 
 
Table 3.2: Representative examples of results of ITLC quality control of 125I-mAb9 radiolabelling 
efficiency. All  radiolabellings were above 94% labelling efficiency. 
 
 
3.1.4.1.2 Radio Size-exclusion HPLC  
To further validate results, size exclusion Radio-HPLC was also performed. This was in 
order to determine the radiolabelling efficiency of 125I-mAb9, as well as to determine 
the radiochemical and chemical purity of 125I-mAb9. ITLC separates antibody-bound 
radioactivity from free 125I but is not able to detect the presence of undesired antibody 
impurities. Therefore size-exclusion Radio-HPLC was carried out to provide additional 
Solvent  front
Origin
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information on the integrity of the radiolabelled antibody. See section 2.2.9.2 for a 
detailed methodology. 
 
RT= 13.4
 
Figure 3.20: Radio-HPLC analysis of 125I radiolabelled mAb9. A single major peak at retention time 13.4 
minutes is shown. This peak represents a radiolabelling efficiency close to 100%. 
 
 
Radio-HPLC results showed a main peak at retention time 13.4 minutes (figure 3.20), 
similar to that seen in the analysis with the unlabelled antibody (section 3.1.2). HPLC 
results thus confirm that 125I-mAb9 was of a high labelling efficiency. The radioactive 
trace shows a high degree of ‘noise’ due to the high background of the radioactive 
detector (Raytest) as a result of the relatively low levels of activity being analysed. The 
highlighted arrow in the figure represents the retention time where free 125I would be 
expected to elute. These results are similar to those obtained with control 125I 
radiolabelled 4C1 anti-TSHR antibody, which also showed a major intact peak at a 
similar retention time (results not shown). 
 
3.1.4.1.3 SDS-PAGE gel electrophoresis and phosphor imaging system to 
determine molecular weight and purity of 125I-mAb9. 
The resolution of size exclusion HPLC is not particularly high and therefore usually it 
does not separate molecules with fewer than thousands of Da difference. For this 
reason, SDS page gel electrophoresis SDS-PAGE gel electrophoresis was carried out in 
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order to determine the molecular weight and purity of 125I-mAb9. See section 2.2.9.3 of 
methodology for a detailed protocol. 
 
Figure 3.21: SDS page gel autoradiography. 125I-mAb9 is shown at a molecular weight of 150 kDa. 
 
A single band was detected at approximately 150 kDa in SDS-PAGE electrophoresis 
(figure 3.21). It can therefore be concluded that 125I-mAb9 was of high purity. 
These quality control experiments showed that 125I-mAb9 was labelled to a high 
efficiency and without degradation or aggregation of the protein. The next step was 
therefore to study the binding proprieties of 125I-mAb9 to TSHR, both in pre-coated 
tubes and in thyroid cancer and TSHR transfected cells, GPI cells. 
  
3.1.5 125I-mAb9 binding Assays 
3.1.5.1 TSHR Pre-coated tube assays 
Coated tube assay for the measurement of 125I-mAb9 binding to TSHR 
The TSHR coated tube assay assessed the ability of unlabelled mAb9 to compete with 
radiolabelled 125I-mAb9 for the binding to TSHR coated in the tubes. See section 
2.2.10.1 for a detailed protocol. 
Molecular
weight
markers 125I-mAb9 125I-4C1
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A high and a low specific activity of 125I-mAb9 were tested in this assay in order to find 
out the effects of specific activity on receptor binding (figure 3.22). 
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Figure 3.22: Competition assay of of 125I-mAb9 with unlabelled mAb9 to the TSHR in pre coated tubes. 
Increasing concentrations of mAb9 competed with 5 µg mAb9 labelled with 10 MBq of 125I (higher 
specific activity) and 20 µg mAb9 labelled with 10 MBq 125I (lower specific activity). Values are the 
mean of duplicate determinations. 
 
When using 125I radiolabelled mAb9 at a low or high specific activity, only incomplete 
inhibition of binding was seen compared with the complete inhibition seen in figure 3.6 
(figure 3.23). This may be due to a higher non-specific binding of the 125I-mAb9 as 
compared to 125I-TSH. The radiolabelling of antibodies with 125I can potentially damage 
the antigen-binding activity of the antibody through oxidative damage caused by 
binding/attachment of the isotope to the tyrosine rich antigen site. To further explore if 
the mAb9 binding ability was damaged, additional TSHR pre-coated tube assays and 
FACS assays were performed (figure 3.2.3, 3.2.4 and 3.2.5). See sections 2.2.4 and 
2.2.10.1 for a detailed protocol. 
Three preparations were compared:  
• mAb9 incubated alone in an Iodogen tube- ‘oxidised mAb9’. 
• mAb9 co-incubated with cold iodine (potassium [127I] iodide) in an Iodogen tube 
– ‘cold labelled’ mAb9. 
• mAb9 mixed with potassium iodide (KI) – ‘mixed mAb9’. 
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Figure 3.23: Competition assay of 125I-mAb9 with ‘oxidised mAb9’ and ‘cold labeled mAb9’ in TSHR 
pre coated tubes. Indicated concentrations of ‘cold labelled mAb9’ as well as oxidised mAb9 competed 
with 125I-mAb9 in a concentration dependent manner. PRA1A3 was used as a control antibody. Values 
are the mean of duplicate determinations. 
 
1 µg/ml 10 µg/ml
'Oxidised mAb9'
10 µg/ml1µg/ml
'Mixed mAb9'
10 µg/ml1µg/ml
Cold labelled mAb9
 
Figure 3.24: FACS analysis on GPI cells using different mAb9 preparations. ‘Mixed mAB9’ and 
‘oxidised mAb9’ showed a positive shift. No shift was detected with ‘cold labelled mAb9. CHO control 
cells are shown in dark blue and GPI cells are shown in green. 
 
  
Similar experiments were also carried out with 4C1antibody (
 
Figure 3.25: FACS analysis of 4C1 preparations. ‘Oxidised 4C1’ and ‘Mixed 4C1’ show a positive shift. 
No shift was seen with ‘cold
green. 
 
‘Cold labelled mAb9’ and ‘oxidised’ mAb9 were able to compet
binding of TSHR coated in the tubes (
concluded that the oxidation inflicted by the Iodogen labelling method was not 
damaging the antibody
however, ‘cold labelled mAb9’ and ‘cold labelled 4C1’ did not bind to TSHR in GPI 
cells (figure 3.24 and 
 
figure 3.25
-labelled 4C1’. CHO cells are shown in dark blue and GPI cells are shown in 
e with 
figure 3.23). From these results it can be 
’s ability to bind to the TSHR coated in the tubes. 
3.25).  
121 
). 
 
125I-TSH for the 
In FACS, 
122 
 
 
3.1.5.2 125I-mAb9 cell binding assays 
In section 3.1.2, unlabelled mAb9 was shown to bind to the TSHR in GPI cells and pre-
coated tubes. Once the mAb9 was successfully radiolabelled, it was important to 
determine whether it had retained its receptor binding affinity. 125I radiolabelled mAb9 
also bound to TSHR in pre-coated tubes, therefore the next step was to assess the 
binding of 125I-mAb9 to the TSHR in cells.  
 
3.1.5.2.1 Assay development and optimisation 
Effect of temperature and time in TSHR cell binding assays 
The first condition to be considered was the effect that temperature and incubation time 
have on the binding of 125I-mAb9 to the TSHR in FTC-133, TPC-1 and GPI cells. See 
sections 2.2.11.1 and 2.11.2 for a detailed protocol.  
 
Figure 3.26: Effect of temperature and time in the binding of 125I-mAb9 to GPI cells. Cells were 
incubated for up to 6 hours at 4°C, room temperature (RT) and 37°C. Cells incubated at RT showed the 
highest percentage of bound antibody. This assay was carried out with triplicate samples and repeated 
twice.  
 
Incubation at room temperature for around 2 to 3 hours appeared to be the most 
favourable conditions to be used in the GPI cell binding assay, as it gave the highest 
percentage of bound mAb9 (figure 3.26), and the later conditions were thus used in 
future experiments.  
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A TCA precipitation assay was performed over a 6 hour period to find out if the 125I 
remained antibody-bound and did not dissociate during the assay. See section 2.2.11.1 
 of methodology for a detailed protocol.  
 
TCA precipitation assay 
 
Figure 3.27: TCA precipitation assay of  125I-mAb9 over a period of 6 hours. Most of the 125I remained bound to 
the mAb9 antibody  over a period of 6 hours. 
 
This assay showed that at most times and at different temperatures the protein remained 
bound to 125I (figure 3.27) and therefore results were not being confounded by the 
presence of 125I metabolites. 
 
Effect of media in TSHR cell binding assays 
In order to identify the most effective buffer to use in the cell binding experiments, a 
number of different buffers were tested in TSHR transfected GPI cells. 
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Figure 3.28: Graph showing binding of 
difference in binding was observed.
 
The different buffers used were found not to have a significant effect on the binding
there was no significant difference in the proportion of 
DMEM, HBSS, Krebs and PBS/0.1%BSA buffers (
binding experiments any of the buffers could potentially be used. DMEM binding buffer 
was selected to be used in future binding studies.
 
3.1.5.2.2 Immunoreactive fraction asssay
The first step in the assay development was to perform a direct radioimmunoassay in 
order to measure the immunoreactivity of the radiolabelled mAb9, i.e. the propo
radioactive antibody having the ability to bind the TSHR. 
detailed methodology.
133 and TPC-1 cells, however, FTC
binding therefore it was not possible to determine an 
value for these cells. 
that about 5% of the radioactive antibody is able to bind to the TSHR (
 
 
125I-mAb9 to GPI cells in different buffers. No significant 
 
125I-mAb9
figure 3.28
 
 
See section 
 Immunoreactive fraction assays were performed on GPI, FTC
-133 and TPC-1 cells failed to show any antibody 
(immunoreactive fraction) 
The immunoreactivity was calculated to be 5.1 %, which suggests 
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Figure 3.29: Immunoreactive fraction assay with 125I-mAb9 in GPI cells. Graph of reciprocal of fraction 
bound against the reciprocal of cell concentrations. 
 
3.1.5.2.3 Saturation assay using 125I-mAb9 in GPI cells 
Saturation assays were then performed with 125I-mAb9 in order to measure the specific 
radioligand binding to cells at equilibrium to determine both the receptor numbers 
(Bmax) and binding affinity (Kd) of 125I-mAb9. See section 2.2.11.4 of methodology 
for a detailed protocol. mAb9 bound to TSHR in GPI cells (figure 3.30) with a binding 
affinity of 3.6 nM and Bmax of 2816 fmol/mg protein. 
 
125I-mAB9 GPI binding assay 
0 10 20 30
0
1000
2000
3000
4000
Total Binding
Non-specific Binding
Specific Binding
Bmax: 2816
Kd: 3.66 nM
Radioligand concentration (nM)
Bo
u
n
d 
(fm
o
l/m
g 
pr
o
te
in
)
 
Figure 3.30: Equilibrium saturation binding of 125I-mAb9 to GPI cells. 125I-mAb9 bound to GPI cells 
with a kD of 3.66 nM and Bmax 2816 fmol/mg Results represent specific binding (total minus 
nonspecific binding) of triplicate determinations. Mean (±SEM) 
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125I-4C1 GPI binding assay 
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Figure 3.31: Equilibrium saturation binding of 125I-4C1 to GPI cells. Results represent specific binding 
(total minus nonspecific binding) of triplicate determinations. Mean (±SEM) 
 
125I-4C1 bound to GPI cells with a kD of 6.5 nM and Bmax of 695 fmol/mg (figure 
3.31). The binding affinity with 125I-4C1 does not differ greatly from the value obtained 
with 125I-mAb9 (figure 3.30). 
 
3.1.5.2.4 Saturation assay with 125I-mAb9 in FRTL5 cells 
Saturation binding assays were also performed in FRTL5 cells. Although 125I-mAb9 
appeared to bind to FRTL5 cells, the majority of the binding was non-specific binding 
(figure 3.32).  
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Figure 3.32: Equilibrium saturation binding of 125I-mAb9 to FRTL5 cells. Results represent specific 
binding (total minus nonspecific binding) of triplicate determinations 
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From the cell binding assay result, it can be concluded that 125I-mAb9 binds specifically 
to GPI cells with a binding affinity of 3.6 nM. 125I-mAb9 does not, however, bind 
specifically to FRTL-5 cells. 
 
3.5.2.5 Saturation assay with 125I-mAb9 and 125I-4C1 in FTC-133 and TPC-1 cells 
Saturation assays were also performed in FTC-133 and TPC-1 cells using the same 
conditions as previously in the conducted saturation assays. Saturation assays were 
repeated 3 times however no binding was detected. This was possibly due to the very 
low amount of TSHR expression in these cells hence resulting in very negligible 
binding. 
 
3.1.6  Imaging 
3.1.6.1 Imaging of mice injected with radiolabelled mAb9 and 125I-iodide using 
SPECT/CT 
SPECT/CT imaging experiments were performed in mice, in order to assess the binding 
of 125I-mAb9 to the TSHR expressed in the normal thyroid of the mouse. See section 
2.2.12 for a detailed methodology. 
Representative images are shown below and the results are summarised in figure 3.33. 
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Group A (125I radiolabelled mAb9) 
4 hours - High uptake in both thyroid and salivary glands seen 
Salivary gland
Thyroid gland Thyroid gland
Thyroid gland
Salivary gland
Thyroid gland
Sagittal
MIP Coronal
Transverse
 
 
Group A (125I radiolabelled mAb9)  
24 hours – High uptake in the thyroid only 
Thyroid gland (right and left lobe) Thyroid gland (right and left lobe)
Thyroid gland (right and left lobe)
Thyroid gland
MIP
Sagittal
Coronal
Transverse
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Group B (sodium perchlorate followed by 125I radiolabelled mAb9) 
4 Hours - Some uptake seen in the thyroid only 
Thyroid gland Thyroid gland
Thyroid gland
Saggital Coronal Transverse
 
Group B (sodium perchlorate followed by 125I radiolabelled mAb9 
24 hours – No uptake seen 
No uptake thyroid or salivary gland shown
Sagittal
MIP Coronal
Transverse
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Group C (125I-iodide at the same activity as group A) 
4 hours – Uptake seen in both thyroid and salivary gland. Much higher in latter. 
Salivary glandThyroid gland
Thyroid gland Salivary gland
Thyroid gland
Thyroid gland
Sagittal
MIP Coronal
Transverse
 
 
Group C (125I-iodide at the same activity as group A) 
24 hours – Uptake in thyroid only 
Thyroid gland (right and left lobe) Thyroid gland (right and left lobe)
Thyroid gland (right and left lobe)
Thyroid gland 
Coronal
TransverseSagittal
MIP
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Group D (sodium perchlorate followed by 125I-iodide) 
4 hours – No uptake seen 
No uptake thyroid and salivary gland shown
Sagittal
MIP Coronal
Transverse
 
Group D (sodium perchlorate followed by 125I-iodide) 
24 hours – No uptake seen 
 
No uptake thyroid and salivary gland shown
Sagittal
MIP Coronal
Transverse
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  EXPRESSED AS % OF 
INJECTED DOSE    
 
GROUP Mouse   Time (hours)  Thyroid  Salivary gld Salivary gld Salivary gld 
 A 1 4 2.4 0.6 0.9 6.8 
125I-mAb9   24 2.5 0.0 0.0 0.0 
 A 2 4 2.0 3.1 4.8 4.6 
   24 2.4 0.0 0.0 0.0 
  
      
125I-mAb9 B 3 4 0.2 0.0 0.0 0.0 
+  
 24 0.0 0.0 0.0 0.0 
perchlorate B 4 4 0.1 0.0 0.0 0.0 
  
 24 0.0 0.0 0.0 0.0 
  
      
125I-iodide C 5 4 1.2 14.3 13.8 0.0 
  
 24 0.7 0.0 0.0 0.0 
 C 6 4 0.7 7.1 0.0 0.0 
  
 24 0.5 0.0 0.0 0.0 
  
      
125I-iodide D 7 4 0.0 0.0 0.0 0.0 
+  
 24 0.0 0.0 0.0 0.0 
perchlorate D 8 4 0.0 0.0 0.0 0.0 
  
 24 0.0 0.0 0.0 0.0 
 
Table 3.3: % of injected dose of radioactivity in the thyroid gland and salivary gland. 4 and 24 hour time    
points were used. 
 
Group A (mice injected with 125I-radiolabelled mAb9) showed similar activity in the 
thyroid at both 4 and 24 hour time points. It also showed activity in the salivary gland at 
the 4 hour time point, however it did not show any activity in the salivary gland after 24 
hours. Because 125I is taken up into salivary glands via NIS, it is clear that in vivo 
metabolism of the 125I-mAb9 is occurring in vivo resulting in the release of 125I. The 
thyroid uptake in group A may therefore be due either 125I-mAb9 binding to the TSHR 
or to 125I being taken up by to NIS. In order to understand if this uptake was due to the 
actual binding of mAb9 to the TSHR, in group B sodium perchlorate was used to block 
the uptake of iodine by NIS. 
Group B (where perchlorate was added prior to the injection of 125I-mAb9) showed 
no uptake in the salivary glands but some activity in the thyroid in both mice at the 4 
hours time point, however this is less than that seen in Group A and there is no uptake 
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after 24 hours. The lack of uptake in the salivary glands indicates that the perchlorate 
effectively blocked NIS and suggests that the thyroid uptake is due to binding to the 
TSHR in vivo.  
In group C (125I at the same activity as group A) there was activity in the thyroid at 
both 4 hours and 24 hour time points, however the activity was lower than group A, 
which again may suggest the higher uptake in Group A is due to mAb9 binding to 
TSHR. As expected, the salivary gland had activity at the 4 hour time point, this 
correlates with studies that have shown 125I to be taken up by this gland [16, 79]. At the 
24 hour time point, activity was seen in the thyroid however not in the salivary glands, 
since iodide is not organified in these tissues. 
Although all mice were given potassium iodide in order to block the thyroid, this did 
not block the uptake of iodine in those groups which were not also treated with 
perchlorate. 
Group D (perchlorate prior to the injection of 125I) showed no activity in the thyroid 
on all time points as well as no activity in the salivary glands. These results confirm that 
the sodium perchlorate is efficiently blocking the uptake of iodine by the thyroid. 
Although 125I-mAb9 showed binding to the TSHR in the thyroid of mice in group B, the 
percentage of injected dose was extremely low, and thus, results are unable to 
categorically indicate whether the radioactivity seen in the images is due to the specific 
binding of 125I-mAb9 to the TSHR or due to free 125I being taken up by the thyroid via 
NIS.  
 
3.1.7  Radiolabelling of mAb9 with 111In 
As previously discussed, radiolabelling mAb9 with 125I might be damaging its structure, 
and by doing so, hindering its ability to bind to the TSHR. Moreover, most importantly, 
there is a chance that free 125I can be taken up into the thyroid via NIS and interfere with 
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in vivo imaging and biodistribution studies. This problem can potentially be solved by 
radiolabelling mAb9 with a different radioisotope. In this section, mAb9 was 
radiolabelled with 111In. 111In was used due to its beneficial imaging properties and also 
due to its easy availability in the lab but most importantly because it is not taken up by 
the thyroid. 
 
3.1.7.1 Conjugation of mAb9 with SCN-Bz-DOTA 
The first step was to conjugate the chelating agent to the antibody via lysine side chain 
amino groups.  See section 2.2.13.1 for a detailed methodology. 
 
3.1.7.2 Assessing the purity and integrity of the Benzyl-DOTA-mAB9 conjugate. 
3.1.7.2.1 Size Exclusion- HPLC 
Benzyl-DOTA-mAb9 was analysed by size-exclusion HPLC to determine the integrity 
and purity of the newly conjugated mAb9. See section 2.2.13.2 for a detailed 
methodology. A single peak at retention time 13.4 minutes was observed in size 
exclusion HPLC, indicating that Benzyl-DOTA-mAb9 was of high purity and integrity 
(figure 3.34). The molecular size of Benzyl-DOTA-mAb9 was estimated to be around 
150,000 Da according to the gel filtration standards previously analysed by SE-HPLC 
(section 3.1.2, figure 3.2). 
 
  
Figure 3.34: Size-exclusion HPLC 
13.43 minutes. 
 
 
3.1.7.2.2 Assessing the binding ability of 
Once mAb9 had been conjugated to DOTA, it was important to de
conjugated antibody had
compromised in any way. In order to do that a FACS with GPI cells
coated tube assay were performed with the newly conjugated 
See sections 2.2.13.3 and 2.2.13.4 
 
3.1.7.2.3 Benzyl-DOTA
Figure 3.35: FACS analysis 
significant positive shift was seen at both 1 
with ScnBzDOTA-mAb9. A single peak 
Benzyl-DOTA-mAb9 to TSHR.
 retained its receptor binding affinity and that this had
for a detailed methodology. 
-mAb9 FACS 
with Bz-DOTA-mAb9 in GPI (green) and CHO (dark blue) cells.
µg /ml and 10 µg /ml Benzyl-DOTA
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eluted at retention time 
 
termine whether the 
 not been 
 and the TSHR 
Benzyl-DOTA-mAb9.  
 
 A 
-mAb9.  
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Figure 3.36: Competition assay of 125I-TSH with Bz-DOTA-mAb9 to the TSHR in pre coated tubes. 
indicated concentrations of Bz-DOTA-mAb9 competed with 125I-TSH in a concentration dependent 
manner. Values = Mean (±SEM). 
 
Benzyl-DOTA-mAb9 bound to TSHR in GPI cells (figure 3.35). The shift and MFU 
obtained with Benzyl-DOTA-mAb9 were similar to the shift and MFU obtained with 
unconjugated mAb9. Benzyl-DOTA-mAb9 also inhibited the binding of TSHR in the 
coated tube assays by up to 97%, as increased concentrations of antibody conjugate 
competed with 125I-TSH for the binding to the TSHR (figure 3.36). FACS and coated 
tube assay experiments thus indicate that the conjugation of mAb9 does not appear to 
harm its ability to bind to TSHR in GPI cells and in pre-coated tubes.  
 
3.1.7.3 111In labelling to Benzyl-DOTA mAb9 
Once Bz-DOTA-mAb9 was generated, it could then be labelled with 111In. See section 
2.2.14 of methodology for a detailed protocol. 
 
3.1.7.3.1 Assessing labelling efficiency of 111In-mAb9 
Benzyl-DOTA-mAb9111In (111In-mAb9) labelling efficacy was confirmed by SE-HPLC 
and ITLC. See section 2.2.14.1 for a detailed methodology.  Representative results of 
HPLC and ITLC are shown in figures 3.37 and 3.38 below. 
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Figure 3.37: Radio size-exclusion HPLC with 111In-mAb9. A single intact peak eluted at retention time 
13.51 minutes. This peak represents a radiolabelling efficiency close to 100%. 
 
ITLC analysis  
A representative example of ITLC analysis read in a phosphor imager is shown in 
figure 3.38. 
 
Figure 3.38: Analysis of the radiolabelled product using ITLC-SG strips run in 0.1M ammonium 
acetate/EDTA pH 5.5. The origin represents the labelled compound whereas the solvent front represents 
unbound 111In. 
 
Radio HPLC showed a main peak of 111In-mAb9 eluted at retention time 13.5 minutes 
and ITLC showed around 98% of the activity remained in the origin  of the ITLC strip 
Origin
Solvent front
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(figure 3.37 and figure 3.38). It thus can be concluded that a high purity and high 
labelling efficiency 111In-mAb9 was produced. 
 
3.1.8 111In-mAb9 binding assays 
3.1.8.1 TSHR Pre-coated tube assay with 111In-mAb9 
In order to investigate whether 111In-mAb9 retained its TSHR binding ability, a TSHR 
pre-coated tube assay was carried out. This assay determined if cold mAb9 competed 
with 111In-mAb9 for the binding of TSHR coated in the tubes. See section 2.2.14.1.1 of 
methodology for a detailed protocol. 
 
Figure 3.39: Competition assay of 111In-mAb9 with unlabelled mAb9 in TSHR pre coated tubes. 
Indicated concentrations of cold mAb9 competed with 111In-mAb9 in a concentration dependent manner. 
The IC50 of mAb9 was 0.35 nM. Values are the mean of triplicate determinations. 
 
Cold mAb9 competed with 111In-mAb9 for the TSHR coated in the tubes in a 
concentration dependent manner. This indicated that 111In-mAb9 bound to the TSHR in 
the tubes (figure 3.39). As expected, no competition was seen with control antibody 
PR1A3. 
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3.1.8.2 111In-mAb9 saturation cell binding assays 
Saturation binding assays were performed to measure the specific radioligand binding to 
cells at equilibrium in order to determine the number of receptors and binding affinity 
of 111In-mAb9 to GPI, FRTL5, TPC-1 and FTC-133 cell lines. See section 2.2.14.1.2 of 
methodology for a detailed protocol. 
 
3.1.8.2.1 Saturation binding assay in GPI cells 
 
 
Figure 3.40: Equilibrium saturation binding of 111In-mAb9 to GPI cells. 111In-mAb9 bound to GPI cells 
with a kD of 2.1 nM and Bmax 656 fmol/mg. Results represent specific binding (total minus nonspecific 
binding) of triplicate determinations 
 
111In-mAb9 bound to TSHR in GPI cells with a binding affinity of 2.1 nM (figure 3.40) 
and a Bmax of 656 fmol/mg. This is a high affinity binding, however, not as high as the 
binding affinity of 111In-mAb9 to the TSHR coated in the tubes (section 3.1.8.1). 
 
3.1.8.2.2 Saturation Binding assays with 111In-mAb9 in FTC-133 and TPC-1 cells 
Saturation binding assays with 111In-mAb9 were also performed in FTC-133 and TPC-1 
cells. After a number of repetitions, no binding was shown in the abovementioned cells. 
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This may be due to the very low amount of TSHR in these cells resulting in negligible 
binding.  
 
 3.1.8.2.3 111In-mAb9 binding to FRTL5 cells. 
Although 111In-mAb9 bound to FRTL5 cells, the majority of the binding was due to non 
specific binding (figure 3.41). 
 
Figure 3.41: Equilibrium saturation binding of 111In-mAb9 to FRTL-5 cells. Results represent specific 
binding (total minus nonspecific binding) of triplicate determinations 
 
111In-mAb9 binds to TSHR in coated tubes and THSR in GPI cells. It did not, however, 
bind specifically to FRTL5 cells.  Since 111In-mAb9 appeared to bind to TSHR with a 
high affinity, the next step was to perform an imaging experiment in vivo to determine if 
111In-mAb9 bound to the TSHR in the normal thyroid of mice. 
 
3.1.9 SPECT/CT imaging of 111In-mAb9 in mice 
As previously discussed, imaging of mice with 125I-mAb9 may be complicated by the 
fact that free 125I can be taken up to the thyroid via NIS and thus complicates 
interpretation of the imaging  and biodistribution results. Please refer to section 2.2.14.2 
of methodology for detailed protocol. Representative images of the mice at different 
time points are shown below. 
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SPECT/CT scan of M1, 4 hours after 111In-mAb9 i.v injection. No uptake seen in the 
thyroid. 
MIP
Sagittal
Coronal
Transverse
 
              Whole body SPECT/CT scan 
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SPECT/CT scan of M1, 24 hours after 111In-mAb9 i.v injection. No uptake seen in 
the thyroid. 
 
MIP
Sagittal
Coronal
Transverse
 
              whole body SPECT/CT scan 
 
 
 
 
143 
 
 
SPECT/CT scan of M1, 48 hours after 111In-mAb9 i.v injection. No uptake seen in 
the thyroid. 
 
MIP
Sagittal
Coronal
Transverse
 
            Whole body SPECT/CT scan 
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SPECT/CT imaging showed no specific uptake of 111In-mAb9 into the thyroid of either 
Mouse 1 or Mouse 2. Four hours post injection, the majority of the injected 111In-mAb9 
was located in the bladder, heart, liver, lungs and also in the eyes. 24 and 78 hours after 
injection, a similar pattern was observed to the 4 hour post injection time point, 
however, with less overall activity. This distribution pattern corresponds to that 
normally seen with 111In labelled antibodies in mice [189].   
A biodistribution study was performed at 48 hours with both mice. Tables showing the 
biodistribution in different tissues of the mouse are shown in figure 3.43. 
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Figure 3.43: Biodistribution results for  111In-mAb9. The mean amount of radiotracer measured in 2 mice 
is shown. Y axis represents the percent of total activity per g and uptake of injected dose per organ . 
Results show that most activity ended up in the blood. 
 
Results of both the imaging and biodistribution studies suggest that there is no specific 
binding of 111In-mAb9 to the thyroid of mice. The blood and liver showed the highest 
uptake of all the organs, with an uptake of 13-15% injected dose per organ. No further 
animal studies using 111In-mAb9 were performed.  
 
  
3.1.9.1 Blood/Plasma stability study of 
111In-mAb9 bound to TSHR 
111In-mAb9 might be broken down in the blood and hence 
binding ability.   Please refer to section 
methodology. Results of
Figure 3.44: Phosphorimager image of non reduced SDS
111In-mAb9/blood  ex vivo
kDa, 150 kDa and 75 kDa and control 
weights of  250 kDa and 150 kDa.
 
SDS-PAGE electrophoresis of the control antibody 
comprising 6% of the activity at 250 kDA and the remainder at 150 kDa. In the 
mAb9 incubated in the blood either 
that there was an additional band at 75 kDa comprising around 8% of the activity.
These results indicate that it is unlikely that the instability of 
the cause of the lack of receptor targeting since the majority of the labelled antib
appeared to be still circulating intact in the blood.
 
 
 
 
 
 
111In-mAb9 
in vitro but not in vivo. One explanation for this is that 
111In-mAb9 loses its antigen 
2.3.8.1.2 of methodology for
 SDS-PAGE electrophoresis can be seen in (
-PAGE electrophoresis of 
 and in vivo contain three bands corresponding to molecular weights of 250 
111In-mAb9 contains two bands corresponding to molecular 
 
showed two radiolabelled bands 
ex-vivo or in-vivo a similar pattern 
111In
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3.2  Discussion of mAb9 studies 
Monoclonal antibodies have developed into important tools to be used in the diagnosis 
and treatment of cancer. Antibodies and antibody fragments can be constructed so that 
they recognise and bind with high specificity and affinity to cell surface receptors that 
are expressed in a wide variety of malignant tissues [122, 182, 185, 190-194]. This 
property potentially allows radiolabelled antibodies to offer more precise diagnostic 
imaging and also can greatly increase the effectiveness and decrease the potential side 
effects of radiotherapy [183, 187, 190, 195-199]. The first radiolabelled monoclonal 
antibody to be approved by the FDA for the diagnostic imaging of cancer was an 111In 
labelled monoclonal antibody, CYT-103 (OncoScint OV/CR) [200-209]. CYT-103 is a 
murine monoclonal antibody (mAb) that binds to TAG-72, a cell surface antigen 
expressed at high levels on the majority of colorectal and ovarian adenocarcinomas.  
111In CYT-103-mAb imaging in patients with suspected recurrent colorectal carcinomas 
prevents many patients from undergoing unnecessary surgery [200-210]. Two 
radiolabelled antibodies have been approved by FDA for the treatment of non-Hodgkins 
lymphoma . 131I-tositumomab (Bexxar) from Corixa Corporation and 90Y- Ibritumomab 
tiuxetan- (Zevalin®) from Schering corporation [128, 129, 211, 212]. Both are murine 
monoclonal antibodies and target the CD20 antigen expressed on the surface of normal 
and malignant B lymphocytes. These radiolabelled antibodies have proved very 
successful in comparison with chemotherapy, untargeted radiotherapy and unlabelled 
mAbs [128-131].  
In this project, mAb9, a monoclonal antibody that targets the TSHR in the thyroid, and, 
more specifically, thyroid tumour cells, was studied for its suitability as a diagnostic 
imaging and radiotherapy agent to be used in radioiodine resistant thyroid cancer.  As 
the TSHR is almost exclusively expressed in thyroid tissue and its expression is 
maintained in some thyroid tumours, the TSHR is an promising target for directing 
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monoclonal antibodies to the thyroid or thyroid tumour cells As thyroid cancers 
progress, thyroid-associated proteins, such as NIS, may gradually be lost [88, 115, 213]. 
Loss of NIS greatly impairs conventional RAI therapy, as the ability to accumulate 
iodine is dependent on NIS expression [115, 213]. The TSHR may prove to be an 
alternative target in these tumours as TSHR expression is sometimes maintained for 
longer in de-differentiated tumours [115]. 
 
3.2.1 Confirming the purity and immunological integrity of mAb9 
The first step was to confirm the purity and immunological integrity of the mAb9 
monoclonal antibody. In order to demonstrate this, mAb9 was analysed by SE-HPLC 
and SDS page electrophoresis. In SE-HPLC, the approximate molecular weight of a 
protein/antibody can be determined by comparing it with known molecular weight gel 
filtration standards analysed in the SE-HPLC with the same column and under the same 
conditions. This approached showed that the mAb9 peak corresponded to a molecular 
weight of approximately 150 kDa, which corresponded to the reported molecular weight 
of whole IgG antibodies [214-216]. SDS-PAGE gel electrophoresis also confirmed the 
purity of mAb9 by showing two main bands of approximately 53 KDa and 22 KDa, that 
correspond approximately to the antibody heavy and light chain respectively [214, 217]. 
In the SDS-PAGE electrophoresis gel, the band corresponding to the antibody heavy 
chain contained two very close bands, one fainter than the other. The most likely 
explanation for the fainter band is the heterogeneity in the glycosylation of the heavy 
chain of the IgG antibody [218, 219]. IgG contains two identical light chains and two 
identical heavy chains linked through disulfide bonds and are composed of four distinct 
domains;  three constant domains, CH1, CH2 and CH3 and a variable domain [219-
221]. The CH2 and CH3 domains constitute the constant (Fc) portion of the IgG, 
whereas the variable and CH1 domains together constitute the antibody binding 
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fragment (Fab) portion of the IgG molecule [219-221]. IgG molecules have an N-linked 
glycosylation site located at Asn297 in the CH2 domain of the Fc portion of IgG [219, 
222]. Variation in glycosylation can occur between IgG molecules because of 
differences in terminal sialic acid, galactose, N-acetylglucosamine, and fucosylation of 
the core [219, 223]. These differences can lead to as many as 32 possible glycosylation 
patterns [219, 223, 224]. Glycosylation of IgG can be influenced by the cell clone in 
which it is produced, as well as the cell culture conditions such as pH, temperature, and 
medium [219, 222].  
There is no glycosylation occurring in the antibody Fab portion [219, 225], which 
explains why glycosylation exerts little effect on the antigen binding property of the 
antibodies and also why the light chain in SDS-PAGE does not show any extra bands.  
The glycosylation of CH2 domains is essential for the effector functions of IgG 
antibodies such as antibody dependent cellular cytoxicity (ADCC), complement 
dependent cytoxicity (CDC) and rapid elimination of antigen-antibody complexes from 
circulation [219, 222].   
No other bands were detected by the SDS page analysis, indicating that the mAb9 
samples were free of aggregates and impurities. Therefore, the mAb9 antibody was 
considered to be of a sufficiently high purity and integrity.   
 
3.2.2 Binding of unlabelled mAb9 to TSHR pre-coated in tubes 
Once mAb9 integrity and purity was confirmed, the next step was to assess whether 
unlabelled mAb9 bound to the TSHR as expected. This was first investigated by 
performing a ‘coated tube assay’, in which tubes pre-coated with TSHR were used. This 
assay was originally developed for Graves autoimmune thyroid patients with the intent 
to measure the ability of anti-TSHR antibodies, contained in patients serum, to compete 
with 125I-TSH for the binding of TSHR coated in the tubes [226]. In these coated tubes, 
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an engineered chimeric TSHR (chimera A), composed of the N-terminal part of the 
human TSHR cDNA substituted with amino acids 1–165 of the rat LH-CG receptor, is 
immobilized to the polystyrene tubes [226]. Specific binding of 125I-labeled bovine TSH 
to this TSHR chimera A has been shown to be preserved and indistinguishable from the 
wild type TSHR [226]. Coated tube assay studies carried out with mAb9 showed that 
mAb9 competed with 125I-TSH for the binding of TSHR. Binding of 125I-TSH was 
inhibited by more than 90% and the binding affinity was 0.43 nM. Therefore these 
results concluded that mAb9 bound to the receptor coated in the tube with high affinity. 
Jacqueline A. Gilbert et al. [227] tested mAb9 using the same coated tube assay system 
and also concluded that mAb9 was inhibiting the binding of 125I-TSH to the TSHR 
coated in the tubes, with an apparent binding affinity of 0.022 nM. The binding affinity 
in Gilbert’s study was around 10 fold higher than the binding affinity obtained in this 
experiment. This discrepancy occurred perhaps due to a different batch of mAb9 
antibody being used in these experiments resulting in a different binding affinity or 
alternatively it might be due to differences in the experimental design. 
 
3.2.3  Binding of unlabelled mAb9 to cells. 
The binding characteristics of mAb9 to the TSHR in thyroid cancer and TSHR 
transfected cell lines were studied by performing FACS and immunohistochemistry 
assays using FTC-133, TPC-1, FRTL5 and GPI cells. 
 
3.2.4 FACS with unlabelled mAb9 
To investigate whether the selected cell lines expressed TSHR, as well as to study the 
binding of mAb9 to the TSHR in different cell lines, FACS experiments were carried 
out with TPC-1, FTC-133, GPI and FRLT5 cells. Both 4C1 and mAb9 antibodies were 
used. 4C1 anti-TSHR antibody was obtained commercially and recognises an epitope 
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located in the region of amino acid residues 381 to 384 of TSH Receptor [228]. An 
isotype-matched control antibody was also used as a control as a means to distinguish 
non-specific staining from specific antibody staining. Non-specific antibody staining 
can occur due to the binding to Fc receptors on target cells; non-specific protein 
interactions with cellular proteins, lipids, or carbohydrates, and cell auto-fluorescence 
[184, 229]. These factors can vary depending on the cell type and the isotype of the 
primary antibody [184, 229]. For this reason it is essential that isotype controls are 
matched to the species and isotype of the specific primary antibodies. [184, 229].  
4C1 antibody was shown to bind moderately to the TSHR in FTC-133 and FRTL5 cells, 
however statistical analysis showed no significant difference in the MFU compared with 
the control cells. mAb9 did not show any binding to FTC-133 and FRTL5 cells. Both 
4C1 and mAb9 bound substantially to GPI cells but showed no binding to TPC-1 cells.   
These results suggest that TSHR is expressed to some extent in FTC-133, FRTL5 and 
GPI cells, however, while 4C1 antibody was able to bind to all cell lines except TPC-1 
cells, mAb9 solely bound to GPI cell lines. One possible explanation for the 
discrepancy between the binding of mAb9 and 4C1 to FTC-133 and FRTL5 cells is that 
mAb9 recognises a TSHR binding epitope that is not present in these cells but is present 
in GPI TSHR transfected cell lines. Shepherd et al.  [34] compared the epitope 
specificity and variable region sequences of novel monoclonal antibodies which 
recognise native hTSHR [230]. This study found that 4C1 recognised antibodies in the 
native hTSHR in position 381-384 of the receptor [230]. Other studies also confirmed 
this recognition of this binding epitope on the TSHR by 4C1 [228].   
Antibodies to different epitopes of the receptor can influence thyroid function [227, 
230].  The epitopes of TSHR to which mAb9 binds are not known and further studies 
are needed to characterise them [231].  From these results it can be assumed that 381-
384 residues are present in FTC-133, GPI, FRTL5 cells since 4C1 antibody bound to all 
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these cell lines but the epitope to which mAb9 binds in the transfected GPI cells is not 
present in the non-transfected FTC-133 and FRTL5 cell lines. GPI FACS shift patterns 
showed that some cell populations expressed TSHR in higher quantities than others. 
This may be due to the transfection methods used in the production of this particular 
cell line that resulted in some cells having high expression of the TSHR while others 
have low expression of TSHR. Transfected cell lines often show different levels of 
expression depending on particular gene/plasmid combinations introduced and the 
methodology used. 
In a similar FACS study where 4C1 antibody, amongst others, was used in GPI cells, a 
similar shift  was obtained to the one observed in this study [230]. Another study used 
the same GPI cell line with different anti-TSHR antibodies and also reported a similar 
pattern [232].  
 
3.2.5 Immunohistochemistry to characterise TSHR in cells 
Immunohistochemistry with 4C1 and mAb9 antibodies failed to show specific binding 
to the TSHR in the thyroid cancer cell lines TPC-1 and FTC-133 with both antibodies. 
GPI was the only cell line that stained positively for the TSHR with both 4C1 and 
mAb9 antibodies.  
In GPI cells, different staining patterns of TSHR were seen, with some groups of cells 
showing more positive staining for TSHR than others, indicating that some cells 
expressed high numbers of receptors while others expressed lower levels of TSHR. This 
coincides with the profile obtained in  FACS where different levels of TSHR expression 
were also reported. 
GPI cells showed TSHR staining in the cytoplasm as well as in the nucleus. There is 
convincing evidence showing that some GCPRs are localised in the nucleus. This 
suggested mode of genomic regulation by GPCRs implies the endocytosis and nuclear 
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translocation of peripheral-liganded GPCR and (or) the activation of nuclearly located 
GPCR by endogenously produced, non-secreted ligands.  
Although there are no specific studies conducted with TSHR to date, it may be that 
TSHR, like other GCPRs, is translocated and localised in the nucleus [233]. 
Although 4C1 antibody showed some binding to the TSHR in FTC-133 cells in the 
FACS analysis, in the immunohistochemistry studies no TSHR positivity was observed 
with 4C1. It is possible therefore that this antibody was not suitable for this purpose and 
that the levels of expression in these cells were lower than the sensitivity of this assay. 
 
3.2.6 Characterising TSHR in cell lines 
3.2.6.1 RT-PCR to evaluate the expression of TSHR in cells. 
To further evaluate the expression of TSHR in the selected cell lines, TSHR mRNA 
expression was determined in the cells using relative quantitative PCR. Relative 
expression of TSHR in the different cells was compared to CHO, the non-expressing 
cell line. FTC-133 and GPI cells revealed some expression of TSHR mRNA; in GPI 
cells considerably more was detected than in FTC-133 cells. TPC-1 revealed negligible 
relative fold expression of TSHR. The results obtained were thus comparable in some 
respects to those from the FACS and immunohistochemistry assays, in which GPI cells 
showed the highest level of TSHR expression and staining  with the mAb9 and 4C1 
antibodies while no or moderate staining was observed in FTC-133 cells. TPC-1 cells 
showed negligible staining for TSHR. It is important to note that RT-PCR only gives an 
account of the mRNA levels of the receptor and hence the fact that these cells express 
TSHR mRNA does not necessarily prove that there will be TSHR protein in these cells. 
While one study by Schmutzler  C  [234] reported mRNA expression in FTC-133 cell 
lines,  another study did not show TSHR mRNA expression as well as  expression of 
most thyroid specific genes in both TPC-1 and FTC-133 cells [235]. This discrepancy 
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seen in the TSHR expression in FTC-133 cells observed in different studies may be due 
to different TSHR primer sequences being used, or also due to the FTC-133 cell lines 
used in different labs being slightly different from one another due to different media 
and growing/passaging conditions being used. 
  
3.2.6.2 Western blot analysis to detect TSHR protein in cells 
 
The next step was to perform Western blot experiments to detect TSHR protein in TPC-
1, FTC-133 and GPI cell lines. TSHR, a member of the GPCR family, is composed of a 
large extracellular domain or ECD, of a molecular weight of 45 kDa, a seven 
transmembrane region and a c-terminal cytoplasmic tail [11, 27, 236, 237]. The ECD 
region is thought to be solely responsible for ligand interaction, while the 
transmembrane and cytoplasmic regions are involved in signal transduction [11, 27, 
236, 237].  TSHR expressing GPI cells were constructed in Da Costa et al. laboratory 
[238] by using an ECD region anchored via glycosylphosphatidylinositol (GPI) to CHO 
cells. In the latter paper, immunoblotting studies, using both Graves disease patient 
serum and anti-TSHR antibodies detected a TSHR band of around 70 kDa [152]. In the 
present study 4C1 antibody detected a single band of around 68 kDa, which therefore 
corresponds to the TSHR in GPI cells.  4C1 antibody however failed to detect TSHR 
protein in the western experiments in FTC-133 and TPC-1 cell lines, suggesting that 
there is low expression of TSHR in these cell lines. In the Western blots, mAb9 did not 
detect TSHRs in FTC-133, TPC-1 and GPI cell lines.  
The reason for the lack of detection of TSHR in GPI cells with the mAb9 antibody is 
that Western blot is carried out under denaturing conditions. It might be that the 
denaturation of the cell line lysate changes the conformation of the TSHR protein 
binding epitope in GPI cells therefore not permitting mAb9 to bind to the TSHR protein 
in its denatured form.  
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3.2.7 Radiolabelling of mAb9 with 125I 
After the purity and integrity of the mAb9 antibody had been confirmed, TSHR 
expression in the cell lines used characterised, and binding of unlabelled mAb9 to the 
cells studied, the next step was to label mAb9 antibody with 125I. Labelling was 
performed using the Iodogen tube method. In this method, a water-insoluble oxidant 
[196-tetrachloro-3t~,6t~-diphenyl glycoluril, Iodogen] is dissolved in an organic solvent 
and it is coated on the walls of the glass reaction tube [179]. 125I is incorporated into 
tyrosine amino acids of the antibody by chemical oxidation. By using this method, 
oxidation damage to the antibody can be diminished during the radiolabelling process.  
After labelling mAb9 with 125I, the labelling efficiency of 125I-mAb9 was measured with 
Radio-HPLC and ITLC. Both radio-HPLC and ITLC results showed a high labelling 
efficiency 125I-mAb9. However, resolution of size exclusion HPLC and ITLC is not 
particularly high and therefore usually it does not separate molecules with less than a 
few thousands of Da difference and it cannot always detect partial degradation of 
proteins/antibodies. For this reason, SDS page gel electrophoresis was also performed. 
SDS page electrophoresis analysis indicated that 125I-mAb9 was of high purity, with a 
single band of around 150 kDa  and no further impurities or aggregates were detected.  
 
3.2.8 125I-mAb9-TSHR binding assays 
3.2.8.1   Pre coated tube assays 
The binding of the newly labelled 125I-mAb9 to the TSHR was first investigated in 
TSHR pre-coated tubes [226].  When using 125I radiolabelled mAb9 at a low specific 
activity, only incomplete inhibition of binding was seen. This indicated that the integrity 
of the radiolabelled complex integrity might have been disrupted. A loss of integrity 
could result from three possible reasons. First, oxidation by the Iodogen pre-coated tube 
method itself might have damaged the structure of the antibody. Second, radiolabelling 
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of mAb9 could have damaged the structure of the antibody. Lastly, the initially 
radiolabelled 125I-mAb9 might not have been of a sufficiently high specific activity to 
allow sufficient competition with the unlabelled antibody. The immunointregrity of an 
antibody depends on the preservation of its antigen binding activity [239]. Previous 
studies have shown that modification in the amino acid sequence of the hypervariable 
region of an antibody can result in the binding strength of the antibody being reduced 
[240]. The antibody sites targeted during a radiolabelling procedure include tyrosine 
residues, oligosaccharide moieties, δ-amino groups of lysine, β- or γ-carboxyl and thiol 
groups, as well as glutamic acid and thiol groups generated by the reduction of cystine. 
Most antibodies have tyrosine residues in their hypervariable region [239]. The 
antibody sites targeted on mAb9 when radiolabelling with 125I are thought to be the 
tyrosine residues on the mAb9, and it is thus possible that the labelling process might 
have disrupted the conformation of mAb9. 
To investigate whether cold labelling, oxidation or the addition of iodine to mAb9 was 
damaging its structure, TSHR coated tube assay studies and FACS experiments were 
carried out.  
In these assays, three preparations were compared.  In the first preparation, the 
oxidation effects of Iodogen on mAb9 were studied and in order to do this mAb9 was 
incubated alone in an Iodogen tube to produce ‘oxidised mAb9’. In the second 
preparation, the effects of cold labelling iodination on mAb9 were studied, and in order 
to do this mAb9 was co-incubated with cold potassium iodide in an iodogen tube to 
produce ‘cold labelled mAb9’. In the final preparation, mAb9 was simply mixed with 
cold iodine, and this was called ‘mixed mAb9’.  
In the TSHR coated tube assay, ‘oxidised mAb9’ was able to compete with 125I-TSH for 
the binding of TSHR. This showed that oxidation of mAb9 by Iodogen was not 
damaging the structure of the antibody. ‘Cold labelled mAb9’ was also able to compete 
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with 125I-TSH and therefore substitution of radioiodine into the antibody was not likely 
to be damaging the ability of the antibody to bind to the TSHR in coated tubes. 
FACS analysis suggested that the oxidation step itself was not interfering with the 
binding of mAb9 and 4C1 to GPI cells, however the cold iodide labelling of both mAb9 
and 4C1 impaired the ability of these antibodies to bind to the TSHR in all of the cells 
used. These results contradicted the coated tube assay results in which cold labelled 
mAb9 was able to bind to the TSHR coated in the tubes.  
It is possible that the substitution ratio of cold labelled antibody was higher than the 
radiolabelled antibody and hence it had a harsher effect on mAb9 than the radiolabelled 
material. Also, the coated tubes are coated with a TSHR chimera produced in the lab 
which has a different conformation from the TSHR construct transfected into the GPI 
cells. Perhaps iodination of mAb9 changes the conformation of the antibody portion that 
binds to the TSHR in GPI cells but does not alter the antibody portion that binds to the 
TSHR construct coated in the tubes. Also, it might be possible that the secondary 
antibody used in FACS is not recognising the cold labelled mAb9 and 4C1 reaction and 
thus no positive shifts were shown. 
It can be concluded that the oxidation inflicted by the Iodogen labelling method  and the 
cold labelling of mAb9 were not damaging the antibody’s ability to bind to the TSHR 
coated in the tubes. Howver, some doubt remains as to the effect of cold iodine labelling 
on the ability of mAb9 and 4C1 to bind to the TSHR in GPI cells. 
 
3.2.8.2 Cell binding assays 
The binding of 125I-mAb9 to TSHR in cell lines was further studied in thyroid cancer 
(TPC-1 and FTC-133), TSHR transfected (GPI) and rat thyroid cancer cells (FRTL5) by 
performing direct radioligand cell binding assays. The efficiency of the binding of 
radiolabelled compounds to cells may be affected by several conditions which include 
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the incubation time and temperature of incubation at as well as the characteristics of the 
binding buffer. For this reason the effect of the temperature and time on the binding 
efficiency of mAb9 to TSHR in the cells as well as the effect of different binding 
buffers were tested before saturation cell binding assays were conducted. The 
temperature that gave the highest binding efficiency was room temperature and the 
optimal incubation time was between 2 and 3 hours. A study using different buffers at 
room temperature incubated for approximately two hours determined that most buffers 
used produced a similar outcome in the cell binding assays. Therefore room temperature 
and 2 to 3 hours incubation time were used in further binding assays. 
After determining the best incubation conditions, a direct radioimmunoassay was 
performed to measure the immunoreactivity of the labelled fragments, i.e. the 
proportion of radioactive antibody fragments that have the ability to bind to the antigen. 
The immunoreactivity was calculated to be 5.1 %, which  indicates that only about 5% 
of the radioactive antibody was able to bind to the TSHR. The immunoreactivity of 
mAb9 is, thus, very low compared to most antibodies studied and thus raises doubts 
about the quality of the antibody. 
 
3.2.8.2.1 Saturation assay 
Radioligand binding assays were performed on all the thyroid cancer cell lines in order 
to measure the specific radioligand binding to cells at equilibrium, and to determine 
both the receptor numbers (Bmax) and the binding affinity (Kd) of mAb9 by analysis of 
non specific binding and total binding. Non-specific binding occurs in many types of 
binding assays and it is therefore crucial to account for this.  
Unlabelled mAb9 was used as the competitor to measure non-specific binding to ensure 
that all the target receptors were occupied, under which conditions any binding 
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observed would be to other receptors, or due to interactions with the cell membrane. 
The concentration used (1000 µM) was adequate to block all the receptors. 
GPI cell lines showed a high level of TSHR expression as well as a relatively high 
binding affinity.  FRTL5 bound to TSHR, however the majority of binding was due to 
non specific binding. A study by van der Kallen et al. [241] also detected a binding site 
in FRTL5 cells with extremely low affinity and high capacity which represented a non-
specific binding site: Kd= 56±24 nM and BMax (binding capacity) 134±20. [242] 125I-
mAb9 did not show any binding to FTC-133 and TPC-1 cells, as expected since these 
cells  had been shown to express very low or negligible amounts of TSHR. 
Radiolabelled antibodies must retain their receptor binding capacity if they are to 
function as effective radiopharmaceuticals and although the immunoreactive fraction 
was found to be low the saturation binding study with GPI cells did show high levels of 
specific binding indicating that 125I-mAb9 most likely kept its receptor binding capacity 
to the TSHR in GPI cells. 
 
3.2.9 SPECT/CT imaging experiments 
Imaging experiments were performed in order to assess the binding of 125I-mAb9 to the 
TSHR present in the thyroid of normal mice. In order to perform this study, mAb9 was 
labelled with 125I, a radioactive nuclide used for SPECT/CT imaging of small animals.  
Metabolism of the 125I-mAb9 conjugate after its systemic injection into mice can lead to 
the formation of radiolabelled metabolites including free 125I, which can be taken up 
into the thyroid by the NIS. This would confound the imaging results as a radioactive 
signal detected in the thyroid could be caused wholly or partly by the accumulation of 
free 125I rather than being caused by the binding of 125I-mAb9 to TSHRs on the thyroid 
of the mice. To ensure that 125I-mAb9 binding rather than that of free 125I was measured, 
binding of mAb9 to the thyroid was imaged in the presence and absence of the NIS 
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inhibitor sodium perchlorate. In the absence of perchlorate, approx 2.4% binding was 
observed in the thyroid, whereas ~0.2% binding was observed in the thyroid in the 
presence of perchlorate. The substantial reduction in 125I-mAb9 binding to the thyroid 
after the pre-treament with perchlorate indicates that a large proportion of the 
administered 125I-mAb9 underwent metabolism and was released as free 125I, which 
accumulated in the thyroid. 
The 0.2% binding observed after perchlorate treatment suggests that mAb9 may be 
binding to TSHRs. In a further control group mice were administered with free 125I in 
the presence and absence of perchlorate. When 125I was administered it produced an 
uptake of 1.7% in the thyroid, but this uptake was completely blocked by perchlorate 
treatment. This suggests that the relatively low signal of 0.2% achieved in the mAb9 + 
perchlorate group is not the result of a sub maximally effective dose of perchlorate 
being used. 
Previous studies have shown that radioiodine is taken up by the salivary gland, stomach, 
lactating breast and nasal mucosa via NIS [91, 243]. This explains why activity in the 
salivary gland is also seen at the 4 hour time point in mice injected with either 125I-
mAb9 or free 125I in the absence of perchlorate. Lack of uptake of 125I into the salivary 
gland in perchlorate treated mice indicate that perchlorate is effectively blocking NIS 
and thus thyroid uptake may be due to 125I-mAb9 binding to TSHR in vivo.  
Although 125I-mAb9 showed some binding to the TSHR in the thyroid of mice, the 
percentage of injected dose was extremely low, and thus, results are unable to 
categorically indicate whether the radioactivity seen in the images is due to the specific 
binding of 125I-mAb9 to the TSHR or due to free 125I being taken up by the thyroid via 
NIS. 
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3.2.10 111In-labelled mAb9 
When using 125I radiolabelled compounds, there is always a chance that free 125I can be 
taken up into the thyroid via NIS and interfere with in vivo imaging and biodistribution 
studies.  Although in the imaging and biodistribution studies 125I-mAb9 was 
radiolabelled to an efficiency close to 100% and sodium perchlorate was used to block 
the uptake of 125I into the thyroid, it is still possible that free 125I will, to some extent, 
interfered with the interpretation of the results. This problem can potentially be solved 
by radiolabelling mAb9 with a radioisotope that does not get taken up into the thyroid. 
For this reason in this project, 111In was used because it is not taken up by the thyroid 
but also due to its useful imaging properties ready availability. 
111In does not form strong interactions directly with antibodies/proteins but can form 
highly stable complexes with a number of bifunctional chelating agents, chelating 
agents which have a chemically active group that can bind covalently to the antibody. 
The Macrocyclics chelating compound p-SCN-Benzyl-DOTA was selected to be 
conjugated to mAb9.  
 
3.2.11.1  Conjugation of mAb9 with p-SCN-Bz-DOTA 
SCN-Bz-DOTA conjugates to the antibodies via lysine side chain amino groups.  After 
conjugation, the antibody was purified in order to remove any free chelate before the 
111In was added. In order to assess the purity and integrity of Bz-DOTA-mAB9, prior to 
radiolabelling, a size exclusion HPLC (SE-HPLC) was performed.  
The SE-HPLC indicated that the integrity and purity of mAb9 was not altered by the 
addition of Bz-DOTA. FACS analysis with Bz-DOTA mAb9 revealed that the chelated 
compound was still able to bind to TSHR in GPI cells.  Bz-DOTA mAB9 was also still 
able to compete with 125I-TSH for the binding of TSHR in the pre-coated tubes. This 
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again confirmed that the conjugated chelator was not influencing the ability of mAb9 to 
bind to the TSHR.  
 
3.2.10.2  111In labelling of BzScnDOTA mAb9 
Bz-DOTA mAb9 was radiolabelled with 111In. A range of concentrations of mAb9 and 
111In were evaluated and different incubation times were employed until an optimal 
radiolabelled compound of around 99% labelling efficiency was produced. After the 
radiolabelling of the mAB9 with 111In, ITLC and size exclusion HPLC indicated that the 
radiolabelled compound was of high purity. 
 
3.2.10.3 111In-mAb9 binding assays 
Once stable 111In-mAb9 was produced successfully, the next step was to investigate 
whether the radiolabelled complex retained its binding capacity. A TSHR pre-coated 
tube assay showed that 111In-mAb9 still kept its ability to bind to the TSHR. and its 
binding was inhibited by 80% with cold mAb9.  
111In-mAb9 binding to TSHR in GPI cells was demonstrated in a saturation binding 
assay. The number of receptors- Bmax- was estimated to be 656 fmol/mg  and binding 
affinity, Kd, 2.1 nM. The binding affinity of 125I-mAb9 in GPI cells was 3.66 nM, 
similar to  binding affinity of 111In-mAb9 to the same cells. This suggests that 111In-
mAb9 binds the TSHR in GPI cells with a similar affinity to 125I-mAb9. There appears 
to be a big difference between the number of receptors observed in GPI cells in 125I-
mAb9 and 111In-mAb9 saturation assays. This variability may be due to different 
passages of GPI cells being used when the saturation assays were performed. 111In-
mAb9 bound to the TSHR in FRTL5 cells, however most binding was due to non-
specific binding. A study by van der Kallen et al. [241] also reported non specific 
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binding to FRTL5 cells [242]. 111In-mAb9 did not bind to FTC-133 and TPC-1 cells, 
presumably due to the very low or negligible expression of TSHR in these cells. 
 
3.2.11 SPECT/CT imaging of 111In-mAb9 in mice 
As explained previously, 125I-mAb9 can be metabolised into free 125I, which can be 
taken up by the thyroid and interfere with imaging and biodistribution results. For this 
reason mAb9 was radiolabelled with 111In and after in vitro studies confirmed its 
binding to TSHR, the next step was to perform preliminary animal studies in order to 
assess the binding of 111In-mAb9 to the TSHR expressed in the normal thyroid of the 
mouse. SPECT/CT animal studies did not show specific binding of 111In-mAb9 to the 
TSHR and radioactivity was widely distributed in the body of the mice after 111In-mAb9 
injection. This radioactive distribution pattern corresponds to that previously seen n 
mice [244].  Results of both the imaging and biodistribution studies suggest that there is 
no specific binding of 111In-mAb9 to the thyroid of mice, and for that reason no further 
animal studies were conducted with 111In-mAb9. 
 
3.2.11.1 Blood/Plasma stability study with 111In-mAb9 
111In-mAb9 bound to TSHR in coated tubes and in GPI cells in vitro, however, it failed 
to show specific binding to the TSHR of normal mice in vitro. One explanation for this 
is that 111In-mAb9 might be broken down in the blood as a result lose its antigen 
binding ability.  In order to investigate this possibility, in vivo and ex vivo stability 
studies were performed in the blood of mice.  
The control 111In-mAb9 showed two bands on SDS-PAGE, one at molecular weight 250 
kDa and the other at 150 kDa. The 250 kDa band (presumably an antibody dimer) 
contained 5% of the total radioactivity whereas the 150k Da band contained 95% of the 
total activity. 
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111In-mAb9 incubated in the blood either ex vivo and in vivo gave similar results. In 
both studies, bands were also detected at 250 kDa: comprising 6% of total activity and 
150 kDA (86% total activity) and also showed a band at 75 kDa containing 8% total 
activity). This indicates that it is not extravascular metabolism in mice causing the third 
band to appear, but that there may be some break down of 111In-mAb9 in the blood. 
Although this suggests that the antibody may be break down in the blood of mice to a 
small extent, there is still a considerable amount of intact radiolabelled 111In-mAb9 
(86%) circulating in the blood at 6 hours, and hence it is unlikely that the small degree 
of breaking down of the antibody in the blood is causing radiolabelled antibody not to 
bind in vivo. 
 
3.2.12  Conclusion for mAb9 studies 
mAb9, a purified IgG2b monoclonal antibody developed from an experimental murine 
model of hyperthyroid Graves’ disease, has been shown in previous studies to exhibit 
potent thyroid stimulating activity [227]. In the latter studiy, mAb9 induced full 
stimulation of TSHR and acted as a full agonist for the receptor. It also demonstrated 
high affinity in vitro for binding of the TSHR coated in tubes and CHO cells stably 
transfected with the TSHR receptor [227]. In this study, mAb9 was investigated both in 
vitro and in vivo for its potential to act as a imaging and treatment tool for radioiodine 
resistant thyroid cancer. In vitro studies showed that 125I and 111In radiolabelled mAb9 
were able to bind specifically to TSHR pre-coated in tubes and in GPI cells (CHO cells 
stably transfected with the TSHR). In vivo, though, the outcome was different. Both 
111In-mAb9 and 125I-mAb9 failed to show specific binding to the TSHR in the normal 
mice. Possible reasons for this are discussed in chapter 5. Radiolabelled mAb9 is 
therefore unlikely to be of use the diagnosis and treatment of radioiodine resistant de-
differentiated thyroid cancer. 
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CHAPTER 4. RHTSH STUDY 
mAb9 bound to the TSHR in vitro however it did not bind to the TSHR in vivo. For this 
reason, mAb9 is unlikely to be of use in the diagnosis and treatment of radioiodine 
resistant thyroid cancer. A new approach was therefore needed to target the TSHR. 
In this study human recombinant thyroid stimulating receptor (rhTSH) was used to 
target the TSHR. rhTSH binds to the TSHR and is commercially available. It was 
approved for clinical use by the FDA(1998) [245, 246] and in Europe (2001) [247]. It 
has a combined molecular weight of 30,000 Da, which makes it advantageous for a 
tumour targeting compound due to its relatively small size.  
Due to these features, radiolabelled rhTSH was evaluated as a potential candidate to 
stage radioiodine resistant thyroid cancer. The overall objective of this study was to 
radiolabel rhTSH and study its binding to the TSHR both in in vitro and in vivo. 
 
Aims of rhTSH studies: 
• Radioiodinate rhTSH with 125I and produce a radiolabelled compound with high 
purity. 
• Study the structure and chemical properties of rhTSH and 125I-rhTSH using SDS 
page electrophoresis, size exclusion HPLC and reverse phase HPLC. 
• Assess the binding of 125I-rhTSH to TSHR pre-coated tubes and in thyroid 
cancer cells. 
• Investigate the binding of 125I-rhTSH to the thyroid and grafted thyroid tumours 
in mice in vivo with SPECT/CT imaging to establish if radiolabelled rhTSH can 
be used as a potential imaging and treatment agent for radioiodine resistant 
metastatic thyroid cancer. 
 
  
4.1 rhTSH study results
4.1.1 Radioiodination of rhTSH using enzymatic substitution
rhTSH was first radioiodinated with 
substitution method. Please 
showed that most of the radioactivity remained in the bottom
indicates a  high purity labelled 
(figure 4.1-A). SDS-
which correspond to the 
(figure 4.1-B). These results indicate that a high purity and high integrity 
radiolabelled rhTSH was obtained. 
 
Figure 4.1: Phosphorimager images of ITLC and SDS PAGE electrophoresis analysis of 
A: ITLC strips showing 95% labelling efficiency (calc
gel electrophoresis of 1125
correspond to the rhTSH β
 
The effect of increasing concentrations of la
125I-rhTSH labelling efficiency was determined using 
2.3.2 for a detailed protocol. The results demonstrated that increasing concentrations of 
lactoperoxidase and glucose oxidase indep
(figure 4.2). Both the 
lactoperoxidase resulted in labelling efficiencies 
 
 
 
125I using the lactoperoxidase enzymatic 
refer to section 2.3.1 for a detailed protocol. ITLC analysis 
 of the ITLC strip
125I-rhTSH with approximately 95% labelling efficiency 
PAGE gel electrophoresis analysis showed two main intact bands 
α subunit (17 kDa) and β subunit (21 kDa) but no extra bands 
 
ulated by the phosphorimager software). B: SDS 
I-rhTSH showing two main bands of approximately 21 kDa and 17 kDa, which 
-subunit and α-subunit respectively.  
ctoperoxidase and glucose oxidase in the 
 ITLC. Please refer to section 
endently increase the labelling efficiency 
0.005 and 0.5 µg quantities of glucose oxidase and 
of close to 100%. 
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125I-rhTSH.   
 
  
Figure 4.2: Relationship between glucose oxidase and lactoperoxidase in the 
reaction against the labelling efficiency. The labelling efficiency increases sharply after an addition of 
0.001 µg glucose oxidase and 0.1 µg lactoperoxidase.
 
4.1.2 HPLC Studies with rhTSH and 
4.1.2.1 Size exclusion HPLC
To further confirm the
carried out. First, unlabelled 
HPLC. See section 2.3.3
12.33 minutes (figure 
Figure 4.3: UV size exclusion HPLC chromatogram (280 nm) 
time 12.33 is shown. 
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For this reason, carbonic anhydrase and lysosyme were also analysed and used as 
additional molecular weight standards. Carbonic anydrase and lysosyme have 
theoretical molecular weights of approximately 
which are similar to the molecular weight of rhTSH (~30 kD
(~14 kDa). The retention time obtained in the SE
anydrase, 12.52 minutes
with rhTSH, 12.33 minutes (
predicted molecular weight of approximately 30 kDa.
 
Figure 4.4: UV size exclusion chromatogram (280 nm) of BioSep molecular weight stand
were detected at retention time 12.63, 13.23 and 19.4 minutes. 
 
Figure 4.5: UV size exclusion HPLC chromatogram of carbonic anydrase and lysosyme. Two peaks were 
obtained at retention times 12.52 and 14.58
respectively. 
 
29 kDa and 14.7 kDa, respectively, 
a) and the rhTSH 
-HPLC chromatogram with carbonic 
 (figure 4.5), was very similar to the retention time obtained 
figure 4.3). This indicates that the rhTSH analysed has the 
 
 
 minutes corresponding to carbonic 
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In order to investigate the effects of the radioiodination of rhTSH with 
was analysed by radio
detailed protocol.  
In the radio-SE-HPLC a 
followed by smaller peaks at retention times 19.27, 20.85, 24.19 and 26.22 minutes 
(figure 4.6).  The 13.30 minutes retention time peak most likely shows the radiolabelled 
rhTSH whereas the peak at 20.
other extra peaks seen are probably a result of radiolabelling impurities 
the mixture. There is a shift of approximately 1 minute in the retention time of 
rhTSH in comparison wi
has altered  the structure of rhTSH.
Figure 4.6: Size exclusion radio
at retention time 13.30 followed by minor peaks at r
 
4.1.2.2 Reverse phase HPLC
RP-HPLC studies were carried out in order to 
determine whether rhTSH retains its structure/integrity after being
Unlabelled rhTSH was analysed by RP
acetonitrile(ACN)/TFA (pH 2.5) as a mobile phase in a C18 column. rhTSH was run in 
a 5 to 50% ACN gradient for 35 minutes, 
(figure 4.7). Please refer t
 
-SE-HPLC. Please refer to section 2.3.1.2 
main peak at retention time 13.30 minutes was detected 
85 minutes most likely corresponds to the free 
th rhTSH, which might indicate that the radiolabelling method 
 
-HPLC analysis of 125I radiolabelled rhTSH. A
etention times of 19.27, 20.85, 24.19, 26.72. 
 
further study the purity of rhTSH and 
-HPLC using 0.1% TFA/water and 
and then 50 to 100% ACN 
o section 2.3.4 for a detailed protocol. 
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125I. The 
being present in 
125I-
 
 major intact peak eluted 
 
 radiolabelled.  
for 10 minutes 
  
Figure 4.7: Gradient elution pattern of rhTSH in RP
followed by 50 to 100% in 10 minutes was used as indicated.
Figure 4.8: UV chromatogram of the elution of rhTSH from RP
phase 0.1%TFA/water and ACN/TFA (pH 2.5). A number of sharp peaks eluted from the column with 
two main separated peaks at retention times 29.13 and 29.77 minutes
 
rhTSH eluted as a number of sharp peaks (
separation of the sharp peaks, a number of gradients were tested (not shown). The 
gradient that achieved the best separation was 5 to 20% ACN 
for 30 minutes, 35 to 100% ACN 
was separated into 3 main groups of peaks 
and 22 minutes (figure 
peaks. 
-HPLC. A gradient of 5 to 50% in 35 minutes 
 
-HPLC using a C18 column and   mobile 
. 
figure 4.8). In order to try to achieve a be
for 30 minutes, 20 to 35% 
for 5 minutes (figure 4.9).  With this gradient, rhTSH 
with retention times of 
4.10). It was not however possible to further separate these 
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tter 
approximately 20, 21 
  
Figure 4.9: Organic solvent gradient used to elute rhTSH RP
minutes, 20 to 35% for 30 minutes, 35 to 100% ACN 
Figure 4.10: UV chromatogram and radiochromatogram of the elution of unlabelled rhTSH from a RP
HPLC using a C18 column and   0.1%TFA/water and ACN/TFA (pH 2.5)
was repeated at least 3 times
 
125I-rhTSH was then analysed using the same co
understand if the radiolabelling changed the structure of rhTSH
Figure 4.11: Radiochromatogram of the elution of 
0.1%TFA/water and ACN/TFA (pH 2.5)
55% of rhTSH was recovered from the column. Each run was repeated at least 3 times.
-HPLC. A gradient of 5 to 20% ACN 
for 5 minutes was used as indicated.
  as a 
. 
nditions with RP
 (figure 4.11
125I-rhTSH from a RP-HPLC 
 as a mobile phase. A number of different peaks were obtained. 
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for 30 
 
 
-
mobile phase. Each run 
-HPLC in order to 
). 
 
with a C18 column and   
 
  
As with unlabelled rhTSH, several peaks were obtained rather than a single peak (
4.11) but with retention times considerably 
The different peaks obtained in SE
possibly be due to damage
2.5. In order to explore this p
treated with either pH 2.5 or pH 7 was carried out
detailed protocol.  
Figure 4.12:  SDS gel electrophoresis of 
treated rhTSH showed a main
A band at 30 kDA which represented 10% of the total radioactivity 
 
rhTSH treated with pH7 and pH 2.5 showed 
kDa, which most likely represent the 
resolution was not high enough to separate them onto two distinct bands (
A band at around 30 kDa is also shown at both pH7 and
around 10% of total activity. This band most likely corresponds to the rhTSH dimer. 
This similarity between results at pH 2.5 and pH 7 suggests that pH 2.5 does not 
affect/damage the structure of rhTSH and 
 
4.1.2.2.1 Ion pairing RP
In order to try to optimise the separation of rhTSH in the RP
analysed using ion pairing RP
bigger than the unlabelled compound.
-HPLC analysis with rhTSH and 
 caused to rhTSH by the pH of the mobile phase which is pH 
ossibility, a SDS-PAGE electrophoresis with 
. Please refer to section 
 
125I-rhTSH treated with pH 2.5 and pH 7.  Both 
 band ranging from 17 to 21 kDa containing 90% of the total  radioactivity. 
was also detected
identical bands that range from 21 to 17 
α and β subunit of rhTSH merged together as 
 pH 2.5, which represents 
125I-rhTSH.  
-HPLC 
-HPLC. Two different ion pairing RP
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figure 
 
125I-rhTSH could 
125I-rhTSH 
2.3.4.1 for a 
pH 2.5 and pH7 
. 
the 
figure 4.12).  
-HPLC, rhTSH was 
-HPLC conditions 
  
were studied: 0.01 M Triethylammonium acetate (TEAA) at pH 5.5 and 0.1 M TEAA
pH 7. See section 2.3.5 for a detailed protocol.
rhTSH in 0.1M TEAA/water pH 7 and 0.01M TEAA/water pH 5.5 eluted as a single 
peak at early retention times of 8.77 and 8.68 respectively (
TEAA/water pH 5.5, a broader peak and a ce
compared with TEAA at pH 7. 
the preferred mobile phase to analyse rhTSH
 
Figure 4.13: RP-HPLC of rhTSH with 0.01M TEAA/water pH 5.5 and 0.01MTEAA/water pH 7.
eluted at 8.77 and 8.68 minutes respectively
 
In order to assess the effects of the radioiodination 
was analysed by RP-HPLC at the selected conditions of 0.1M TEAA/water pH7.
 
figure 
rtain degree of tailing was seen, when 
The TEAA/pH7 mobile phase was therefore selected as 
 with. 
. 
with rhTSH with 
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4.13). In 0.1MM 
 
 rhTSH 
125I, 125I-rhTSH 
 
  
Figure  4.14: Radio RP-HPLC chromatograms of 
TEAA/water pH 7. Three main peaks are shown at retention times 4.11 minutes, 5.6 minutes and 8.89 
minutes. 
 
In contrast to unlabelled rhTSH, in which a single peak was obtained, 3 main peaks 
eluted with 125I-rhTSH 
radioiodination or oxidation of rhTSH with 
rhTSH. 
In order to investigate if the oxidation process was damaging the structure of rhTSH, 
rhTSH was incubated with lactoperoxidase and glucose oxidase to produce ‘oxidised 
rhTSH’ and in order to investigate if the labelling process was damaging the str
rhTSH, rhTSH was incubated with glucose oxidase, lactoperoxidase and sodium [
iodide: ‘cold labelled rhTSH’. ‘Oxidised rhTSH’ and ‘cold labelled’ rhTSH were 
analysed in ion pairing RP
analysis showed a single sharp peak at retention time 8.33 minutes (
identical to the peak obtained with unlabelled rhTSH (
the oxidation of rhTSH is not altering the structure of rhTSH.
125I-rhTSH with 0.01M TEAA/water, pH 5.5 and 0.1M 
(figure 4.14). These extra peaks possibly indicate that the 
125I is significantly altering the structure of
-HPLC with 0.1M TEAA/water pH7. ‘Oxidised rhTSH’ 
figure 4.1
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ucture of 
127I] 
figure 4.15), 
3). This indicates that 
  
Figure 4.15: ‘Oxidised rhTSH’ a
retention time 8.33 minutes is detected.
Figure 4.16: ‘cold labelled’ rhTSH 
retention time 3.0 and 3.8 minutes
 
Analysis of the ‘cold labelled’ rhTSH (
times of 3.0 and 3.8 minutes, however, no peak is shown at 
minutes, as was obtained with unlabelled rhTSH and oxidised rhTSH. This indicates 
that the iodination process is most likely affecting the structure of rhTSH.
 
4.1.3 125I-rhTSH binding assays
The next step was to investigate whether 
pre-coated tubes and cells expressing the receptor. 
In order to identify the most
experiments, a number of different buffers were tested in order to determine which 
buffer gave rise to the highest binding to THSR expressing GPI cells. Please refer to 
section 2.3.6 in methodology f
nalysis in RP-HPLC with 0.1M TEAA/water pH7. A main peak at 
 
analysis in RP-HPLC with 0.1M TEAA/water pH7. 
 was detected. 
figure 4.16) showed two peaks at low retention 
 
125I-rhTSH bound to the TSHR both in TSHR 
 
 effective binding buffer to be used in the cell binding 
or a detailed protocol. The percentage of rhTSH that 
174 
A peak at 
a retention time of 8 
 
  
bound to the TSHR in GPI cells was 
buffer in comparison with the other binding buffers tested (
further experiments, HAMS
Figure 4.17: Effect of buffers used on binding to cells in cell binding assay
highest percentage of binding. 
control cell line. P<0.0001
 
 
 
4.1.3.1 Coated tube assay with 
In order to determine if 
TSHR pre-coated tubes was carried out. (Please refer to section 
for a detailed protocol). Increasing concentrations of rhTSH inhibited the binding of 
125I-rhTSH to the TSHR in the coated tubes in a concentration dependent manner, with 
maximal inhibition of around 90% being achieved. (
TSHR coated in the tubes with an IC
that 125I-rhTSH retained its receptor binding ability.  
Figure 4.18: Competition assay 
125I-rhTSH competed with rhTSH for the binding of TSHR in the tubes
HAMS-F12 HBSS
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significantly higher with HAMS
figure 
-F12 buffer was employed in cell binding experiments. 
 
s. HAMS
ANOVA with Dunnett post-hoc was performed using HAMS
. 
125I-rhTSH  and cold labelled rhTSH
125I-rhTSH bound to TSHR, a competition binding assay using 
figure 4.18
50 of 360 nM. Coated tube assay studies indicated 
 
of 125I-rhTSH with unlabelled rhTSH to the TSHR in pre coated tubes. 
. 
Krebs PBS/0.1 BSA
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4.1.3.2 Cell binding assays with 125I-rhTSH 
The next step was to assess the binding of 125I-rhTSH to the TSHR in TSHR expressing 
cells. In order to do this, competition assays and saturation binding assays were 
performed. Cell binding assays were performed in GPI, TPC-1 and FTC-133 cells. 
Please refer to section 2.3.6 for a detailed protocol. 
 
4.1.3.2.1 Saturation assay with 125I-rhTSH in GPI cells 
A saturation binding assay was carried out in GPI cells in order to determine the kD and 
Bmax of 125I-rhTSH. Results with GPI cells showed that 125I-rhTSH bound specifically 
to these cells with a binding affinity of 2.8  nM and a Bmax of 1292 fmol/protein 
(figure 4.19).  
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Figure 4.19: Equilibrium saturation binding of 125I-rhTSH to GPI cells. 125I-rhTSH bound specifically to 
GPI cells with a kD of 2.8 nM and a Bmax of 1092 fmol/mg. Results represent specific binding (total 
minus nonspecific binding) of triplicate determinations. Mean (±SEM) 
 
4.1.3.2.2 Saturation assay with 125I-rhTSH in TPC-1 and FTC-133 cells 
Saturation assay results with 125I-rhTSH in TPC-1 and FTC-133 cells demonstrated no 
binding (results not shown). 
  
4.1.3.3 Competition assay with 
Results from the competition assay
rhTSH inhibited the binding of 
manner (figure 4.20). rhTSH bound to the TSHR with an IC
 
Figure 4.20: competition assay of 
binding of 125I-rhTSH in a concentration dependent
achieving an inhibition of 98%. rhTSH bound to the TSHR with a IC
 
 
 
4.1.4 125I-rhTSH internalisation and externalisation assays
4.1.4.1 Internalisation assay
The receptor-mediated internalisation of 
find out if 125I-rhTSH 
to section 2.3.7 for a detailed procedure.
Figure 4.21: Internalisation assay to determine the amount of conjugate that is internalised over a period 
of 120 minutes. The bound excess competitive inhibitor was also used to determine the deg
specific binding. Around 80% of conjugate was internalised and 20% was membrane bound after 120 
minutes incubation. 
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125I-rhTSH by around 98%, in a concentration dependent 
50 of 980 nM.
 
125I-rhTSH with unalabelled rhTSH in GPI cells. rhTSH inhibited the 
 manner with the highest concentration
50 of 980 nM.
 
 
125I-rhTSH was studied in GPI cells in order to 
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Internalisation was very rapid with approx 80% of the cell associated radiolabelled 
conjugate being internalised after 15 minutes, whereas the membrane-bound fraction 
accounted for the other 20% of the total conjugate at this time point (figure 4.21). The 
non specific binding of rhTSH was on average less than 5% of the total activity.  
From these results it is apparent that the degree of internalisation is greater than the 
remaining  rhTSH found on the outer-membrane of the GPI cells. Externalisation assays 
provide more information about the degree of recycling of the radiolabelled ligand. 
Because of the possibility of metabolism of internalised 125I-labelled proteins the 
internalisation/externalisation assay may be misinterpreted by assuming that the 
supernatant radioactivity is immunoprotein bound when in fact the activity may be due 
to low molecular weight metabolites in solution.  
In order to discriminate between these two possibilities, the supernatants were collected 
and a TCA precipitation assay was performed so that protein was precipitated out of the 
solution. Please refer to section 2.3.8 in methodology for a detailed procedure. Results 
show that more than 90% of the radioiodine remains protein bound and that metabolism 
does not confound interpretation of the results (figure 4.22). 
 
Figure 4.22: TCA precipitation assay to determine the amount of protein bound radioactivity over a 
period of 120 minutes. The percentage of the total counts of supernatant and pellet sample are shown. 
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4.1.4.2 Externalisation assay 
An externalisation assay was carried out in order to determine the rate of rhTSH 
externalisation and the integrity of externalised rhTSH. Please refer to section 2.3.7 for 
detailed protocol. 60 % of the internalised activity had become externalised after 120 
minutes (Figure 4.23). There was no major difference between externalisation in the 
presence and absence of competitor, suggesting that most of the externalised rhTSH was 
degraded.  
 
Figure 4.23: Time dependant externalisation of pre-internalised 125I-rhTSH in GPI cells, in the presence 
and absence of competitor. 60% of internalised activity became externalised and there was no major 
difference in the presence and absence of competitor. 
 
As with the internalisation assay, a control experiment was also carried out to ensure 
that the immunoconjugate remained bound to 125I. Please refer to section 2.3.8 for a 
detailed protocol. Results show that more than 85% of the radioiodine remained protein 
bound and that, as above, the metabolism of 125I-rhTSH does not confound 
interpretation of the results (figure 4.24). 
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Figure 4.24: TCA precipitation assay to determine the amount of protein bound radioactivity over a 
period of 120 minutes. This graph is displayed as a percentage of the total counts of supernatant and pellet 
sample. 
 
4.1.5 In vivo binding 
125I-rhTSH selectively bound to the TSHR both in TSHR pre coated tubes as well as 
TSHR expressing GPI cells.  For this reason it was considered worthwhile to assess the 
binding of 125I-rhTSH in vivo.  
Biodistribution and imaging studies were carried out to investigate the binding of 125I-
rhTSH to the thyroid and subcutaneously grafted FRTL5 tumours in mice. Animals 
were injected intravenously with either 125I-rhTSH alone or 125I-rhTSH together with an 
excess of unlabelled rhTSH (blocking control) and scanned using SPECT/CT at several 
time points post injection. Please refer to section 2.3.8 in methodology for detailed 
protocol. A representative image at the 2.5 hour time point is shown in Figure 4.25.  
For the bioodistribution study, mice were injected with either 125I-rhTSH or 125I-trypsin 
inhibitor as a negative control tracer due to its similar molecular weight to the rhTSH 
(23 kDa). Mice were killed and tissues dissected and counted 2 hours after injection.  
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4.1.5.1 125I-rhTSH SPECT/CT imaging studies  
In the SPECT imaging studies, accumulation of 125I-rhTSH in the kidney and the 
bladder was clearly visible after 1 hour (figure 4.25). However, no thyroid uptake was 
observed. There was uptake in the tumour in both the blocking control and 125I-rhTSH, 
at all time points. Invivo-scope software analysis was used to quantify the signal in the 
tumour. (figure 4.26). Please refer to methodology for detailed protocol. 
 
2.5 hours
rhTSH-125I
Blocking 
control
Sagittal Coronal TransverseMIP
 
Figure 4.25: SPECT/CT imaging of mice at 2.5 hour time point after 125I-rhTSH injection. Upper half: 
125I-rhTSH MIP, Sagittal, Coronal and Transverse region of mice and lower half: Blocking control: 
Sagittal, Coronal and Transverse region of mice and lower half. The red arrow points to the grafted 
FRTL5 tumour. 
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Figure 4.26: Invivoscope ROI quantification analysis of 125I-rhTSH and blocking control. 3 mice were 
analysed at 0.5, 1,2,3,4,5,6 hours post 125I-rhTSH injection. 
 
Quantitative analysis of the ROI’s demonstrated  a constant activity in tumour with 125I-
rhTSH at all time points up to 6 hours (around 0.17 MBq) (figure 4.26). With the 
blocking control, an increase in the activity in the tumour is observed ranging from 0.13 
MBq at 30 minutes to 0.23 MBq at 6 hours (figure 4.26).   This suggests that most 
uptake is in fact occurring due to non specific mechanisms. 
 
4.1.5..2 Biodistribution 
Biodistribution studies were conducted in order to confirm the imaging results and to 
explore whether 125I-rhTSH bound to the thyroid and FRTL5 grafts in mice. Please refer 
to section 2.3.8.1 for a detailed protocol. 
125I-rhTSH uptake measured in the tumour and thyroid was higher than that obtained 
with the 125I Trypsin Inhibitor (TI) -control (figure 4.27). However the levels measured 
in the blood were much higher with 125I-rhTSH indicating that 125I-rhTSH is circulating 
for longer in the blood than 125I-TI. The uptake of 125I-rhTSH was also higher than that 
of 125I-TI in the intestine, pancreas, spleen, stomach, liver, heart, lung, muscle and tail. 
Since the uptake of 125I-rhTSH was not only higher in the tumour and the thyroid but 
also in receptor negative organs, it cannot be concluded that the uptake observed with 
125I-rhTSH in the thyroid and tumour is due specific receptor binding. 
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Figure 4.27: Biodistribution of 125I-rhTSH in mice. The average amount of radiotracer measured in mice, 
is shown. Y axis represents the percent of total activity per g and uptake of injected dose per organ. 
 
4.1.5.3 Blood stability studies 
Blood stability studies were performed to see whether the radiolabelled rhTSH 
remained intact in vivo during the imaging study. TCA precipitation assays and SDS-
PAGE electrophoresis were carried out on blood samples after injection of 125I-rhTSH 
into mice.   Please refer to section 2.3.8.1.2 for a detailed protocol.  
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Figure 4.28: TCA precipitation assay  on blood removed from mice 2 hour post injection of 
125I-rhTSH and 125I-TI. The percentage in the pellet in 125I-rhTSH  and 125I-TI is shown. 
 
  
Results from the TCA precipitation assay showed that the majority of the activity 
remained in the pellet with both 
both 125I-rhTSH and 125
Figure 4.29: Phosphorimager image of reduced and non reduced SDS
rhTSH incubated in the blood of mice. Two animals were injected i.v. with 
their blood removed. 
 
Results from SDS-PAGE electrophoresis of  
under reducing conditions s
represents the α and β
band at approximately 30 kDa which represents the rhTSH dimer. These studies 
therefore show that the stability of 
 
4.1.5.4 Second biodistribution study of 
One possible explanation for the lack of blocking of receptor uptake observed in the  
SPECT/CT imaging study 
which may have been insufficient to saturate the receptors. A second biodistribution 
study was therefore performed using a higher dose of cold rhTSH. This study also used 
an alternative non-specific control tracer
in the hope that its kinetics would match those of 
to section 2.3.8.2 for a detailed protocol.
125I-rhTSH and 125I-TI (figure 4.2
I-TI remained intact in the blood during the 
 
-PAGE
125
125I-rhTSH in blood samples analysed 
howed a band ranging from 16 to 22 kDa, which most likely 
 subunit of rhTSH (figure 4.29). The non reduced gel showed a 
125I-rhTSH was most likely not compromised 
125I-rhTSH in tumour grafted mice
might be that an insufficient dose of cold rhTSH
, 
125I-labelled Carbonic anydrase (Mw
125I-rhTSH more closely. 
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Figure 4.30: Biodistribution of 125I-rhTSH, 125I-CA and blocking control in mice. The average amount of 
radiotracer measured in 2 mice, is shown. Y axis represents the percent of total activity per g and uptake 
of injected dose per organ . Results show uptake of the blocking control and CA control in the tumour and 
thyroid was much higher than with 125I-rhTSH.  
 
The results of this biodistribution study (figure 4.30) unexpectedly showed that the 
radioactive uptake in the thyroid and tumour with the blocking control and 125I 
radiolabelled carbonic anydrase control was higher compared to that of 125I-rhTSH. This 
was also the case for all other tissues sampled. These results suggest that the uptake 
observed for 125I-rhTSH in the tumour and thyroid was primarily due to non specific 
mechanisms. 
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4.2 Discussion of rhTSH studies 
Radiolabelled proteins and peptides have emerged as useful agents in the diagnosis and 
treatment of cancer [155, 156]. Radiolabelled peptides offer the advantages of being 
small, low in antigenicity, fast in clearance and rapid in tissue and tumour penetration 
[248, 249]. Furthermore, with the advance in peptide and protein synthesis techniques it 
is easy and relatively cheap to produce new peptides/proteins to be tested as potential 
radiopharmaceuticals [248, 249]. 
As previously discussed, some differentiated thyroid cancers de-differentiate and lose 
the expression of NIS, and thereby the ability to readily take up radioiodine into the 
thyroid [109, 250, 251]. This impairs the staging of recurrent disease with radioactive 
iodine. There have been reports, however, that showed that some radioiodine resistant 
thyroid cancers still express the TSHR [247]. Therefore, TSHR could potential be used 
as a marker for radioiodine resistant de-differentiated thyroid cancer.  
In chapter 3, mAb9 anti-TSHR antibody was investigated for its potential to target 
radioiodine resistant thyroid cancer. mAb9 monoclonal antibody bound specifically to 
the TSHR in vitro, however it did not bind specifically the TSHR in the thyroid of mice 
in vivo. For this reason, an alternative approach for targeting radioiodine resistant 
thyroid cancer was evaluated in which radiolabelled rhTSH (Genzyme) was used 
instead of mAb9 to target radioiodine resistant thyroid cancer. TSH is an endogenous 
ligand for the TSHR and it was considered appropriate to use because of its relatively 
small size of approximately 30 kDa. Also, Corsetti et al. [181] previously 
radioiodinated rhTSH with 125I and performed binding assays that showed 125I-rhTSH to 
bind to TSHR expressing cells (PTC-1) [181]. In these studies, 125I-rhTSH also 
appeared to bind to PTC-1 tumour xenografts in mice [181]. However, these 
experiments were just preliminary and further experiments are required in order to 
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conclusively show that this is the case. In this chapter experiments were carried out to 
try and confirm these findings. 
 
4.2.1 Radioiodination of rhTSH with 125I 
The first step was to radiolabel rhTSH with 125I. Several different methods can be 
employed in the radioiodination of proteins, antibodies and peptides and they usually 
differ mostly in the nature of the oxidising agent for converting I- into the reactive 
species of I2 and I+ [169]. These reactive species most often substitute into tyrosine 
residues of proteins, however substitution can also occur in histidine, cysteine and 
tryptophan residues [169]. These methods include the two oxidation methods 
chloroamine-T [252] and the Iodogen [253] method, and enzymatic substitution method 
which uses lactoperoxidase enzyme [172]. 
The first step in this study was to attempt to produce a high purity 125I radiolabelled 
rhTSH. The direct hydrogen peroxide enzymatic radioiodination method was used for 
this purpose. This radioiodination method was first introduced by Marchalonis et al. 
[172] and employs lactoperoxidase in the presence of a trace of hydrogen peroxide to 
oxidise the radioactive iodide [172]. The hydrogen peroxide used in this reaction can 
either be used directly or produced in solution by glucose oxidase. This technique may 
result in less denaturation to susceptible proteins than Chloramine-T and Iodogen [172]. 
In this study the lactoperoxide method in which glucose oxidase generates hydrogen 
peroxide in situ was used. 
The most effective concentrations of glucose oxidase and lactoperoxidase for the 
lactoperoxidase/glucose oxidase labelling method were experimentally determined and 
they coincided with the amounts used by Corsetti et al. [181]. In order to estimate the 
radiolabelling purity, ITLC was used. ITLC results showed a labelling efficiency close 
to 100%. ITLC is a good indicator of the approximate labelling efficiency of a 
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radiolabelled compound, however, alone it does not provide information on the 
presence of small aggregates and impurities in the radiolabelled compound and for this 
reason a SDS-PAGE gel electrophoresis was also conducted. SDS-PAGE results 
showed two bands of 21 kDa and 17 kDa, which  most likely represent the α and β 
subunit of the rhTSH respectively . The predicted molecular weights of the α and β 
subunit of rhTSH are 13,829 and 15,840 Da respectively, and the theoretical molecular 
weight for the rhTSH dimer is 29,660 Da [96]. Cole et al. ran rhTSH in a SDS-PAGE 
electrophoresis and detected bands of 20,940 Da and 16,630 Da corresponding to α and 
β subunit respectively [96]. Both ITLC and SDS-PAGE results clearly indicated that a 
high purity 125I radiolabelled rhTSH was therefore prepared.  
 
4.2.2 HPLC studies with rhTSH 
HPLC studies were conducted to study in more detail the purity of rhTSH and 125I-
rhTSH. Due to its intermediate size of 30,000 Da, it is not certain whether the most 
suitable method to analyse it would be size exclusion HPLC or reverse phase-HPLC 
(RP-HPLC). Usually size exclusion HPLC is used to separate and analyse 
proteins/compounds of higher molecular weight, whereas RP-HPLC is most efficient 
for the analysis of smaller molecular weight peptides. Therefore experiments were 
carried out with each of these systems to identify the optimal conditions for the analysis 
of rhTSH. Ion pairing RP-HPLC can further improve separation and therefore was also 
used to analyse rhTSH. 
 
4.2.2.1 Size exclusion-HPLC (SE-HPLC) 
The first HPLC system to be evaluated was size exclusion HPLC (SE-HPLC) and 
results showed a single peak corresponding to the approximate molecular weight of 
rhTSH. The size of a compound analysed in SE-HPLC can be determined by measuring 
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their retention times from a column calibrated against known standards. In this 
particular case, the SE-HPLC did not manage to separate the different components of 
the molecular weight markers into distinct peaks. This is probably because the type of 
SE-HPLC column used, YMC, has very small pores and, thus does not separate the 
larger molecules, just smallest ones. Small proteins in this column usually elute 
relatively quickly from the column and there is poorer resolution between bigger and 
smaller proteins but better resolution of small proteins from lower molecular weight 
contaminants. In order to overcome this problem, a compound with a similar molecular 
weight to the α subunit, lysosyme, and one with similar molecular weight to the rhTSH 
dimer, carbonic anydrase, were analysed in the SE-HPLC. Carbonic anydrase and 
lysosyme have a theoretical molecular weight of 29 kDa and 14.7 kDa respectively, 
which are similar to the theoretical molecular weight of the rhTSH dimer of 29,660 and 
α subunit, 13.820 Da. The retention time obtained with carbonic anydrase was very 
close to the retention time obtained with rhTSH, which indicates that the rhTSH 
analysed by the SE-HPLC eluted as a rhTSH dimer of an approximate molecular weight 
of 30,000 Da. Radiolabelled 125I-rhTSH eluted approximately 1 minute later than 
unlabelled rhTSH in this SE-HPLC column. This could be caused by the radioiodination 
process altering the structure of rhTSH. 
 
4.2.2.2 Reverse phase HPLC (RP-HPLC) 
The resolution of SE-HPLC is not very high and therefore there usually needs to be 
differences of around thousands of Da in order to achieve separation [254]. For this 
reason smaller proteins and peptides of hydrophobic nature are usually better analysed 
using reverse phase-HPLC (RP-HPLC) rather than size-exclusion HPLC. Moreover, 
separation in RP-HPLC offers the advantages of the resolution being improved by the 
use of buffered mobile phases and ion-pairing agents [254].  
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The separation in RP-HPLC depends on the hydrophobic binding of the solute molecule 
from the mobile phase to the immobilised hydrophobic ligands attached to the 
stationary phase [254].  The solute mixture is initially applied to the stationary phase in 
the presence of aqueous buffers, and the solutes are eluted by the addition of organic 
solvent to the mobile phase (usually acetonitrile). Elution is usually achieved by 
gradient elution where the amount of organic solvent is increased over a period of time. 
The solutes are, therefore, eluted in order of increasing molecular hydrophobicity, rather 
than size [254]. 
RP-HPLC is a very useful technique for the analysis of peptides and proteins due to a 
number of factors.  First, it is possible to achieve excellent resolution using a range of 
chromatographic conditions for very closely related molecules as well as structurally 
very distinct molecules. Second, the mobile phase characteristics can be changed in 
order to manipulate chromatographic selectivity and lastly, excellent reproducibility of 
repetitive separations carried out over a long period of time can be achieved, due to the 
stability of the stationary phase materials under a varied range of mobile phase 
conditions [254]. A number of factors should be taken into account when considering 
RP-HPLC separation analysis. These factors include column components and 
specifications, the solvents used, elution gradient, flow rate and sample preparation 
[254].  
Trifluoroacetic acid (TFA) at pH 2.5 is normally used as a starting condition mobile 
phase in RP-HPLC as the low pH can suppress the ionisation of the acidic groups in the 
solute molecules and generate sharper peaks [254]. Most peptides elute from a C18 
reverse phased column in 30%ACN, and in order to improve separation a shallower 
gradient can be used. 
rhTSH was analysed initially in a 0.1%TFA/pH 2.5 mobile phase solution. If the solute 
was homeogenous, rhTSH should elute as a single peak, however rhTSH analysis 
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showed several peaks indicating heterogeneity in the sample. In order to try and 
optimise the elution of rhTSH, different gradients were tested in an attempt to further 
separate the different peaks. Of the different gradients tested, just one (5 to 20% ACN 
for 30 minutes, 20 to 35% for 30 minutes, 35 to 100% ACN for 5 minutes) achieved a 
better peak separation, as it managed to clearly separate the peaks into 3 main groups. 
125I-rhTSH was also analysed in RP-HPLC using the same conditions as that used with 
unlabelled rhTSH and as with rhTSH, several peaks were seen but with longer retention 
times suggesting that the components had become more hydrophobic. 
One reason why rhTSH and 125I-rhTSH analysed in 0.1%TFA/water at pH 2.5 were 
showing a number of different peaks in the RP-HPLC could be due to the low pH 2.5 
damaging the structure of rhTSH. In order to investigate this possibility, an SDS-PAGE 
gel electrophoresis was carried out with rhTSH treated at pH 2.5 and pH 7. There was 
no indication that the low pH was in fact damaging the rhTSH, and for that reason it is 
unlikely that the extra peaks obtained with rhTSH and 125I-rhTSH analysed in RP-
HPLC were the result of degradation caused by the low pH. 
 
4.2.2.3 Ion pairing RP-HPLC 
The retention times of solutes such as proteins and peptides can be modified by adding 
ion pairing agents to the mobile phase. Ion pairing agents bind to the solute through 
ionic interactions, which can result in an increase in the solute hydrophobicity and by 
doing so change its selectivity. Ion pairing RP-HPLC has the advantage of improving 
the chance of achieving complete resolution of the sample components. 
In order to try and improve separation on the RP-HPL, ion pairing RP-HPLC was tested 
with triethylammonium acetate buffer (TEAA) at both pH 5.5 and pH 7.  TFA and 
TEAA are both weak hydrophobic ion pairing agents hence any change in retention 
times found with the TEAA system relative to the TFA system are mainly due to a 
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change in the pH and the resulting differences in the ionization of the carboxyl side 
chains of glutamic acid and aspartic acid and the terminal carboxyl group [254]. 
Peptides exhibit increased hydrophilic character in the TEAA system and for that reason 
retention times are reduced dramatically.  
When unlabelled rhTSH was analysed, a single sharp rhTSH peak was obtained with 
pH 7. At pH 5.5 a broader single peak with a degree of tailing was obtained. After these 
analyses it was concluded that the optimal method to analyse rhTSH was ion pairing 
RP-HPLC with TEAA/water pH7. 
The next step was therefore to determine if the radioiodination of rhTSH was 
damaging/altering the structure of rhTSH. In order to do this, 125I-rhTSH was analysed 
under the previously determined optimal conditions: TEAA/water at pH 7. Two extra 
peaks were shown with 125I-rhTSH in comparison with rhTSH. This indicated that the 
radioiodination process was possibly damaging the structure of rhTSH. Also, the 
recovery of 125I-rhTSH from the column was measured and showed that around 40% of 
125I-rhTSH was being retained in the column.  
The radioiodination process can potentially interfere with the receptor binding site of a 
ligand and damage the binding ability of the protein through oxidative damage caused 
by the labelling reagents. Damage may also occur as a result of substitution of the 
isotope into the receptor-binding site if the latter is tyrosine-rich. These possibilities 
were explored by RP-HPLC using the previously optimised  conditions. To investigate 
whether oxidation was damaging rhTSH, rhTSH was incubated with glucose oxidase 
and lactoperoxidase: to produce ‘oxidised rhTSH’ and to investigate whether the iodine 
substitution process was damaging the rhTSH, rhTSH was incubated with glucose 
oxidase, lactoperoxidase and cold iodine (Na[127I]I) to produce ‘cold labelled rhTSH. 
Results showed that oxidation of rhTSH did not appear to affect rhTSH, however cold 
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labelling of rhTSH did appear to inflict some degree of damage to rhTSH. It is however 
unknown if this would interfere with the binding of rhTSH to the TSHR. 
 
4.2.3 Binding of radiolabelled rhTSH to the TSHR in vitro 
Radiolabelled peptides must retain their receptor-binding capacity if they are to function 
as effective radiopharmaceuticals. In order to investigate 125I-rhTSH’s receptor-binding 
ability, studies were conducted in tubes pre-coated with TSHR and in cells expressing 
the TSHR.  
 
4.2.3.1 Coated tube assay 
A competition assay was carried out in which tubes coated with TSHR were used to 
assess the ability of rhTSH to inhibit the binding of 125I-rhTSH.  
rhTSH inhibited the binding of 125I-rhTSH in a concentration dependent manner, with 
the maximal concentration of rhTSH achieving 90% inhibition. The IC50 value of 
rhTSH was 360 nM. This indicated that 125I-rhTSH bound to the TSHR coated in the 
tubes. 
 
4.2.3.2 Cell binding assays: 
The next step was to study the ability of 125I-rhTSH to bind to the TSHR in cells. 
Saturation and competition radioligand binding assays were carried on the thyroid 
cancer cell lines: FTC-133, and TPC-1 cells and a TSHR transfected cell line, GPI cells, 
in order to determine both the receptor number (Bmax) and the binding affinity (Kd) of 
125I-rhTSH in the different cells. In addition to specific binding to target receptors, 
radioligands may also bind non-specifically to other sites, notably the cell membrane. 
These non-specific interactions may be occurring due to the charge and hydrophobicity 
of the ligand, more so than because of the sequence-specific structure [255]. 
194 
 
 
Unlabelled rhTSH was used as the competitor to measure non-specific binding to ensure 
that all the target receptors were occupied, so that any binding observed would be to 
other receptors, or be due to interactions with the cell membrane. There are many 
characteristics that can influence the outcome of binding assays, one of them is the 
binding assay buffer used. In order to identify which binding assay buffer yielded the 
most favourable results, the percentage of binding was studied with different binding 
buffers in TSHR expressing GPI cells. HAMS-F12 was found to be the most efficient 
buffer, and therefore this buffer was used in subsequent binding assays. 
Measurable Bmax and Kd values were obtained for GPI cells only. FTC-133 and TPC-1 
cells showed no binding, most probably due to the very low or negligible expression of 
TSHR in these cells, as demonstrated by RT-PCR, FACS and Western blot experiments 
carried out in chapter 2. 
Studies in GPI cells showed rhTSH to bind to TSHR with a a Kd of 2.8 nM and Bmax 
of 1092 fmol/mg. Cornelis et al. used 125I radiolabelled bovine TSH (125I-bTSH) in 
TSHR transfected GPI cells and reported a Kd of 1.56 nM [256]. The reported binding 
affinity of 1.56 nM was thus similar to the Kd obtained in this study. In another study, 
the binding of 125I-rhTSH was used in TSHR transfected cell lines and a Kd of 56 nM 
was reported, which is slightly lower than the Kd obtained in this study [257]. The 
differences between the kD in the paper and this study, could be due to the use of two 
different batches of rhTSH. Different batches of rhTSH have different degrees of 
sialylation and sulphation and it has been shown that this can affect biological activity. 
The differences reported in these studies could also be a result of differences in 
experimental setting such as incubation times, binding buffers, binding buffers, pH and 
other conditions that can influence the results of a binding assay. 
Competition binding assays carried out in TSHR expressing GPI cells showed that 
rhTSH inhibited the binding of 125I-rhTSH to the TSHR in a concentration dependent 
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manner with the highest concentration of rhTSH inhibiting the binding to the TSHR  by 
around 98%. This assay reported an IC50 of 980 nM, which is considerably higher than 
the Kd obtained in the saturation assay studies. 
 
4.2.4 Internalisation and externalisation assays 
In the thyroid, TSH binds and activates the TSHR, a G protein coupled receptor, and 
consequently triggers G-protein-regulated effectors including adenyl cyclase, 
phospholipase C, calcium channels) [258].  Most activated GPCRs are rapidly 
desensitised at the cell surface in a process that involves phosphorylation and B-arrestin 
binding. GPCRs are internalised via clathrin-coated pits or other less understood 
pathways, and they can be either dephosphorylated and efficiently recycled back to the 
cell surface or sorted from endosomes to lysosomes and degraded [258]. The rate of 
GPCR internalisation, recycling and lysosomal sorting differ widely among receptors 
[258]. Previous studies suggest that the TSHR is recycled back to the cell surface [69]. 
However, additional studies need to be conducted in order to conclusively determine 
how exactly the TSHR is internalised and show conclusively whether it is recycled back 
to the cell surface or degraded in lysosomal vesicles. 
Internalisation and externalisation assays are commonly used tools for in vitro 
characterisation of novel radiopharmaceuticals [250, 259-261]. An optimal receptor–
ligand would, in addition to having high tumour specificity, also provide lysosomal 
targeting and trapping of the radioisotope, coupled with rapid recycling of the receptor 
to the surface [262, 263]. In this way the radioisotope could accumulate and be retained 
in target cells for some time and consequently a high imaging contrast or strong 
therapeutic effect could be achieved. 
Results from internalisation assays showed 80% of cell associated radiolabelled 
conjugate was internalised at two hours, whereas around 20% of the total conjugate 
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accounted for the membrane-bound fraction at this time point. These results indicate 
that most of the radiolabelled rhTSH is internalised. These results are in accordance 
with previously reported studies that concluded that the majority of TSH is internalised. 
Due to the possibility of 125I being metabolised into free 125I, internalisation assays may 
be confounded by assuming that the supernatant radioactivity is bound to the protein 
when in fact the activity may be due to free iodide in solution. A TCA protein 
precipitation assay confirmed that most of the 125I was still bound to the rhTSH, as there 
was just a small amount of metabolised free 125I detected. It was therefore unlikely that 
the small degree of free 125I was interfering with the accurate interpretation of the 
internalisation assay.  
The presence and integrity of externalised ligand can be detected in externalisation 
assays performed in the presence and absence of competitor. Externalisation assays are 
undertaken by performing internalisation into the cells and then incubating them further 
for 2 hours . After the incubation time the externalised fraction can be determined. After 
2 hours incubation at 37°C approximately 60% of internalised activity had become 
externalised. There was however no significant difference between externalisation in the 
presence and absence of competitor, suggesting that most or all of the externalised 
peptide was degraded. A study by Baratti-Elbaz et al. [264] reported the majority of 
internalised receptor molecules (90%) were recycled to the cell surface. The study used 
stably transfected L cells that express the TSH receptor, 125I-labeled bTSH, and anti-
TSHR antibodies. These results have reported substantially higher recycling of rhTSH, 
however some other studies also reported a lower amount of TSH being recycled back 
onto the membrane, with most of it being degraded in the lysosomes. 
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4.2.5 In vivo binding 
In vitro experiments performed previously confirmed that 125I-rhTSH bound specifically 
to the TSHR both in the TSHR coated tubes and in TSHR expressing GPI cells. For this 
reason, it was considered worthwhile to investigate the binding of 125I-rhTSH in vivo. 
FRTL5 cells are a fast growing rat thyroid cell-line, which maintains functional 
characteristics of iodide uptake and thyroglobulin synthesis over prolonged periods of 
culturing. FRTL5 cells derive from primary cultures of Fischer rat thyroid glands. 
FRTL5 cells are employed in a series of assays which measure thyroid stimulatory or 
inhibitory factors [265]. 
In chapter 3.1.2.2.1, FRTL5 cells were demonstrated to express the TSHR, and 125I-
rhTSH was also shown to bind specifically to FRTL5 in previous studies. Due to these 
features, these cells were injected subcutaneously in mice with the intention of studying 
the binding of 125I-rhTSH to a the TSHR in vivo. 
 
4.2.5.1 SPECT/CT imaging studies in mice with 125I-rhTSH 
SPECT/CT imaging studies were first carried out with mice. Three mice bearing FRTL5 
grafted tumours were selected for imaging. These mice were injected i.v with 125I-
rhTSH and were scanned at intervals of 1 to 6 hours post injection.  
As explained previously, interpretation of results from this experiment is complicated 
by the fact that radioiodine released in-vivo by metabolism of the labelled peptide may 
also be taken up by the thyroid via the sodium iodine symporter (NIS). In order to 
control for this possibility, mice were given potassium iodide in their water 3 days prior 
to experiments as well as sodium perchlorate administered intraperitoneally 
immediately before injection of the 125I-rhTSH. Sodium perchlorate is a potent inhibitor 
of the NIS function and thus an effective inhibitor of active iodide transport [4, 266-
268]. 
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A blocking study using co-injection of unlabelled rhTSH was also carried out in order 
to determine whether any uptake observed was due to specific or non-specific binding. 
Some degree of non-specific binding is expected due to hydrophobic and ionic 
interactions with other sites on the cell surface, however, this percentage must be 
relatively low enough to allow specific binding to be observed [269]. The tumour region 
of mice was quantified using invivo-scope software.  The quantification analysis 
indicated that no substantial differences in the activity in the tumour was observed 
between 125I-rhTSH and the blocking control. It would be thus expected that the 
blocking control study should have shown reduced activity in the tumour and the 
thyroid, and this therefore raises questions about the specificity of the 125I-rhTSH uptake 
in the tumour. These results suggest that most of the binding of 125I-rhTSH to the  
FRTL5 grafted tumours is in fact due non-specific binding although one alternative 
possible explanation is that the dose of cold rhTSH was not enough to saturate TSHR 
receptors and effectively block the binding of 125I-rhTSH 
.  
4.2.5.2 Biodistribution with 125I-rhTSH 
Biodistribution studies were performed in order to assess the binding of 125I-rhTSH to 
TSHR in both the thyroid and the FRTL5 grafted tumours in mice. Trypsin inhibitor 
(TI) was initially used as a control in the biodistribution studies as it has a similar 
molecular weight to rhTSH, 23 kDa. In order to block the uptake of free 125I into the 
thyroid and tumour via NIS, mice were given water with potassium iodide as well as 
injected with sodium perchlorate prior to the 125I-rhTSH, as detailed in 2.3.8.1. 
In this biodistribution study the uptake of 125I-rhTSH in the tumour and the thyroid was 
much higher than the 125I-TI control and this could be interpreted to be specific binding 
to the receptor. However, the activity seen in the blood was also higher than the control 
so it can be assumed that 125I-rhTSH is circulating for longer in the blood than the 125I-
199 
 
 
TI. Possibly as a result of this longer half-life in the blood, the uptake of 125I-rhTSH was 
not only higher in the thyroid and the tumour but also higher in non specific organs such 
as muscle, heart, liver, spleen and pancreas compared to 125I-TI. Since there is no 
significant expression of THSR in these organs, this suggests that the increase in 
activity seen in the tumour with 125I-rhTSH in comparison to control 125I-TI is due to 
non specific mechanisms. It also suggests that the control used, 125I-TI, is not an 
appropriate control to be used with rhTSH because of its more rapid clearance. 
 
4.2.5.3 Second biodistribution study with 125I-rhTSH 
A second biodistribution study was conducted to address the question of whether the 
amount of cold rhTSH added in the blocking control was not enough to saturate the 
receptors and therefore not enough to completely block the binding of 125I-rhTSH to the 
thyroid and tumour. A different 125I radiolabelled control peptide with a similar 
molecular weight to rhTSH, carbonic anydrase (CA) was also used in these 
experiments. 
In this study, the blocking control and the 125I-CA control showed higher uptake than 
the 125I-rhTSH group in the tumour as well as in the thyroid. This clearly suggests that 
most uptake of radioactivity occurring in the tumour and thyroid was due to non 
specific binding and not due to the specific binding of 125I-rhTSH to the TSHR in the 
thyroid and grafted tumour. 
Corsetti et al. [181] in a similar study showed that 125I radioiodinated rhTSH bound to 
TSHR in PTC-1 TSHR positive cell lines. In this study rhTSH was successfully 
radioiodinated with 125I and binding assays were performed to assess its binding to 
TSHR expressed in PTC-1 cells. This study showed that 125I-rhTSH bound to the TSHR 
in these cells with a high affinity. The authors of this study then carried out 
biodistribution studies to assess the binding of 125I-rhTSH to PTC-1 tumours grafted 
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into mice. 125I-rhTSH appeared to bind to PTC-1 xenografts in mice compared with non 
TSHR expressing cell xenografts. However, there were some potential flaws in this 
study that may have misguided the author to this conclusion.  
Only two animals of each cell line (two did not express TSHR, ARO and two expressed 
TSHR, PTC-1) were used for the biodistribution studies, and no statistical analysis was 
employed. Perhaps the slightly higher uptake reported in TSHR positive grafted 
tumours was therefore due to the variability of data. Also, there was no blocking control 
included so perhaps most of the binding that reported in the study was due to non 
specific binding.  
 
4.2.5.4 Stability of 125I-rhTSH blood in vivo and ex vivo studies 
One possible reason why 125I-rhTSH showed binding to the TSHR in vitro but not in 
vivo may be due to the 125I-rhTSH breaking down in the blood. In order to investigate 
this possibility 125I-rhTSH was incubated in blood both in vivo and ex vivo and after 2 
hours the blood was analysed using TCA precipitation assays and SDS-PAGE 
electrophoresis. The results showed that most of the 125I-rhTSH structure remained 
intact, and for that reason it could be concluded that 125I-rhTSH was not breaking down 
in blood and instability of the tracer was not the cause of the imaging and 
biodistribution results obtained. 
 
4.2.6 Conclusion of rhTSH studies 
rhTSH presented as a promising potential radioligand to target the TSHR in radioiodine 
resistant thyroid cancer, and robust in vitro binding to TSHR expressing cells was 
encouraging. However, in vivo studies showed that rhTSH does not bind in vivo, and for 
that reason rhTSH cannot therefore be considered a suitable candidate to target the 
TSHR in radioiodine resistant thyroid cancer. 
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CHAPTER 5. GENERAL SUMMARY AND CONCLUSIONS 
 
Differentiated thyroid cancer (DTC) is usually treated with total thyroidectomy, 
followed by 131I radioiodine ablation in order to eliminate any thyroid remnants. To 
diagnose and stage recurrent thyroid cancer, radioactive iodine (RAI) whole body 
scanning (WBS) is used [76, 77, 80]. Some thyroid cancers de-differentiate and lose the 
expression of the sodium iodide symporter (NIS), which is responsible for the uptake of 
radioactive iodine into the thyroid and thyroid tumours [108, 210, 243]. Without this 
transporter, the disease cannot be staged and treated with radioactive iodine WBS, 
therefore a new approach is needed. 
There have been some reports that showed that radioiodine resistant thyroid cancers still 
express the thyroid stimulating hormone receptor (TSHR) [114, 118]. These studies 
indicated that TSHR might be a valuable target to stage and treat radioactive resistant 
de-differentiated thyroid cancer, and therefore experiments were carried out to 
investigate this. 
Monoclonal antibodies have emerged as useful tools to target specific receptors in a 
number of cancers and therefore the aim of the first part of this study was to use 
radiolabelled mAb9, a whole IgG anti TSHR monoclonal antibody, to target TSHR in 
radioiodine resistant thyroid cancer in vitro and in vivo. FTC-133, TPC-1 and GPI cell 
lines were used in this study and the expression of TSHR in these cells was evaluated 
using FACS, RT-PCR and Western blot studies to ensure that these cell lines expressed 
the TSHR. Results from these studies showed that GPI cells expressed TSHR at high 
levels but that the non- transfected human cell lines FTC-133, TPC-1 as well as the rat 
FTRL5 cell line  had much lower or undetectable levels of TSHR expression.  
Thereafter, mAb9 was radiolabelled with 125I and 111In, and in vitro binding studies in 
the above mentioned TSHR expressing cells showed that 125I-mAb9 and 111In-mAb9 
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bound to the THSR in GPI cells with a high binding affinity but showed no or 
negligible binding to the other cell lines. This showed that the antibody retained its 
binding ability after radiolabelling and showed specific interactions with receptor 
expressing cells, but not receptor negative cells in vitro. In vivo studies in mice were 
then carried out to evaluate the specific binding of 125I-mAb9 and 111In-mAb9 to the 
TSHR in the thyroid of mice, a tissue known to express TSHR, however no significant 
binding in vivo was seen. Thus, these studies concluded that although radiolabelled 
mAb9 bound to TSHR with a high affinity in vitro, it failed to bind to the TSHR in the 
thyroid of mice. For this reason, mAb9 was considered not suitable to be used as a 
potential aid in the diagnosis and treatment of radioiodine resistant thyroid cancer and 
hence no further studies were carried out with radiolabelled mAb9. 
In the second part of this study, rhTSH was explored for the targeting of the TSHR. 
This approach appeared promising due to a previous preliminary study that showed 
radiolabelled rhTSH bound to TSHR expressing cells and grafted thyroid tumours in 
mice [181]. Studies were carried out to evaluate the robustness of this strategy by 
testing whether radiolabelled rhTSH bound to TSHR in a number of different 
experimental contexts as those used in the preliminary paper. In in vitro binding studies, 
the ability of 125I-rhTSH to bind to TSHR was tested in a number of cell lines that were 
not previously used in the preliminary study. Furthermore, different radiolabelling 
methods were employed and extensive optimisation steps were undertaken until the best 
radiolabelled product was achieved.  
Additionally, because an n number of only two animals was used in the preliminary 
study, it was not possible to show if the binding observed was statistically significant. In 
the studies carried out in this thesis, a higher n number of animals were tested, which 
allowed to determine if any binding observed was actually statistically significant.  
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In the first stage of this study, rhTSH was radiolabelled with 125I and cell binding assays 
were carried out to assess its binding in vitro. 125I-rhTSH was shown to bind to the 
TSHR expressing cells and therefore the next step was to evaluate the binding of 125I-
rhTSH in vivo to grafted thyroid tumours and to the thyroid of mice. SPECT/CT 
imaging studies and biodistribution studies failed to show specific binding of 125I-
rhTSH to the thyroid and thyroid cancer grafted tumours. The conclusion of these 
rhTSH studies was therefore that although radiolabelled rhTSH bound to the TSHR in 
vitro, it did not bind to either grafted tumour or the thyroid in mice in vivo. These 
studies concluded that, like radiolabelled mAb9, 125I-rhTSH was not a suitable 
diagnosis/treatment tool to be used in radioiodine de-differentiated thyroid cancer. 
However, the animal model used in these in vivo studies was not ideal, as it was shown 
in vitro that most binding of 125I-rhTSH to these tumour cells was due to non specific 
binding.  
The reasons for the lack of uptake of mAb9 and rhTSH in vivo are not clear. It may be 
that the levels of TSHR expression in the thyroid of mice are not high enough for 
effective targeting despite being sufficient to maintain normal thyroid function in these 
animals. Future studies should therefore include a measurement of these expression 
levels using a suitable ex vivo technique. Another possible reason for lack of uptake 
could be due to endogenous TSH competing for radiolabelled rhTSH in mice. This issue 
could be addressed in future studies by performing experiments where mice were given 
thyroxine to block their levels of endogenous TSH before carrying out experiments with 
radiolabelled rhTSH and mAb9. A dose response curve could also be performed to 
determine if higher concentrations of 125I-rhTSH could overcome any competition from 
mice endogenous TSH in vivo. The in vitro binding studies of radiolabelled mAb9 and 
rhTSH were performed in cells expressing the human TSHR and although published 
studies have reported that both compounds also bind to the mouse receptor it would be 
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appropriate to perform studies to confirm that radiolabelled mAb9 and rhTSH do bind 
to the mouse receptor in vitro.  
Although the hypothesis behind this project is that de-differentiated thyroid cancer cells 
continue to express TSHR, the cell lines studied were found to express only very low 
levels of TSHR. The published literature is divided on this issue. Gerard et al. [116] 
used immunohistochemistry to analyse the expression of TSHR in human follicular and 
papillary thyroid cancer samples and concluded that TSHR expression persisted 
virtually in all cases of thyroid cancer. Matsumoto H. et al. [118] used 
immunohistochemistry and detected decreased expression of TSHR in poorly 
differentiated human thyroid cancer samples. Park HJ et al. [117] and Ohta et al. [119] 
found TSHR mRNA to be expressed in thyroid cancer, however at lower levels than in 
the thyroid controls. Elisei et al. [120] did not detect expression of TSHR mRNA in 
human samples of primary anaplastic thyroid cancer. 
 It is therefore important that the levels of TSHR expression in a series of clinical 
examples be confirmed before extensive targeting studies aimed at this receptor are 
undertaken. An important component of any further studies should be robust non-
transfected cell lines that have been confirmed to express higher levels of TSHR (if 
indeed such lines exist). These cell lines could then be used to create more robust mice 
models to further test the binding of 125I-rhTSH in vivo. 
Whole antibodies might not be ideal to use in vivo due to their large sizes. In a future 
project, antibody fragments with better pharmacokinetic properties could be tested. The 
ideal tumor-targeting antibodies are intermediate-sized multivalent molecules, which 
provide rapid tissue penetration, high target retention and rapid blood clearance. Recent 
biodistribution studies [266] indicate that bivalent antibodies such as diabodies (60 
kDa), and minibodies (80 kDa) may be best suited for tumor imaging and therapy due to 
a higher total tumor uptake and better tumor-to-blood ratios than intact IgG molecules. 
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Also, some small molecules TSHR agonists have been developed and these could be 
radiolabelled and tested for their potential use in the diagnosis and treatment of 
radioiodine resistant thyroid cancer [267, 268].  
Another plausible future option would be to find a different approach to target 
radioiodine resistant thyroid cancer, however so far no new biomarker has been found to 
be uniquely associated with de-differentiated thyroid cancer. 
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